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Abstract 
The combination of nucleophilic nitrenoids and gold-catalysis has rapidly emerged as a 
powerful tool in the assembling of different nitrogen-containing motifs. The research 
presented in this thesis describes the advances in the field and the exploration of 
pyrimidium N-heteroaryl aminides as building blocks in the formation of several fused 
imidazoheterocycles. 
From the initial discovery of this reaction and its application in the synthesis of 
imidazo[1,2-a]pyrimidines, the scope of this convergent gold-catalysed strategy has 
been adapted to allow the access to fourteen classes of biologically relevant structures. 
The proposed mechanism and optimisation will be discussed alongside the 
accommodation of a wide range of useful functionalities difficult to introduce by other 
methodologies. 
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Nitrogen-containing heterocycles are prevalent scaffolds in nature, with a fundamental 
role in living systems and as synthetic frameworks.
1
 Particularly, the family of the fused 
imidazoheterocycles contains many biologically relevant structures,
1b
 as demonstrated 
by their ubiquity in several commercially available drugs such as Alpidem,
1c
 Divaplon 
or Zolpidem
1d
 (Figure 1). Thus, C–N bond forming strategies that provide rapid and 
efficient routes for the assembly of these systems are actively pursued.
2
 
 
Figure 1: Commercially available drugs based on the fused imidazoheteroaryl scaffold 
The present thesis explores the design and development of a novel type of reactivity that 
has been successfully employed in the synthesis of several of these fused 
imidazoheteroaryl scaffolds in a modular and convergent fashion. This apporach offers 
a common, simple and practical route to access valuable frameworks. 
1.1 Nitrene transfer processes  
The use of nitrenes as reactants represents one of the most direct approaches to 
introduce nitrogen into a molecule. These neutral monovalent species with six valence 
electrons are highly reactive and prone to insert into various types of bond, giving 
access to aminated products (Scheme 1).
3
 However, due to their reactive nature they can 
show poor discrimination and selectivity. Thus, nitrenes are more commonly employed 
as part of a metal complex. Rhodium, ruthenium or copper, among other metals, often 
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appear catalysing reactions such as C–H amination and aziridination that have 
extensively been exploited in the synthesis of nitrogen-containing structures.
3,4
 
 
Scheme 1: Nitrene and metallanitrenes for the C–N bond formation 
A common route for the generation of these metallanitrenes follows the formation of a 
iminoiodane precursor 6 obtained by reaction of a carbamate or sulfamate with 
iodine(III) oxidants such as PhI(OAc)2 (Scheme 2). The interaction between 
iminoiodane 6 with a suitable metal species generates complex 7 in situ which may 
undergo several important processes (e.g. stereospecific insertion into tertiary C–H bond 
8).
5
 This strategy has seen used in some late stage transformations in the total synthesis 
of several natural products such as (-)-tetrodoxin (Scheme 2).
6
  
 
Scheme 2: Generation of metallanitrenes and their application in C–H insertion reactions 
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As an alternative to the use of metallanitrenes as nitrene transfer agents, other species 
have been developed that display similar chemical reactivity, known as nitrene 
equivalents or nitrenoids. Certain controversy exists regarding the actual definition of 
the term nitrenoid. While Marek and co-workers postulate that only organometallic 
species carrying both an electrofuge and a nucleofuge (Scheme 3) should receive that 
denomination 11-13,
7
 compounds such as iminoiodinane 6, iminophosphoranes and 
metallanitrenes are frequently referred to as nitrenoids in literature.
8
 In any case, most 
of these compounds have in common their application as electrophilic amination 
reagents. For the purpose of this thesis, nitrenoids are defined as relatively stable 
compounds able to behave as source of nitrene character over the course of the reaction. 
 
Scheme 3: Nitrenoid structures as defined by Marek and co-workers
9
 
The advent of π-acid catalysis has facilitated the development of novel strategies for the 
direct formation of C–N bonds.10 A particularly attractive emerging aspect within the 
field relies on the generation of α-imino metal carbenes 21 as synthetic intermediates in 
powerful ring-forming transformations (Scheme 4).  
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Scheme 4: Reactivity basis for the generation of α-imino metal carbenes through the use of 
nucleophilic nitrenoids 
These species can be accessed by coordination of an alkyne 17 to a π-acidic metal, 
giving an electrophilic π-system 18 able to interact with a suitable nitrogen-based 
nucleophile 19. The resulting vinyl metal carbenoid 20 may evolve to the α-imino metal 
carbene 21 by elimination of a leaving group on the nitrogen atom (LG). Subsequently, 
intermediate 21/21’ can be trapped through different pathways (e.g. 1,2-migration, 
cyclopropanation, C–H insertion, 4π-electrocyclisation) to access the desired 
framework. Overall, the whole sequence can be seen as a nitrene transfer process where 
compound 19 behaves as a nucleophilic nitrenoid. It must be noticed that these 
compounds are stable and isolable species and the nitrene character is only invoked on 
π-activation of the triple bond: by first donating an electron-pair (triggering the 
development of carbenic character adjacent to the newly formed carbon-nitrogen bond 
20) and then losing a nucleofuge as the intermediate metal carbenoid species evolves.  
Interestingly, metallanitrenes intermediates can also lead to related α-imino metal 
carbenes by reaction with π-systems, although these nitrene equivalents present a 
contrasting electrophilic behaviour.
11
 For instance, the sulfamate-derived rhodium 
nitrene from 22 may intramolecularly cyclise into intermediate 23, in equilibrium with 
α-imino rhodium carbene 24 through a 1,3-shift (Scheme 5).11b 24 may then be trapped 
by the tethered functionality which rearranges into the isolable N-(sulfonyl)imine 26. 
Alternatively, this imine can be reduced to the more stable amine 27 in good yield.  
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Scheme 5: Metallanitrenes in the generation of α-imino metal carbenes 
The use of nucleophilic nitrenoids through π-acid catalysis provide a new paradigm in 
the formation of aza-heterocycles due to their versatility and sought-after features such 
as mild conditions, simple reaction set-ups and work-ups, good atom economy and 
generally robust precursors. A review on these areas as contained in the present Chapter 
was published in: P. W. Davies and M. Garzón, Asian. J. Org. Chem. 2015, 4, 694–708. 
1.1.1 Gold carbenes 
Over the past decade, the development of transformations involving gold catalysis has 
seen remarkable growth accounting for the specific carbophilic nature and stability 
towards air and moisture that these metal complexes provide. The selectivity for π-
bonds ensures a superb functional group compatibility which has been exploited in the 
synthesis of several complex motifs.
12
  
α-Oxo gold carbenes 28 are particularly appealing building blocks due to their 
selectivity and high reactivity towards different nucleophiles. These versatile 
intermediates have been largely accessed through the metal-catalysed decomposition of 
α-diazo carbonyl compounds 29.13 Attending to the hazardous and potentially explosive 
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character of these precursors, more recent diazo-free alternatives involving the use of 
alkynes have been gathering notable interest. A number of tethered functional groups, 
including sulfoxides,
14
 oximes/nitrones,
15
 amine N-oxides,
16
 and nitro groups
17
 have 
been employed as oxidants assisting the internal formation of α-oxo gold carbenes.12a 
The intermolecular generation of gold-carbenes will be discussed in more depth in 
Chapter 2. 
 
Scheme 6: Common strategies for the synthesis of α-oxo gold carbenes 
In contrast with α-oxo gold carbenes 28, the nitrogen version has received less extensive 
attention due to the limitations in their synthesis from diazo precursors, which are 
unstable compounds prone to undergo cyclisation to 1,2,3-triazoles.
18
 The recent use of 
nucleophilic nitrenoids under gold catalysis has provided a powerful tool for the 
generation of α-imino gold carbenes 38 in the assembly of valuable nitrogen-containing 
heterocycles (Scheme 7). 
Chapter 1 
8 
 
 
Scheme 7: Nucleophilic nitrenoids in the formation of α-imino gold carbenes through gold catalysis 
In many transformations described in this chapter gold-carbon double bond 38 and 
metallated carbocation 38’ have been employed indistinctly to indicate the carbenic 
reactivity, regardless of the dominant resonance form. The nature and nomenclature for 
the C–Au bond in various intermediates is a subject of continuing debate.19 Due to the 
mixture of π and σ character of these complexes, the actual bonding in the reactive 
intermediate is going to be greatly influenced in each case by the ligands in the metal 
and the coordinated organic fragment. Differences in bond distances, orbital 
participation or charge distribution across related metal-carbon species may have an 
impact in the resulting reactivity and chemo-/regioselectivity.  
Strong σ-donors and weak π-acid ligands (e.g. NHCs, electron-rich phosphines) will 
give more electron density to the gold centre, increasing the gold-to-carbon π-
backbonding and resulting in a carbene-like reactivity (Scheme 8 – Top, bonding model 
proposed by Toste
19d
). This is exemplified in the work of Toste et al.,
19d
 where a typical 
carbene behaviour, the stereospecific cyclopropanation of cis-stilbene 39, is 
progressively encouraged by the σ-donating ability of the ligand (Scheme 8 – Top). By 
contrast, π-acceptor ligands such as phosphites and electron-poor phosphines reduce the 
electron density on the gold to be donated into the carbon centre, favouring the 
carbocation resonance form 38’. 
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Scheme 8: Top: Bonding model for gold carbenes and cyclopropanation of cis-stilbene; Bottom: 
Friedel-Craft-type alkylation of arenes induced by electrophilic gold(I) species 
This is beautifully represented in the carbophilic addition of α-diazoesters 42 published 
by Lan and Shi (Scheme 8 – Bottom).20 Here, an electrophilic gold(I) catalyst 
completely switches the reactivity of a substrate that otherwise presents carbenic 
character in the presence of rhodium or copper complexes (45 and 46 respectively). 
The recent isolation and inspection of the crystalline structure for complex 47 in the 
solid state led Fürstner and Seidel to propose an alternative bonding model (Figure 2).
19b
 
Based on the long C–Au distance (2.039(5) Å) and shortening of the C–C bonds 
adjacent to the gold from the aromatic substituent (1.429(7) and 1.444(6) Å), they 
suggested that there is not significant back-donation from the gold and instead, the 
carbenic centre is π-stabilised by the organic fragment 47’. The model is supported by 
DFT calculations in other gold-complexes. 
19e
 However, in complex 47 the structure is 
stabilised by the presence of strongly-donating groups. As Echavarren and co-workers 
pointed out: “Predictably, in cases in which the carbene centre cannot obtain sufficient 
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stabilization from substituents, the back-donation from gold is a source of stabilization, 
and the gold carbene bonding model is still a pertinent representation.”19a 
 
Figure 2: Bond lengths in the solid-state structure for compound 47 and the proposed 
representation of the bonding. The counterion [NTf2]
-
 is not shown 
Additionally, it should be kept in mind that while α-imino gold carbene 38 is often 
invoked as the species responsible for the evolution to the final structure (Scheme 7), 
vinyl gold carbenoid 37 also has electrophilic character. Therefore, reaction at the 
carbon centre could proceed from either intermediate.  
1.1.2 Nucleophilic nitrenoids 
The development of synthetic transformations employing nucleophilic nitrenoids can be 
traced to the Schmidt-type reaction with alkyl azides (Scheme 9),
21
 where a carbocation 
51 generated from the Brønsted or Lewis acid activation of a carbonyl, alkene or 
alcohol 48-50 is attacked by an azide group 52. The subsequent 1,2-migration onto the 
nitrogen centre 53 proceeds with elimination of N2, leading to the formation of two new 
carbon-nitrogen bonds 54. The potential of this reaction in nitrogen heterocycle 
synthesis can be seen in the work done by Aubé
21e
 and Pearson
22
 (Scheme 10) for the 
generation of fused scaffolds from the ring expansion of an alkyl azide-substituted 
cyclic ketone 55 or exocyclic alkene 58 respectively.  
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Scheme 9: Reactivity basis of the Schmidt-type reaction 
 
Scheme 10: Schmidt-type reaction in the synthesis of nitrogen-containing heterocycles 
Adapting this concept to gold-activated triple bonds allows combining the versatility of 
alkynes as building block with the excellent functional group compatibility associated 
with gold catalysis, providing a remarkable tool for the assembly of complex scaffolds. 
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1.2 Intramolecular reactions 
1.2.1 Azides as nucleophilic nitrenoids 
The gold-catalysed intramolecular cyclisation of homopropargyl azides 63 under gold 
catalysis reported by Toste and collaborators (Scheme 11) represents the first example 
of α-imino gold carbenes generated from the action of a nucleophilic nitrenoid.23 
Analogously to a Schmidt-type process, coordination of the metal to the triple bond 64 
triggers the nucleophilic addition of the azide in a 5-endo-dig fashion, giving vinyl gold 
carbenoid 65. This intermediate extrudes N2, evolving into a gold carbene 66 that 
undergoes a 1,2-migration from the adjacent methylene or methine position as the 
elimination of gold regenerates the catalyst. The resulting 2H-pyrrole 67 tautomerises to 
the desired pyrrole 68.
24
 
 
Scheme 11: Synthesis of substituted pyrroles from homopropargyl azides 
The reaction tolerated different primary and secondary azides alongside with alkyl- and 
aryl-substituted alkynes and could be adapted for the synthesis of tetrahydroindoles 69. 
Chapter 1 
13 
 
The excellent chemoselectivity discriminated between 1,5-azido-alkyne over a 1,5-
enyne, as seen in the formation of compound 70. 
Iterations on this concept using different alkynyl azides have been employed in the 
synthesis of other useful heterocyclic frameworks (Scheme 12).
17,23,25
 
 
Scheme 12: Top: Tandem cyclisation-ring expansion. Bottom: Synthesis of isoquinoline scaffolds 
through a 6-endo-dig cyclisation of 2-alkynylbenzyl azides 
Once the α-imino gold carbenes intermediate is formed, it can evolve following other 
pathways to the 1,2-migration. Zhang and co-workers took advantage of alkynes 
conjugated to an electron-deficient alkene 76 (Scheme 13)
26
 in order to first 
regioselectively direct the intramolecular attack of an azide group following a desired 5-
exo-dig cyclisation (77→79). Secondly, on formation of 80, the intermediate undergoes 
a 4π-electrocyclic ring closure to give the bicyclic pyrrole 82. Alternatively, external 
nitriles were later employed to capture the reactive species 80 giving analogous fused 
imidazole systems.
27
 
A thermally-induced [3+2]-dipolar cyclisation to the triazole 78 was observed 
competing with the formation of the α-imino gold carbene 80 on increase of the length 
of the tethered azide (n > 1). The yields of this by-product could be reduced by using 
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the azidoenyne precursor 76 immediately after purification along with a higher catalyst 
loading. 
 
Scheme 13: Tandem cyclisation-ring closure for the synthesis of 2,3-dihydro-1H-pyrrolizines 82 
The groups of Zhang and Gagosz independently reported the reaction of 2-alkynylaryl 
azides 83 under gold catalysis as means to generate an electrophilic carbenic 
intermediate 86/86’, that could be trapped by both internal and external nucleophiles to 
deliver substituted indole derivatives 89 (Scheme 14).
28
 This can be seen as an 
umpolung process, where the typical nucleophilic character at the C3 position of the 
indole is reversed in 86/86’. The scope of nucleophiles included several aromatic and 
heteroaromatic systems as well as alcohols and enolates. Interestingly, trapping of the α-
imino gold carbene species 86 with allylic alcohols 87 triggered a Claisen 
rearrangement to the 2,2-disubstituted indolin-3-one 88.
29
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Scheme 14: Synthesis of substituted indoles 89 and indolin-3-ones 88 from 2-alkynylaryl azides 83 
 
Scheme 15: Gold-catalysed cascade cyclisation of 2-azidoaryl ynamides 90  
A particularly impressive variation of this concept was achieved by modifying the 2-
alkynylaryl azides precursor incorporating an ynamide 90 (Scheme 15).
30
 As a result, a 
wide range of different N-tethered functionality could be employed to capture the 
incipient α-imino gold carbene (via C-H insertion onto aryl- 92 and heteroaryl groups 
94 or cyclopropanation 96/98), providing a simple route for the assembly of several 
indole-fused polycyclic frameworks. 
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Scheme 16: Gold-catalysed synthesis of substituted quinolines from 2-alkynylaryl azides 
Interestingly, by using propargylic carboxylates 100 the reactivity of the gold-activated 
2-alkynylaryl azides 101 can be directed away from the α-imino gold carbene and 
towards a rearranged gold-allenoxy complex 102 that undergoes a 6-endo-trig 
cyclisation 103. The subsequent 1,2-shift from the adjacent substituents can happen 
either simultaneous (103→105) or after the extrusion of N2 (103’→104→105), giving 
functionalised quinolines 106 on release of the gold species. Precursors with two 
different propargyl substituents (R
2
 ≠ R3) afforded mixtures of regioisomers with ratios 
according to the migratory aptitude of each group (H > vinyl > alkyl > Me). 
1.2.2 Azirines as nucleophilic nitrenoids 
In addition to azides, 2H-azirines 107 have also been used as nucleophilic nitrenoids in 
the intramolecular generation of α-imino gold carbene species (Scheme 17).31 In this 
case, after the addition onto the π-acid activated alkyne 108, the nucleofuge-elimination 
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step is replaced by the opening of the strained three-membered ring 109, leading to the 
familiar vinyl gold intermediate 110. 
 
Scheme 17: 2H-azirines in the gold-catalysed intramolecular synthesis of functionalised pyridines 
2-Propargyl-2H-azirines 113 were prepared following a two-step procedure from 
carbonyl 112 through the oxime. On activation by gold 114, a 5-endo-dig cyclisation is 
triggered giving 116. It was proposed that the cationic charge in 116 could be stabilised 
by the overlapping with the vinyl gold π-system (represented in 115). The intermediate 
then follows a ring fragmentation and 1,2-migration in either a sequential 
(116→117/117’→119) or concerted manner (116→118→119) giving polysubstituted 
pyridines 120 after elimination of gold. The concerted pathway is more supported by the 
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authors as well as by DFT calculations.
32
 A great number of different substituents were 
tolerated in azirine scaffold, propargylic position and alkyne. 
1.3 Intermolecular reactions 
1.3.1 Aminides as nucleophilic nitrenoids 
As seen above, previous routes for the generation of α-imino gold carbenes in the 
synthesis of N-heterocycles required a link between the alkyne and the nucleophilic 
nitrenoid in order to control the cyclisation. Davies and co-workers were the first ones 
to realise that a suitable functionality (represented by Z, Scheme 18) could be 
incorporated into the nitrene equivalent 121, trapping the carbenic centre immediately to 
the formation of intermediate 122/123.
33
 As a result, nitrogen containing cycles 124 can 
be accessed in a formal cycloaddition process. This convergent approach enables the 
use of versatile precursors that allow the synthesis of complex nitrogen-containing 
heterocycles.  
For this strategy, pyridinium N-acyl
33,34
 and -heteroaryl
35
 aminides 125 were employed 
as nucleophilic nitrenoids that on addition to the gold-activated π-system, eliminate a 
pyridine leaving group to reveal the carbenic character. By its interaction with the 
tethered heteroatom (Y in Scheme 18), polysubstituted oxazole 127-128 and fused 
imidazole motifs 129 are generated in an efficient and general manner. The process can 
be seen as a formal [3+2]-dipolar cycloaddition where the aminide behaves as N,O- and 
N,N-dipole equivalents. Ynamides and indolylalkynes were employed as π-systems that 
coordinate to gold, introducing regiocontrol in the addition of the nucleophile due to the 
predictable reactivity that these compounds provide (Scheme 28 and Scheme 35).  
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Scheme 18: Aminides as nucleophilic nitrenoids in ring-forming reactions 
The following intermolecular ring-forming methodologies build upon this idea of 
envisioning the reaction as a formal dipolar cycloaddition. A more thorough analysis of 
aminides as nitrene equivalents will be further discussed in Chapter 2 as it is the main 
topic of the present thesis. 
1.3.2 Isoxazoles and azirines as nucleophilic nitrenoids 
The following two nucleophilic nitrenoids are combined in the same section due to their 
similarities in mechanism and resulting products. Both strategies are based on a formal 
[3+2] dipolar cycloaddition onto a π-activated alkyne 130 where the addition and 
subsequent ring opening of isoxazoles
36
 131/133 or azirines
37
 134 lead to 
polysubstituted pyrrole scaffolds 132/135 through an intermediate α-imino gold carbene 
(Scheme 19). Ynamides 139 are employed again (cf. Scheme 18) as electronically 
biased triple bond in order to introduce regiocontrol in the intermolecular process. 
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Scheme 19: Nucleophilic nitrenoids in the intermolecular synthesis of pyrrole derivatives 
 
Scheme 20: Proposed mechanism for the isoxazole-based synthesis of 2-aminopyrroles 
In the isoxazole system (Scheme 20),
36
 nucleophilic attack of the heterocycle 131/133 
onto the gold-activated ynamide 130 forms the vinyl gold carbenoid species 136. N–O 
bond cleavage gives intermediate 137 which cyclises to acylpyrrole 138. Following 
deauration to 140, this system can evolve into two different products depending on the 
substitution pattern in the isoxazole precursor. The 3,5-disubstituted species 131 (R
4
 = 
H) undergoes a hydride shift affording 4-acylated-2-aminopyrroles 132. Trisubstituted 
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isoxazoles 133 (R
4
 ≠ H) are suggested to follow a water-aided deacylation to provide 
aromatisation 135. 
Analogous to the intramolecular version (Scheme 17), the reaction between azirines 134 
and gold-activated ynamides 130 are proposed to evolve into the cyclic intermediate 
143 (Scheme 21) either by direct addition of the gold-enamide moiety to the azirine 2H-
position (141→143) or by stepwise, gold-assisted N–C bond cleavage to give a α-imino 
gold carbene intermediate that undergoes a 4π-electrocyclisation 
(141→142/142’→143).37 
 
Scheme 21: Proposed mechanism for the 2H-azirine-based intermolecular synthesis of 2-
aminopyrroles 
Overall, both nucleophilic nitrenoids can be seen as 1,3-N,C-dipole equivalents in a 
formal cycloaddition process. Substantial structural variations and functionality can be 
tolerated in each of the constituents, although ynamides with straight-chain aliphatic 
groups are prone to undergo competitive 1,2-C–H insertion pathways to the α,β-
unsaturated amines. This feature will be also characteristic of other intermolecular 
reactions with nucleophilic nitrenoids discussed in Chapter 2. 
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Interestingly, Liu and co-workers found that 2-aminopyrrole products 147 afforded by 
reactions with 2-ester-substituted 2H-azirines 145 (X = CO2Et) presented a divergent 
regioselectivity consistent with the cleavage of the azirine Cα–N bond (Scheme 22).
38
 
According to the proposed mechanism, the intermediate 145 would undergo a 1,2-
hydrogen shift 146 followed by addition and ring opening. The formation of a single 
regioisomer 147 rules out an intermediate α-imino gold carbene (i.e. 142 in Scheme 21) 
as this requires the cleavage of the Cβ–N. This is further supported by the formal [4+3] 
cyclisation observed when aryl-ynamides bearing electron-donating groups were 
employed (149→150), giving 1H-benzo[d]diazepines 151. 
 
Scheme 22: Diversity in the formal cycloaddition with 2H-azirines 
1.3.3 Azides as nucleophilic nitrenoids 
Following the development of the aforementioned azirine-based strategy for the 
synthesis of pyrroles, several groups simultaneously envisioned vinyl azides as opened 
azirines and therefore able to provide a vinyl nitrene/1,3-N,C-dipole reactivity in the 
synthesis of analogous 2-aminopyrroles and 1H-benzo[d]diazepines.
37-39
 While the 
precise mechanism is not fully clear yet, Liu and co-workers proved that vinyl azides 
153 undergo a thermally-induced cyclisation to the 2H-azirines 154 upon heating 
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(Scheme 23, Top).
38,40
 Hence, it is possible that the actual reaction intermediate is again 
the three-membered ring.  
It is noteworthy that Huang’s conditions applied to 2H-azirine 160 (Eq. 2) gave a much 
lower yield of the resulting 2-aminopyrrole 159 than with vinyl azide 157 (Eq. 1),
39
 fact 
that was attributed to the partial poisoning of the gold catalyst by the more nucleophilic 
aza-heterocycle 160. 
 
Scheme 23: Vinyl azides in the intermolecular synthesis of pyrroles. Top: Thermally-induced 
formation of 2H-azirines. Bottom: Comparison of the reactivity between 157 and 160 
A more direct use of azides as nitrene transfer reagent in intermolecular reactions was 
developed by Lu and Ye,
41
 by employing benzyl azides 162 in combination with gold-
activated ynamides 161 (Scheme 24). Analogously to the work done by Ohno and 
collaborators using 2-azidoaryl ynamides (Scheme 15),
30a
 the generated α-imino gold 
carbene intermediate 164 is trapped by the functionality attached to the ynamide (i.e. 
C-H insertion into an aryl group), giving in this case polysubstituted 2-aminoindole 
derivatives 167.  
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Scheme 24: Intermolecular azide-based synthesis of 2-aminoindoles and 3-amino-β-carbolines 
Additionally, the reaction can be adapted to indolyl azides 168, where the nucleophilic 
C3 position of this heterocycle captures the gold carbene 170, leading to 3-amino-β-
carbolines 169. Use of an external oxidant such as AgOAc proved beneficial for this 
reaction, giving in some cases near quantitative yields of the desired product.  
Surprisingly, there are no mentions to the formation of a competitive 1,2,3-triazole 
product, found in other reactions involving azides and triple bonds (cf. Scheme 13).
42
 
This could be related with a quick generation of the intermediate 165, which 
circumvents the dipolar cycloaddition pathway. 
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1.3.4 Other nucleophilic nitrenoids 
In addition to the previously covered nitrene transfer reagents, two recent 
methodologies showcase the use of novel nucleophilic nitrenoid types in intermolecular 
reactions with the added feature that non-heteroatom-polarised gold-activated alkynes 
(i.e. ynamides or 3-indolylalkynes) are required for the control of the regiochemistry. 
The first one is a variation of the isoxazole-based strategy (Scheme 20)
36
 where 
anthranile derivatives 171 (i.e. benzo[c]isoxazoles) are employed to access the α-imino 
gold carbene 174 (Scheme 25).
43
 The electrophilicity of this intermediate triggers an 
ortho-aryl C–H insertion to furnish 7-formyl indoles 173.  
 
Scheme 25: Anthraniles in the intermolecular synthesis of 7-formyl indoles 
Terminal ynamides were mainly employed as π-systems to coordinate the gold catalyst. 
While aryl-substituted ynamides also underwent smooth conversion to the target 
product, alkyl-substituted systems afforded unsaturated products consistent with 1,2-C–
H insertion. Additionally, terminal/symmetrical alkynes 176 underwent reaction with 
anthranile 175, although these less reactive triple bonds required higher temperatures 
and substoichiometric amounts of MsOH (believed to facilitate the deauration process) 
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to reach moderate yields. Interestingly, a competing hydride shift pathway was not 
observed with alkyl-substituted terminal alkynes. 
 
Scheme 26: Proposed mechanism for the gold-catalysed synthesis of 2-imidazolyl-1-
pyrazolylbenzene scaffolds 
Finally, Ballesteros and collaborators work unveiled azomethine imine-type 
heterocycles 181
44
 as nucleophilic nitrenoids in the synthesis of 2-imidazolyl-1-
pyrazolylbenzene scaffolds 189 (Scheme 26).
45
 These complex heterocycles are the 
result of a cascade multicomponent reaction where an N-propargyl benzotriazole 
precursor 178 undergoes an initial gold-catalysed 5-endo-dig cyclisation (179→180) 
generating an isolable triazapentalene derivative 181. This compound reacts with a 
second gold-activated alkyne to give an α-imino gold intermediate after N–N bond 
scission (184→185) which is trapped by an external nitrile 186. Intramolecular ring 
Chapter 1 
27 
 
closing (187→188) forms the imidazole part of the molecule which is sequentially 
treated with MsOH (to aid the protodeauration) and base to afford the desired product 
189.  
Overall, this is a highly efficient and atom-economic process where 4 new C–N bonds 
are created in a single pot. 
1.4 Conclusions 
In summary, gold carbenes are highly versatile intermediates that provide a quick and 
efficient route for the synthesis of a wide range of diverse scaffolds. The development 
of novel nucleophilic nitrenoids through gold catalysis has resulted in the flourishing of 
many methodologies to access previously elusive α-imino gold carbene reactivity 
patterns. The evolution of these species through subsequent 1,2-migration, 
cyclopropanation, C–H insertion or 4π-electrocyclisation pathways allow the 
assembling of valuable nitrogen-containing heterocycles. These transformations are 
characterised by a superb functional group compatibility, excellent chemoselectivity and 
efficiency. 
The number of nucleophilic nitrene transfer reagent has undergone a remarkable growth 
over the last years. The early work in the field has been dominated by intramolecular 
reactions where azide-substituted substrates were employed to direct the cyclisation 
towards the synthesis of pyrroles, quinolines and indole derivatives. Analogously, the 
use of 2H-azirines has facilitated the formation of polysubstituted pyridines. More 
recently, these processes have been complemented with intermolecular strategies using 
pyridinium N-aminides, 2H-azirines, isoxazoles, azomethine imines or vinyl/benzyl 
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azides in the synthesis of five-membered heteroaromatics. The combination of these 
nitrene equivalents with π-activated triple bonds can be seen as a formal cycloaddition 
process, where electronically-biased alkynes are generally exploited to establish 
regiocontrol in the addition. 
The present thesis explores the development and study of one of these families of 
nucleophilic nitrenoids as well as their application through gold-catalysis in the 
synthesis of novel N-cyclic scaffolds and influence in following methodologies. 
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2.1 Site-specific generation of gold-carbenes 
Over the previous chapter the use of nitrene transfer reactions onto gold-activated 
alkynes have been shown as a particularly fertile area for the synthesis of complex aza-
heterocycles. Early strategies in this field relied on intramolecular cyclisation modes in 
order to selectively direct the formation of the versatile α-imino gold carbene 
intermediate.  
 
Scheme 27: Gold-activated alkynes in the intermolecular generation of α-oxogold carbenes 
The development of intermolecular processes stems from the work done in site-selective 
generation of α-oxo gold carbene from gold-activated alkynes. Zhang and collaborators 
first demonstrated that pyridine-N-oxides 191 could be used as intermolecular oxidants 
in the generation of oxetanones 196 and dihydrofuranones 198 from propargyl 195 and 
homopropargyl alcohols 197 respectively (Scheme 27).
46
 Similarly to the reactivity-
basis previously discussed for nucleophilic nitrenoids (Scheme 7), coordination to gold 
renders the alkyne electrophilic 190, allowing attack of the oxidant. Subsequent loss of 
pyridine derivative 193 leads to the reactive α-oxo gold carbene 194 which can be 
captured by the tethered alcohol giving the desired cycle. By using terminal alkynes the 
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carbenic centre in 192 was selectively formed on the terminus of the triple bond 
introducing control over the size of the ring. 
In order to establish regiocontrol for the addition of the oxidant onto internal alkynes 
Davies and co-workers proposed ynamides 139 as suitable substrates for the gold 
catalysis.
47
 In these compounds, the contribution of the gold keteniminium resonance 
form 199 to the structure of the metal-activated π-system creates an electronic bias 
across the triple bond (Scheme 28 – Top). As a result, the attack of the nucleophile is 
directed selectively to the α-position of the ynamide 200.  
 
Scheme 28: Top: Gold-activated ynamides in site-selective formation of α-oxo gold carbenes; 
Bottom: Gold-catalysed synthesis of α,β-unsaturated imines and carboxylic ester 
This concept was adapted to the generation of α-oxo gold carbenes by using alkyl-
substituted ynamides 201 (Scheme 28 – Bottom). Unlike preceding methodologies, no 
Brønsted acid was required to obtain productive catalysis and commercially available 
pyridine-N-oxide 202 could be used as external oxidant. Interestingly, on formation the 
metal carbene undergoes a 1,2-C–H insertion into an adjacent C(sp3) position, allowing 
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the regioselective synthesis of valuable α,β-unsaturated imides 203. The E-isomer was 
the predominant or sole product formed. The reaction tolerated a wide range of 
substituents and could be extended to highly reactive ynol ethers 204 in place of 
ynamides, giving α,β-unsaturated carboxylic ester 205. A similar reaction was 
independently reported by Zhang and co-workers where sterically biased all-carbon 
substituted alkynes were used.
46c
 
2.1.1 Pyridinium aminides in nitrene transfer reactions 
Concurrently in time to the previous transformation (Scheme 28), Li and Zhang 
published a gold-catalysed ynamide-based methodology for the site-specific generation 
of α-imino gold carbenes 209.48 These intermediates were obtained by reaction of alkyl-
substituted ynamides 206 with N-tosyl pyridinium N-aminide 207, undergoing an 
analogous 1,2-C–H insertion process for the synthesis of α,β-unsaturated amidines 210. 
Again, addition of the nucleophile into the gold-activated ynamide is regioselective. 
This is the first reported example of pyridinium N-aminides being used as 
intermolecular nitrene transfer reagents.
49
  
 
Scheme 29: Gold-activated ynamides in site-selective formation of α-imino gold carbenes 
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The 1,2-C–H insertion reaction of a putative gold-carbene (i.e. 209→210 in Scheme 29) 
is one of several quenching pathways. Concurrently with the above mentioned 
methodology, Davies and co-workers proposed the formation of α-imino gold carbenes 
as basis for a formal [3+2]-dipolar cycloaddition strategy, leading to a convergent 
synthesis of trisubstituted 1,3-oxazoles 213 (Scheme 30).
33
 Here, pyridinium N-acyl 
aminides 211 are similarly employed as nitrene transfer reagents for the reaction with 
gold-activated ynamides. Additionally, after initial attack of the nucleophile 211, the 
acyl residue appended to the nucleophilic nitrogen can capture the resulting 
electrophilic intermediate 221/223 (Scheme 31).  
 
Scheme 30: Gold-catalysed synthesis of trisubstituted oxazoles 
The highly reactive ynol ethers can also be used in place of ynamides as electronically 
biased π-systems that lead to the formation of analogous alkoxyoxazole systems 218. 
Superb chemoselectivity and regioselectivity were obtained with the excellent 
functional group tolerance accounting for a broad substrate scope that includes alkyl, 
vinyl, alkynyl and different aryl and heteroaryl substituents at the three available 
positions of the ring (Scheme 30). This strategy has been recently revisited, expanding 
the substrate scope in every direction while providing a more efficient route for the 
Chapter 2 
34 
 
synthesis of aminides.
34b
 Additionally, the loading of both catalyst and aminide has been 
reduced. As a result, not only have more elaborated systems been accessed, but also 
thio-, N-phosphoramide and N-indole-derived ynamides were employed for the first 
time under gold catalysis. 
 
Scheme 31: Proposed mechanism for the gold-catalysed synthesis of trisubstituted oxazoles 
The proposed mechanism for this reaction is initiated by the regioselective attack of the 
aminide 211 onto the gold-activated ynamide 220, giving the vinyl gold carbenoid 221. 
Several routes are suggested for the evolution of this intermediate. Elimination of the 
nucleofuge in 221 would lead to α-imino gold carbene 223 which could cyclise to 224’ 
either by interaction of the oxygen lone pair with the electrophilic centre (223’→224) or 
undergoing a 4π-electrocyclisation (223→224’). Considering the tolerance of this 
strategy towards alkyl groups adjacent to a metal-carbene centre (e.g. 215 in Scheme 
30), prone to experience competitive 1,2-insertion reactions (cf. Scheme 29), the authors 
indicate that a fast cyclisation must be occurring. Therefore, an alternative pathway is 
also envisioned where vinyl gold carbenoid 221 undergoes a bis-hetero 4π-
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electrocyclisation with concerted scission of the N–N-bond (221→222→224’). The 
oxazole 213 would be finally obtained after deaurative aromatisation of 224’. 
Chatzopoulou and Davies proved that this reactivity was not limited to heteroatom-
substituted triple bonds. Using other π-rich systems such as 3-indolyl- or aniline-based 
alkynes 225 all-carbon substituted oxazoles 226 were accessed (Scheme 32).
34a
 Similar 
to ynamides, delocalisation of the more remote nitrogen lone pair across the π-system is 
crucial for the regioselective cycloaddition of these unsymmetrical alkynes. A reactivity 
trend was observed in correlation with the ability of the remote heteroatom to donate 
electron density. Thus, while good yields were obtained from the free indole and aniline 
systems 228-299, no reaction occurred with the m-aniline or p-anisole derivatives 230-
231. Interestingly, a single regioisomer 232 was formed from the reaction with an 
alkyne bearing two nominal directing groups. 
 
Scheme 32: Gold-catalysed synthesis of all-carbon substituted oxazoles from alkynes bearing a 
remote nitrogen atom 
Higher temperatures, longer reaction times and a re-optimisation of the catalyst to 
gold(I) phosphite 227 were required in order to achieve productive catalysis. While 
good yields were obtained by reaction with aryl- and cyclopropyl-substituted 
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alkynylindoles, complex mixtures of oxazole and 1,2-C–H insertion product were 
observed when using alkynylindoles bearing alkyl chains. This may be related to the use 
of more forcing conditions and the different electronic environment around the metal-
ynamide complex.  
2.1.2 Pyridinium aminides as N,O-dipole equivalent 
Conceptually, this transformation can be viewed as formal a [3+2]-dipolar 
cycloadditions where N-acyl aminides 211 are used as N-nucleophilic N,O-dipole 
equivalents. [3+2]-Dipolar cycloadditions reactions are usually accompanied by a series 
of desirable characteristics such as efficiency, simplicity, wide scope, selectivity and 
atom economy; as exemplified by the iconic metal-catalysed synthesis of 1,2,3-
triazoles.
50
 Here, azides are employed as general 1,3-N,N dipoles that in combination 
with activated alkynes offer a straightforward way to connect building blocks 
containing different functionalities. However, adapting this concept to the assembling of 
other azole systems has been limited by the reachability of the required dipole 
equivalents. An alkyne-based [3+2]-dipolar cycloaddition for the synthesis of oxazole 
rings requires the in situ generation of electrophilic acyl nitrenes, induced by either 
thermal or photochemical decomposition of acyl azides.
3,51
 Acyl nitrenes are highly 
reactive and prone to undergo other rearrangement and insertion pathways, which in 
practice make them unsuitable for the cyclisation. A modified methodology has recently 
been published where copper-stabilised acyl nitrenes lead to the formation of 
disubstituted oxazoles.
52
 In stark contrast, N-acyl aminides are bench-stable solids, easy 
to functionalise and handle making them attractive substrates in these cyclisations.
34b
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2.1.3 Pyridinium aminides as N,N-dipole equivalent 
At the start of this PhD the goal was to adapt the aminide-based formal [3+2]-dipolar 
cycloaddition strategy to the synthesis of unexplored imidazole based scaffolds. To this 
end pyridinium N-(heteroaryl) aminides 233 were selected as prospective 1,3-N,N-
dipole equivalents that in combination with a gold-activated alkyne could trigger a 
cycloaddition process (Scheme 33). Similarly to the oxazole-forming methodology 
(Scheme 31) it was initially suggested that these aminides could behave as both 
nucleophilic nitrenoids and reactant to quench the resulting organogold intermediate 
234 (either from a vinyl gold carbenoid or a gold carbene) in the assembly of fused 
imidazoheterocycles 236. Ynamides were again chosen as alkyne derivative in order to 
induce regioselectivity in the addition of the nucleophile. 
 
Scheme 33: Proposed reactivity basis for the gold-catalysed synthesis of fused imidazoheterocycles 
A number of challenges were, nevertheless, anticipated when considering this 
transformation. First, the reactivity of the endocyclic nitrogen in 233 is known to be 
reduced by an intramolecular hydrogen bonding with the α-proton of the pyridine.53 
This could lead to an incomplete catalytic processes where intermediate 234 is unable to 
cyclise to the desired heterocycle. Secondly, the several basic nitrogen atoms present in 
starting materials, products and possible by-products could act as coordination sites for 
the metal, reducing the effective concentration of active species. Despite these possible 
pitfalls, a successful outcome would potentially provide a practical, simple and 
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convergent method for the regioselective synthesis of novel substituted fused 
imidazoles. Part of the work that will be presented in chapters 2 and 3 has been 
previously published in: M. Garzón and P. W. Davies, Org. Lett. 2014, 16, 4850–4853.  
2.2 Results and Discussion 
2.2.1 Preparation of pyridinium N-(pyrimidin-2-yl) aminide 
For the initial study of the proposed reactivity, pyridinium N-(pyrimidin-2-yl) aminide 
239 was selected as a suitable precursor (Scheme 34). This aminide is a bench-stable 
crystalline solid, soluble in several common organic solvents and readily accessible. 
Additionally, the characteristic resonances of the pyrimidine ring in starting material 
and products can be easily tracked in the 
1
H-NMR spectra of reaction mixtures, 
simplifying analysis during the screening process. 
 
Scheme 34: Synthesis of aminide 239 
Following the reported method by Builla and co-workers,
54
 commercially available N-
aminopyridinium iodide 237 was used in combination with 2-chloropyrimidine 238 to 
obtain the desired ylide 239 (Scheme 34). Whilst the reported procedure specified a 
work-up consisting of a filtration through celite followed by flash chromatography in 
silica gel and recrystallization in ethanol, it was noticed that some impurities persisted 
after the purification. Concerned of the effect that such contaminant could introduce in 
the subsequent catalysis, the procedure was slightly modified. Once the reaction reached 
completion it was allowed to reach room temperature. The solvent was removed under 
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reduced pressure and the residue redissolved in dichloromethane as unlike acetonitrile, 
this is not miscible with water. By washing the mixture several times with NaOH [2.5 
M] most of the impurities were removed which suggests that they originate from 
incomplete deprotonation of the exocyclic nitrogen. A final chromatography stage 
ensured the purity of the product.  
2.2.2 Synthesis of functionalised ynamides 
 
Scheme 35: Regioselectivity in the gold-catalysed transformation of ynamides 
The development of ynamides as common building blocks in organic chemistry has 
blossomed over the last decade. The increased used of these systems results from their 
high versatility but also, by the design of more efficient and general methods for their 
preparation.
55
 These compounds have seen extended use in ring-forming reactions,
30b,56
 
including the total synthesis of some natural products,
57
 and more recently in gold-
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catalysed intermolecular transformations, due to the predictable reactivity of their π-
system (Scheme 35).
58
  
Almost all the ynamides used in the following investigation were obtained using the 
copper-catalysed amidative cross-coupling methods reported by Evano,
59
 Stahl,
60
 and 
Hsung (Scheme 36).
61
 These reactions are characterised by mild conditions, high yields 
and excellent functional group tolerance. Furthermore, the versatility and readily 
interconversion between the precursors of each procedure allow generating great 
structural variation from simple starting materials.  
Numerous aldehydes 251 can be converted through the Ramirez olefination,
62
 into the 
dibromoalkenes 252 required for the Evano method (Scheme 36 – Top). The main 
limitation is the use of a high excess of base and the low yields obtained with aniline-
based sulfonamides. 
 
Scheme 36: Synthesis of ynamides through copper-catalysed cross coupling 
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Alternatively, Stahl’s procedure (Scheme 36 – Bottom) employs terminal alkynes 253 
under copper-catalysed oxidative cross-coupling conditions to tether the sulfonamide 
moiety. This offers a more direct methodology as many alkynes are commercially 
available, although again, sophisticated substrates may be synthesised from aldehyde 
precursors using either Corey-Fuchs
63
 or Seyferth-Gilbert
64
 protocols. In order to reduce 
the formation of homocoupling side products, large excess of sulfonamide and slow 
addition of the alkyne (generally added using a syringe pump over 4 hours) are required. 
While it is a more involved procedure, the excess of sulfonamide can be recovered and 
the previously problematic protected anilines are well tolerated. 
Finally, both terminal alkynes 253
65
 and dibromoalkenes 252
66
 can be readily converted 
into the bromoalkynes 254 used in the ynamide forming reaction reported by Hsung 
(Scheme 36 – Middle). These substrates are less stable than the intermediates employed 
in the other two methodologies and they usually cannot be stored for long periods of 
time. The again low reactivity against protected anilines is balanced by an otherwise 
greater tolerance to substitution that even allows the formation of N-phosphoryl
67
 and 3-
indolyl
68
 ynamides (Scheme 38 – 268 and 277 respectively). 
All the sulfonamides were prepared according to literature procedures,
69
 by protection 
of the corresponding amine with mesyl chloride. Biphenyl systems 259 and 3-indolyl 
ynamide 263 were accessed through palladium-catalysed cross-coupling Suzuki and 
Sonogashira strategies (Scheme 37).
70
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Scheme 37: Synthesis of precursors for ynamides  
Overall, a wide range of ynamides covering different structural and electronic variations 
were obtained by combination of the three methods (Scheme 38). 
 
Scheme 38: Ynamides synthesised through copper-catalysed strategies. Method A: Evano; Method 
B: Stahl; Method C: Hsung 
Chapter 2 
43 
 
2.2.3 Catalyst screening 
A reaction survey was initiated using a near equimolar mixture of N,N-methylmesy-
substituted ynamide 264 (1.0 eq.) and aminide 239 (1.2 eq.) under inert conditions, 
where several solvents, temperatures, reaction times, concentrations and catalysts were 
screened. All the reactions were followed by TLC until completion or no further 
progress was detected. The optimal conditions for the oxazole-forming reaction 
(Scheme 30)
33
 were tested initially: Gold(III) precatalyst dichloro(2-
pyridinecarboxylate)gold (PicAuCl2)
71
 in toluene at 90 ºC (Table 1- Entry 1). 
Remarkably, despite the multiple basic nitrogen atoms present in the reaction media, 
productive catalysis was observed with 66% yield after 40 hours of reaction. Formation 
of the desired imidazo[1,2-a]pyrimidine 284 was confirmed by 
1
H-NMR spectroscopy 
(Figure 3 – Top spectrum). However, on attempted isolation of the fused bicycle by 
flash chromatography a small impurity co-eluted (Figure 3 – Bottom spectra). Based on 
the presence of similar resonances for aromatic and aliphatic protons this impurity was 
proposed to be an isomer of the desired product. Analysis of the mixture by HPLC-MS 
allowed the detection of the impurity and confirmed it to be an isomer of 284 although 
the separation between compounds was never enough to use preparative HPLC for their 
isolation. Further attempts to isolate and characterise this isomeric impurity using other 
eluents and recrystallization techniques were not successful.  
The sluggish behaviour of the reaction in toluene was partially attributed to the low 
solubility of the aminide 239. These ylides are fairly polar due to the compensation of 
charges in the structure. As a result, the ynamide 264 degraded after the prolonged 
heating reducing the available concentration to form the imidazopyrimidine. 
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Table 1: Survey of the conditions for the reaction between aminide 239 and ynamide 264
a
 
 
Entry Catalyst Solvent (ºC) Time (h) Rec 264 (%)b  284 (%)b 
1 PicAuCl2 toluene (90) 40 7 66 (4) 
2 PicAuCl2 1,2-DCB (90) 18 - 73 (12) 
3 PicAuCl2 1,4-dioxane (90) 5 - 73 (11) 
4c DTBPAuCl+AgSbF6 1,4-dioxane (90) 24 - 86 
5
c
 (C6F5)3PAuCl+AgSbF6 1,4-dioxane (90) 24 - 76 
6c Ph3PAuCl+AgSbF6 1,4-dioxane (90) 24 30 65 
7c XPhosAuCl+AgSbF6 1,4-dioxane (90) 24 67 8 
8 AgSbF6 1,4-dioxane (90) 24 95 - 
9 227 1,4-dioxane (90) 24 - 88 
10 227 1,4-dioxane (70) 48 7 64 
11 227 1,4-dioxane (50) 48 65 29 
12d 227 1,4-dioxane (90) 22 40 58 
13e 227 1,4-dioxane (90) 24 - 90 
14 - 1,4-dioxane (90) 24 98 - 
15 TFA 1,4-dioxane (90) 24 95 - 
 
a Reaction conditions: Catalyst (5 mol%), 264 (0.10 mmol), 239 (0.12 mmol) heated at the given 
temperature in the named solvent (0.10 M with respect to 264 unless otherwise specified). b Yields 
calculated by 1H-NMR spectroscopy against a known quantity of internal standard (1,2,4,5-
tetramethylbenzene). Yields in parenthesis relate to a co-eluting isomer. c Catalyst formed in situ by 
combination of AgSbF6 (5 mol%) and corresponding gold(I) chloride precursor (5 mol%). 
d 0.05 M 
reaction concentration. e 0.20 M reaction concentration. 
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Figure 3: 
1
H-NMR spectra of 284 isolated from the reaction described in Table 1, entry 3. 
[1] Identification of 284; [2] Spectrum highlighting the signals of the co-eluting impurity 
Therefore, the more polar, high boiling point solvents 1,2-dichlorobenzene (DCB) and 
1,4-dioxane were subsequently screened (Entries 2 and 3 respectively). An improved 
reactivity was seen but, unfortunately, this was accompanied by an increase in the 
formation of the impurity. 
Seeking to improve the selectivity of the reaction, electrophilic gold(I) catalyst 
DTBPAuSbF6 was generated in situ by combination of the corresponding gold chloride 
with AgSbF6 (Table 1 – Entry 4). Interestingly, the total conversion was maintained but 
no by-product was observed in this case, accounting for a higher yield of desired 
product. Other gold(I) species (Entries 5–7) also led to cleaner outcomes, though the 
conversion was dramatically reduced as the electron-donating ability of the ligand 
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increased. Both observations will be discussed later in the proposed mechanism 
(Scheme 44).  
Although no reactivity was accessed using exclusively AgSbF6 as catalytic system 
(Entry 8), different groups have been reporting the non-innocent role played by the 
silver salts in some so-called gold catalysed reactions.
72
 Echavarren and collaborators 
recently detected and isolated a chloride-bridged dinuclear gold(I) complex generated 
when mixing gold(I) precatalyst and silver salt in absence of substrate.
73
 These 
complexes had deleterious effect in the catalysis, thus requiring a careful sequence of 
reagent addition to avoid their formation.  
In order to avoid similar complications, the preformed system 227 was instead used 
which also bypassed the need to weigh and introduce hygroscopic AgSbF6 into the 
reaction. As seen in Scheme 32, 227 has already been successfully used in other gold-
catalysed nitrene transfer reactions, and gratifyingly, a minor increase in the yield was 
produced here compared to the related complex DTBPAuSbF6 (Entry 9 vs Entry 4). 
Diluting concentration or decreasing temperature had a detrimental effect in the system, 
with progressively lower yields and slower reactions (Entries 10–13). Finally, control 
reactions showed that no reaction was observed in the absence of gold or when a 
Brønsted acid was employed in its place (Entries 14–15). 
2.2.4 Studies into the regiochemistry of 284 
The assignment of the structure of 284 was confirmed by nOe experiments. Irradiation 
of the aromatic signal at 7.60 ppm (corresponding to H
4
; Figure 4 – b) showed a nuclear 
Overhauser effect in the adjacent methyl groups of the sulfonamide and also in the 
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proximal pyrimidinic H
3
. The correlation H
4–H3 indicates that the phenyl fragment is in 
3-position of the core heterocycles, proving an attack of the aminide to the α-position of 
the ynamide (Scheme 39). This is further evidenced by the lack of correlation between 
the methyl groups of the sulfonamide fragment and H
3
 (irradiation at 3.35 ppm, Figure 
4– c). 
 
Figure 4: nOe Difference experiments for 284. a) 
1
H-NMR spectrum of 284; b) Irradiation at 7.60 
ppm; c) Irradiation at 3.25 ppm 
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Scheme 39: Confirmation of the regioselectivity of the reactivity to form 284 through nOe 
experiments 
2.2.5 Reaction Scope 
 
Scheme 40: Scope of the reaction between aminide 239 and different ynamides. 
a
 Complex mixture 
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At this point, the scope of the imidazopyrimidine-forming methodology was explored 
by testing a range of different ynamides 264-283 alongside aminide 239 (Scheme 40) 
using the best conditions found during the screening (Table 1, Entry 12). The reactions 
were heated until either total consumption of the ynamide or no further progress was 
detected by TLC (usually 24 h). 
High yields were obtained across a variety of N-substituted ynamides, allowing the 
introduction of N-methyl 284, N-phenyl 287, N-benzyl 288 and even N-phosphoryl 
groups 290. Despite the potential of N-allyl ynamides 302 to undergo aza-Claisen 
rearrangements at high temperatures (Scheme 41),
74
 2-aminoimidazopyrimidine 289 
was obtained in good yield. 
 
Scheme 41: Thermal aza-claisen reaction of N-allyl ynamides 
Substitution at C3 tolerated different aryl groups 291-295, including the bulky o-bromo 
benzene ring 293. This is remarkable as arene fragments have been employed in other 
nitrene transfer reactions to trap α-imino gold carbene intermediates through C–H 
insertion pathways (cf. Scheme 15, Scheme 24 and Scheme 25). Fortunately, no 
competing products were detected even with strong electron-rich systems such as p-
methoxy 292 and o-phenyl-substituted rings 294-295. Similarly, imidazopyrimidines 
bearing π-rich heteroaromatic groups such as thiophene 296, furan 297 and N-
acetylindole 298 were obtained in excellent yields.  
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Conjugated ene-ynamide 278 which can potentially undergo cyclopropanation routes 
into metal-carbenes (e.g. Scheme 15) also gave smooth conversions to the desired vinyl 
heterocycle 299.  
Good yield of the cyclopropyl substituted product 300 was similarly obtained. 
Compared with this system, other alkyl-substituted ynamides proved to be more 
problematic substrates, giving sluggish reactions, partial degradation of the precursor 
and complex mixtures that hampered separation and overall reduced the formation of 
the desired product 301. This was consistent with competing C–H insertion pathways 
previously described in other gold-catalysed nitrene transfer reactions onto 
alkylynamides (Scheme 28).
33,34,48
  
Returning to the reaction survey (Table 1), gold(III) precatalyst PicAuCl2 was observed 
to give faster cycloadditions than the gold(I) complexes under the same conditions 
(Entry 3 vs Entry 9). Expecting to similarly accelerate the reaction with alkylynamide 
280, PicAuCl2 was tested. This resulted in not only an improved rate but also better 
conversions and cleaner outcomes that allowed the isolation and characterisation of the 
sought after heterocycle (Scheme 42). It was proposed that the C–H insertion into the 
alkyl chain is a slower process than the cycloaddition to the fused heterocycle. 
Therefore, the shorter reaction times reduced the formation of side products and 
degradation of the ynamide. Interestingly, no traces of the impurity previously 
encountered during the screening with PicAuCl2 were detected in this case. 
Analogously, other more elaborate alkyl-substituted ynamides 281-283 were introduced 
on the bicyclic scaffold, as demonstrated by the formation of alkyl chloride derivative 
307 and terpene-based citronellal and helional derivatives 308-309. 
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A larger scale synthesis of 309 (0.99 g) was performed using a reduced catalyst loading 
(2 mol%, 22.1 mg). Probably due to the lower concentration of active catalytic species 
this reaction was slower than the one performed with 5 mol% of PicAuCl2 and after 6 
hours part of the starting material remained unconsumed. However the reaction was 
allowed to reach room temperature and purified to prevent the formation of insertion 
products and degradation of the ynamide, giving 309 in a 62% yield. 
 
Scheme 42: Synthesis of alkyl-substituted imidazo[1,2-a]pyrimidines. Yields in parenthesis related 
to those achieved using 227 as catalytic system 
Finally, the strategy was expanded to the use of alkynylindole 310 as an electron-rich π-
system (Scheme 43). These compounds have been employed before as an alternative to 
ynamides in the gold-catalysed synthesis of oxazoles. The addition of the nucleophile is 
similarly determined by the conjugation of the nitrogen lone pair into the gold-activated 
triple bond 311/311’.34a  
A good yield of the desired bis-heteroaryl scaffold 313 was obtained after 24 h of 
reaction at 120 ºC in 1,2-DCB (used instead of 1,4-dioxane to reach the desired 
temperature). Also considering the indole-based structure 298 (Scheme 40), these two 
combined examples showcase the flexibility of the transformation and how it can be 
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finely tuned to regioselectively introduce biologically relevant frameworks into 
different positions of the scaffolds. 
The higher reaction temperature required to achieve productive catalysis when using 
indolylalkynes instead of ynamides was also required in the oxazole-forming reaction 
(Scheme 32). This could be related with a lower contribution of the remote heteroatom 
lone pair into the alkyne due to its additional conjugation into the π-system of the 
aromatic ring. As a result, the electron density of the alkyne would be reduced. 
Considering that these aminide-based nitrene transfer reactions employ π-rich triple 
bonds, the variation in the electronic environment of the coordinated gold would be 
affecting the catalysis. 
 
Scheme 43: Use of electron-rich internal alkynes in the synthesis of biaryl linked products 
2.2.6 Proposed Mechanism 
The successful isolation of imidazo[1,2-a]pyrimidines unveils pyridinium N-(pyrimidin-
2-yl) aminide 239 as a 1,3-N,N-dipole equivalent. By analogy with the oxazole reaction 
(Scheme 31), the suggested mechanism involves the nucleophilic addition of aminide 
239 to the α-position of the gold activated ynamide 130. As discussed before, the 
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selectivity in the attack arises from the electronic difference across the π-system seen in 
the gold keteniminium resonance form 219. 
It is proposed that aminide 239 approaches perpendicular to the plane of the ynamide in 
order to reduce steric hindrance, resulting in vinyl gold carbenoid 314. Reconfiguration 
of the aminide exocyclic nitrogen in 314 aligns the pyridine perpendicular to the π-
system as the pyrimidine fragment is brought into the plane of the aurated carbon centre 
(314→315). The scission of the N–N bond would occur simultaneous with formation of 
the new N–C bond as a positive charge develops across the π-system in a bis-hetero 4π-
electrocyclisation (315→318). A subsequent deauration step delivers the imidazo[1,2-
a]pyrimidine scaffold (318→319) as the aromaticity is regenerated. 
 
Scheme 44: Proposed mechanism for the formation of imidazo[1,2-a]pyrimidines 319 
A more stepwise pathway can also be envisioned where the vinyl gold carbenoid 314 
evolves into an α-imino gold carbene 316 by extrusion of the pyridine leaving group 
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prior to the cyclisation. This electrophilic intermediate can be intramolecularly captured 
by the pyrimidinic nitrogen lone pair leading to 318’. Alternatively, a 4π-
electrocyclisation might also be triggered after liberation of the nucleofuge 
(316→317→318).  
The interaction of the pyrimidine group with the metallated carbon centre (316→318) 
requires the adoption of a cis configuration in the newly formed C–N double bond in 
316. This process might be slowed by the steric clash with the substituents in R
3
 giving 
time for the reactive gold carbene to undergo alternative evolution pathways such as C–
H insertions in adjacent C(sp
3
). However, the preferential formation of cycloaddition 
products in the reaction with alkyl-substituted ynamides (Scheme 42) indicates a fast 
cyclisation probably through the more concerted pathway (314→315→318). 
Additionally, attending to the nature of the metal species, the reaction rate was 
improved with electrophilic gold(I) and gold(III) complexes (Table 1). Therefore, 
formation of gold carbene 316 as the nucleofuge is eliminated by contribution of gold-
to-carbon π-donation in 314 would be a disfavoured process with these catalytic species. 
Returning to the impurity observed in the reaction screening with the gold(III) 
precatalyst PicAuCl2 (Table 1 – Entries 1-3), it was initially proposed to be isomer 286 
(Scheme 45).  
 
Scheme 45: Proposed structure for the isomeric impurity 286 
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Interestingly, imidazo[1,2-a]pyrimidines are known to undergo Dimroth rearrangements 
where, under acid/basic conditions endocyclic and exocyclic nitrogen atoms switch 
places (Scheme 46).
76
 Formation of mixture of isomers through this reaction has had in 
some cases a deleterious impact in development of synthetic processes. An example of 
this can be seen in the synthesis of compound 321, designed as GABAA α2,3-selective 
allosteric modulator, where the last step was hampered by the formation of isomeric 
impurity 322.
77
 Even after an extended screening of conditions a 102:1 mixture of 
isomers was finally obtained, although a subsequent recrystallization step afforded the 
pure compound 321 in 96% yield.  
 
Scheme 46: Isomeric mixture of imidazopyrimidines obtained during the synthesis of GABAA α2/3-
selective agonist 321 and the proposed mechanism through a Dimroth rearrangement
77
 
This rearrangement, nonetheless, can be advantageously exploited in the synthesis of 
the valuable but elusive 2-aminoimidazo[1,2-a]pyrimidine scaffold.
78,79
 Carballares and 
collaborators developed a reaction where 3-substituted isomer 332 was selectively 
converted into the 2-subtituted 333 under basic conditions (Scheme 47 – Top).80 The 
strategy could be coupled with an isocyanide-based multicomponent synthesis of 
imidazopyrimidines,
81
 usually limited by the formation of isomeric mixtures. Although 
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the process tolerates diverse aryl and alkyl substituents, the conversion into the desired 
2-substituted isomer 333 is substrate dependant and the use of basic conditions excludes 
the introduction of more sensitive functionality. The selectivity of this process was 
briefly attributed to a combination of steric and electronic differences between 332 and 
333 due to the presence of the amino group.  
 
Scheme 47: Top: synthesis of 2-aminoimidazopyrimidines through a multicomponent 
reaction/rearrangement sequence.
80
 Bottom: attempted rearrangement reaction 
In an attempt to identify the co-eluting impurity as the 3-amino substituted isomer 286, 
2-aminoimidazopyrimidine 284 was subjected to the reported rearrangement conditions 
(Scheme 47 – Bottom). However, 284 resulted inert and no reaction was observed even 
after prolonged heating. It must be noted that this impurity was not observed in the 
reaction with other aryl- or alkyl-substituted ynamides and this result could have just 
been a misleading one-off with the selected model. As it will be discussed in the 
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following chapter, both PicAuCl2 and 227 can be generally used to catalyse the reaction 
with different aminides.  
2.3 Conclusions 
Pyridinium N-(pyrimidin-2-yl) aminide 239 has been revealed as suitable nitrene 
transfer reagent in the synthesis of novel imidazo[1,2-a]pyrimidines 319. This ylide 
behaves as 1,3-N,N-dipole equivalent in the first example of an alkyne-based [3+2]-
dipolar cycloaddition reaction for the regioselective assembly of substituted imidazole 
scaffolds. The procedure is practical and simple, requiring only the combination of 
stable and readily-accessible precursors without the need of additives or arduous work-
ups, and where the only waste product is pyridine. As a result, generally good to 
excellent yield are obtained, allowing the introduction of challenging and/or otherwise 
unexplored functionality. This strategy can been adapted for the preparation of 
imidazo[1,2-a]pyrimidines at gram scale. 
In the cases where alternative 1,2-C–H insertion pathways were possible (alkyl-
substituted ynamides) the more reactive gold(III) precatalyst PicAuCl2 proved to be 
more effective. Additionally, it has been shown that the reaction is not restricted to 
ynamides as other electron-rich alkynes can be used instead. 
This strategy sets the basis for a nitrene transfer methodology that will be expanded in 
chapters 3 and 4 with the design of new fused frameworks. 
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3.1 Fused imidazoheterocycles 
3.1.1 A common route for the synthesis of fused imidazoheterocycles 
In the previous chapter, the reaction between pyridinium N-(2-pyrimidin-yl) aminide 
239 and a gold-activated π-rich alkyne was introduced as a novel and reliable route for 
the assembling of imidazo[1,2-a]pyrimidines. The chemistry presented in Scheme 46 
already offered a glimpse of the applicability of these scaffolds. Imidazopyrimidines 
and the imidazo-fused diazines/pyridine analogues family are an important class of 
compounds.  
 
Scheme 48: Examples of fused imidazoheterocycles and their biological activity 
For instance, they display an agonist effect against the γ-aminobutyric acid receptor 
(GABAA receptor) which is similar to benzodiazepines, and are used as inhibitors of the 
central nervous system. Therefore, these frameworks are promising lead candidates in 
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the discovery of novel drugs and are recurrent pharmacophores in many molecules with 
potent biological activity such as anticancer,
82
 antiviral,
83
 antimicrobial, antibacterial,
84
 
anti-inflammatory
85
 and/or anxiolytic,
86
 among others. Several of them have progressed 
to market such as Fasiplon
86
 and Zolpidem, based on imidazo[1,2-a]pyrimidine and 
imidazo[1,2-a]pyridine systems respectively (Scheme 48).  
Owing to their attractive therapeutic features as well as their luminescent properties as 
organic materials,
87
 many strategies have been developed over the years for the 
synthesis of these imidazo-fused heterocycles. In particular, assembly of the core 
structure through an aminodiazine/2-aminopyridine precursor tends to be the 
predominant approach. Classical routes are based on substitution or condensation 
reactions with preformed electrophiles such as α-halocarbonyl and 1,3-dicarbonyl 
moieties,
88
 however these methodologies are often compromised by narrow substrate 
scope and the use of lachrymatory and/or difficult to access starting materials.  
Some of these restrictions can be partially circumvented in the three-component acid-
mediated condensation between 2-aminopyridine 334, aldehydes 330 and isocyanides 
331, also known as Groebke-Blackburn reaction (Scheme 49).
89
 The procedure can be 
readily adapted to cover other imidazoazines 339 such as –pyrimidine 329/336, –
pyrazines 335, –isoquinoline 337 and –benzothiazole 338, and is one of the most 
widespread strategies for the synthesis of these imidazo-fused scaffolds. Due to the high 
reactivity of the precursors, the compatibility between substrates restricts the 
possibilities of diversification, limiting the scope of tolerated functionality and, as seen 
in Scheme 47, in occasion leading to mixtures of regioisomers.  
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Scheme 49: Groebke-Blackburn reaction 
Transition-metal-catalysed reactions offer elegant alternatives to the aforementioned 
methods, due to simpler starting materials and better atom economy. This is reflected in 
Scheme 50 where two independent copper-catalysed methods are employed for the one-
pot synthesis of commercially available drugs based on imidazo[1,2-a]pyridine 
scaffolds (Alpidem and Zolimidine). The first example is a three-component coupling 
reaction where formation of intermediate metal-activated propargylic amine 344 
precedes a 5-exo-dig cyclisation to form the fused system 345 (Scheme 51 – Top).90 An 
analogous silver-catalysed intramolecular version of this process was later published by 
Chioua et al.
91
  
The second example is a copper-mediated cyclisation of aryl- and vinylketones 346.
92
 In 
this case, substoichiometric amounts of iodide are oxidised to iodine, in situ generating 
an α-iodoketone that reacts with 2-aminopyridine 341 giving the fused scaffold.87c  
Preliminary results indicated that both reactions can incorporate other substituted 
aminoazines, although the harsh conditions reduce the tolerated substitution.  
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Scheme 50: Copper-catalysed reactions in the synthesis of imidazo[1,2-a]pyridine-based drugs 
The copper-catalysed oxidative cyclisation of 2-aminoazoles 339 with haloalkynes 350 
developed by Gao et al. is one of the most general routes for the synthesis of several N-
bridgehead heterocycles 354 (Scheme 51).
93
 
 
Scheme 51: Synthesis of fused imidazoheterocycles through copper-catalysed oxidative cyclisation 
of haloalkynes 
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Moreover, the narrow substitution scope associated with the instability of haloalkynes 
350 is partially compensated by the possibility of introducing additional functionality 
via subsequent cross-coupling reactions, giving complex structures such as 356. 
A few months prior to the publication of the work described in this thesis,
35
 Toste and 
co-workers reported a gold-catalysed synthesis of imidazo[1,2-a]pyridines 363 (Scheme 
52).
94
 In this reaction, the combination of 2-aminopyridine N-oxide 357 and a metal-
activated triple bond 358 generates a vinyl gold intermediate 359. This evolves into the 
gold carbene 360 by cleavage of the aminopyridine group 361 that subsequently attacks 
the carbenic centre. Intermediate 362, identified in the reaction mixture by LC-MS, can 
be formed by either reaction of a gold carbenoid with the newly formed aminopyridine 
361 or from direct rearrangement of the vinyl gold precursor 359. Final condensation of 
the resulting aminoketone 362 yields the fused scaffold 363. The procedure was 
compatible with a wide range of different terminal alkynes, but failed with internal 
triple bonds. Additionally, the substrate scope was limited to pyridine derivatives due to 
the challenges in the formation of N-oxides from other azines. 
 
Scheme 52: Proposed mechanism for the gold-catalysed synthesis of imidazo[1,2-a]pyridines 
through α-oxo gold carbenoids 
Overall, most of the current strategies for the formation of imidazo-fused heterocyclic 
frameworks have underlying mechanistic similarities and/or have precursors in 
common. Consequently, the resulting compounds present closely related substitution 
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patterns, especially around the imidazole core. This lack of variation in the assembly of 
a structurally diverse family of heterocycles highlights the need for complementary and 
more flexible methodologies. 
At this point of the research project it was considered that the newly developed reaction 
for the synthesis of imidazo[1,2-a]pyrimidines (Scheme 40) could potentially be 
expanded towards other diazine/pyridine-based aminide systems, providing a common 
and general route for the assembly of different fused imidazoheterocycles. 
3.1.2 Pyridinium N-heteroaryl aminides as building blocks 
N-Acyl aminides 211 were presented in chapter 2 as valuable precursors for the 
synthesis of oxazoles (Scheme 30).
34,75
 Not only can they be employed as 1,3-N,O 
dipole but also they have been widely explored in other important transformations such 
as stereoselective reductions,
95
 intramolecular cyclisation with tethered enolates or 
thiocyanates,
96
 or as 1,3-N,C dipole equivalent in [3+2] dipolar cycloadditions
97
.  
In stark contrast, N-heteroaryl aminides 364 have attracted less interest. Virtually all the 
research available for these systems is encompassed by the work done by Alvarez-
Builla and collaborators.
53,98
 These aminides have been mainly used as masked 2-
aminoazines for the selective alkylation of the exocyclic nitrogen in 364 (Scheme 53).
99
 
Attempts into a wider application as building blocks through condensation reactions
100
 
and intramolecular radical arylations
101
 were less successful due to the reduced substrate 
scope.  
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Scheme 53: Pyridinium N-heteroaryl aminides as masked 2-aminoazines 
Traditionally, these aminides were prepared following an ANRORC-type process 
(Addition of the Nucleophile, Ring Opening, Ring Closing) by combination of the 
corresponding 2-heteroaryl hydrazine 372 with 2,4-dinitrophenyl pyridinium chloride 
373 to form hydrazone 374, which under acid catalysis and posterior base treatment 
delivers the desired compound (Scheme 54).
53,102
 The length and inefficiency of the 
sequence may account for the marginal use of these substrates.  
 
Scheme 54: Classical route for the synthesis of pyridinium N-heteroaryl aminides 
A more direct and attractive route was recently developed by Alvarez-Builla,
54,103
 where 
commercially available N-aminopyridinium iodide 237 was employed as precursor for a 
nucleophilic aromatic substitution reaction (SNAr) on π-deficient haloheterocycles 378 
(used in the chapter 2 for the synthesis of pyridinium N-(2-pyrimidin-yl) aminide 239, 
Scheme 34).  
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This methodology greatly expands the scope of tolerated systems to cover a broad range 
of heterocyclic motifs that could ideally be used as candidates for the gold-catalysed 
formal [3+2]-dipolar cycloaddition (Scheme 55). It was, nonetheless, anticipated that 
electronic variations across the different heterocycles might substantially affect the 
feasibility of the reaction. 
 
Scheme 55: Proposed expanded route for the gold-catalysed synthesis of imidazoheterocycles 
3.2 Results and Discussion 
3.2.1 Synthesis of pyridinium N-diazine/pyridine aminides 
Following the optimisation and synthesis of imidazo[1,2-a]pyrimidines discussed in 
chapter 2, several aminides were prepared using Alvarez-Builla’s procedure (Scheme 
56).
54,103
 Using the corresponding 2-chloroheterocycle 378, all the remaining structural 
combinations of diazine ring 380-383 were obtained in good yields. While these 
compounds had already been reported in the original paper, the described work-up 
requires the use large amounts of ethanol as eluent for both the flash chromatography 
and subsequent recrystallisation. This was replaced with a base treatment followed by 
purification using a mixture of 5% of methanol in either ethyl acetate or 
dichloromethane, which greatly reduced the amount of solvent and time employed. 
The more π-rich pyridine ring 384 was unreactive under SNAr conditions and had to be 
synthesised through an alternative aminopalladation reaction (Scheme 56 - Bottom).
103
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Scheme 56: Synthesis of pyridinium heteroaryl N-aminides 
Additionally, most of these aminides could be treated with N-iodosuccinimide to 
selectively halogenate the diazine ring (Scheme 57).
98b
 Iodo-pyrazines/pyrimidine 
derivatives 385 and 386 were synthesised and subsequently modified through Suzuki-
Miyaura cross-coupling reactions using various boronic acids 387.
104
 Following this 
relatively simple sequence, three novel and more complex aminides 388-390 were 
quickly formed in good yields.  
 
Scheme 57: Halogenation/Suzuki-Miyaura cross-coupling sequence for the synthesis of complex 
aminides 
All these compounds were colourful crystalline solids, from green to orange depending 
of the heterocycle attached (Figure 5). Their high stability must be highlighted, as they 
Chapter 3 
68 
 
could be stored on the bench for a period of more than two years with no signs of 
degradation. 
 
Figure 5: Picture of some of the aminides synthesised during this investigation 
3.2.2 Synthesis of fused imidazodiazines/pyridines 
Using the conditions developed in chapter 2 for the synthesis of imidazo-fused scaffolds 
the new library of aminides was explored under gold-catalysis: ynamide 380-390 (1.0 
eq.), aminide 139 (1.2 eq.) and gold(I) phosphite complex 227 (5 mol%) in 1,4-dioxane 
at 90 ºC for 22-24 h (Scheme 58). 
Remarkably, regardless of the combination of diazine and ynamide used, all the systems 
successfully underwent the desired cyclisation pathway, affording novel imidazo[1,2-
a]pyrazine 393-396, imidazo[1,2-c]pyrimidine 397-398 and imidazo[1,2-b]pyridazines 
structures 405-407.  
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Scheme 58: Reaction scope for heteroaryl aminides 380-390. 
a
 Reaction run for 48 h. 
b
 Reaction run 
in 1,2-DCB at 125 ºC 
In most of the cases, the yields were good and comparable to the imidazo[1,2-
a]pyrimidine analogues obtained from the same ynamides (Scheme 40), showing an 
comparable reactivity profile across the different members of the family. Similarly, 
excellent chemoselectivity was observed for pyrazine and pyrimidine aminides bearing 
potentially labile functional groups as halogen atoms 386, aldehydes 388 and 2-
bromopyridines 390.  
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In addition to ynamides, 3-indolylalkynes 310 also afforded the desired bis-heterocyclic 
structures 394, 400 and 406, although again use of more forcing conditions was required 
(1,2-DCB at 120 ºC).  
Crystals of compounds 402 and 398 were grown and analysed through single crystal X-
ray diffraction technique (Figure 6), confirming what was already inferred from the nOe 
experiments carried out in chapter 2 (Scheme 39): the addition to the ynamide 
regioselectively gives 2-amino-substituted imidazoheterocycles 379. 
 
Figure 6: Single crystal X-ray diffraction analysis for compounds 398 and 402. Data was obtained 
and solved by Dr Louise Male. Ellipsoids drawn at 50% probability 
Contrasting with the diazine systems, pyridine aminide 384 was less reactive, giving 
more sluggish reactions and large recoveries of unreacted ynamide (around 40% for 
both 403 and 404 after 48 hours of reaction). Use of gold precatalyst PicAuCl2 in the 
synthesis of imidazo[1,2-a]pyridine 403 resulted in an improvement of the reaction rate 
and efficiency (Scheme 59 – Eq. 1), although with less clean outcomes. Likewise, this 
higher reactivity of the gold(III) species was observed for the diazine systems, giving 
imidazo[1,2-c]pyrimidine 408 in 95% yield in less than two hours (Eq. 2) and with no 
traces of the unidentified impurity seen during the reaction survey done in Chapter 2.  
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Scheme 59: Synthesis of fused imidazoheterocycles using PicAuCl2 precatalyst 
3.2.3 Mechanistic observations 
To gain more insight into the mechanism of the gold-catalysis of Scheme 58, aminides 
411 and 412 were synthesised (Scheme 60). Interestingly, 2,6-dichloropyridine 409 was 
electrophilic enough to undergo a SNAr reaction with N-aminopyridinium iodide 237, 
readily giving pyridinium N-(6-chloropyridin-2-yl) aminide 411. This reactivity 
contrasts with that from monohalogenated pyridines which required an alternative 
strategy for the synthesis of the corresponding ylide 384 (Scheme 56). The reaction with 
409 was further improved when the acetonitrile was replaced with methanol at room 
temperature, probably due to the better solubility of both N-aminopyridinium iodide 237 
and potassium carbonate in this solvent. Similar effect was observed with 2,4-
dichloroquinazoline 410, giving aminide 412 in 99% yield after two hours. 
 
Scheme 60: Synthesis of aminides 411 and 412. 
a
 Reaction performed in MeOH at rt 
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Comparison of the results obtained using structurally related aminides 381, 384, 411 
and 412 in the gold catalysis (Scheme 61) outlined a reactivity trend based on the 
electronics of the attached heterocycle. Moving from pyridine aminide 384 to the 6-
chloro substituted system 411 resulted in a slight increase of the reaction rate and yield 
of the corresponding imidazo[1,2-a]pyridine 417. Chloropyrimidine derivative 381 led 
to a more dramatic increase of reactivity as the reaction reached completion in a couple 
of hours and in almost quantitative yield.  
 
Scheme 61: Comparison of reactivity between structurally related aminides. 
According to the proposed mechanism (simplified in Scheme 61), the cyclisation step to 
the fused system 415 could occur from either vinyl gold carbenoid 413 or from α-imino 
gold carbene 416 after elimination of pyridine. As discussed in chapter 2, the selectivity 
of the reaction and the improvement in the reactivity observed with electrophilic gold(I) 
and gold(III) species suggest that direct cyclisation from vinyl gold carbenoid 
intermediate 413 was the most likely pathway (413→414→415).  
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Based on the contrasting reactivity between pyridine 384 and pyrimidine aminides 381 
it was hypothesised that cyclisation to the fused imidazo-scaffold (414→415) was the 
rate-determining step of the reaction. Therefore, disruption of the aromaticity in the 
pyridine ring would be a less favourable step giving less efficient processes than 
diazines.
105
 
While it was expected that quinazoline 412 would follow this trend due to the lesser 
aromaticty resulting from the extended conjugation, both reaction rate and product yield 
were lower than with the pyrimidine derivative 381. A possible explanation is that the 
steric clash between the bulky quinazoline ring and the pyridinium fragment forces 
aminide 412 to adopt a more favourable conformation 412’ which is also stabilised by 
the hydrogen bonding between the two rings (Scheme 62).  
 
Scheme 62: Proposed mechanism for the formation of imidazoquinazoline 418 
The orthogonal approach of aminide 412’ to the plane of the gold-activated triple bond 
to give vinyl gold carbenoid 420’ would be sterically hindered by the fused benzene 
ring, slowing the addition. In order for the 4π-electrocyclisation to take place 
(421→422), the exocyclic nitrogen in 420 reconfigures aligning the quinazoline system 
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in the plane with the metallated carbon centre (420→421). This requires vinyl gold 
carbenoid 420’ to adopt conformation 420 which is again (cf. 412) sterically hindered. 
As a result, the formation of the fused imidazoquinazoline 421 would be considerably 
slowed down. Nonetheless, imidazo[1,2-c]quinazoline 418 could be incorporated to the 
library of heterocycles available through this transformation. 
Since completing this research,
35
 Zhang and Geng have reported some density 
functional theory calculations (DFT) of the reaction between pyridinium N-(2-pyrimin-
yl) aminide 239 and ynamide 264 that also pointed to the ring-forming stage as the 
turnover-limiting step. For this analysis they employed trimethylphosphite [(CH3O)3P] 
as computational simpler model of the ligand in the gold(I) complex. The calculated 
energy profiles indicated that formation of the 5-membered ring (414→415) was indeed 
strongly endothermic, controlling the rate of the reaction. 
3.2.4 Post-catalytic functionalisation 
At this stage of the investigation, several novel halosubstituted imidazoheterocycles had 
been synthesised as result of the reaction survey (e.g. 397-402 in Scheme 58). Examples 
in the literature show how similar systems can be readily functionalised through metal-
catalysed cross-coupling procedures.
93,106
 However, for the purposes of this research a 
different avenue was pursued. 2,4-Chloropyrimidine was identified as possible 
candidate to be subjected to an iterative aminide-imidazole ring formation sequence 
(Scheme 63). Using the corresponding aminide 381, imidazo[1,2-c]pyrimidine 423 was 
synthesis in larger scale (235 mg, 0.64 mmol). After its isolation, the compound was 
treated with N-aminopyridinium iodide 237 under basic conditions. Gratifyingly, this 
system rapidly formed aminide 424 in excellent yield (Eq. 1).  
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Scheme 63: Post-catalytic functionalisation of imidazo[1,2-c]pyrimidine 423  
In an attempt to prepare fused tricycle 425 (Eq. 2), aminide 424 was combined with a 
second ynamide 264. Different conditions were screened including higher catalyst 
loading (10 mol%) of either 227 or PicAuCl2 and more forcing condition using the 
higher boiling point solvent 1,2-DCB. No reaction was detected in any of the cases, 
recovering large amounts of starting materials. It was proposed that the basic nitrogen of 
the imidazole core in 424 could be stabilising a gold-aminide complex, sequestering the 
catalytic species away from the ynamide 264 and preventing the cyclisation. 
Nevertheless, these preliminary results indicate alternative routes for the further 
diversification of the catalysis products, giving an easy access to complex and varied 
structures. 
3.3 Conclusions 
The gold-catalysed reaction between π-rich alkynes and pyridinium N-heteroaryl 
aminides was significantly expanded to cover the synthesis of six types of 
therapeutically relevant scaffolds: imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine, 
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imidazo[1,2-b]pyridazine, imidazo[1,2-a]pyrazines, imidazo[1,2-a]pyridine and 
imidazo[1,2-c]quinazoline. 
This versatile reaction presents excellent functional group compatibility and 
chemoselectivity, tolerating the introduction of potentially labile electrophilic 
substituents that can be used in post-catalysis transformations. 
The cyclisation step was identified as possible turnover-limiting step in the mechanism, 
due to the correlation observed between the aromaticity of the heterocycle in the 
aminide and the outcome of the reaction.  
Additionally, it is expected that the revealed potential of pyridinium N-heteroaryl 
aminides as flexible and stable building blocks collaborates to increase the relevance of 
these underused substrates in synthetic chemistry. 
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4.1 Fused imidazobenzoheterocycles 
Imidazo-fused heterocycles have been previously introduced as rich and diverse family 
of scaffolds actively pursued due to their varied biologically activity. Structures 
featuring a 5,5-fused system are, however, less ubiquitous as therapeutic agents or 
organic materials. With the increase in skeletal complexity, the number of synthetic 
routes available becomes scarcer.  
The condensation between 2-aminoazoles and α-haloketones represents the most 
extended strategy despite the limitations in terms of availability and compatibility of the 
substrates (Scheme 64). Consequently, from the different combinations of 5,5-fused 
imidazoheterocyles, only the imidazo[2,1-b]benzothiazole motif has received more 
widespread use, being present in some candidates for antitumor
107
 and antibacterial
108
 or 
labelled with 
18
F 429 for their use in PET (positron emission tomography)-based 
imaging in the study of Alzheimer’s disease.109  
 
Scheme 64: Synthesis of an imidazobenzothiazole-base candidate for high-contrast PET imaging in 
the study of Alzheimer’s disease 
Heteroaryl aminides have been identified and investigated as versatile building blocks 
in the assembling of valuable imidazodiazines/pyridines in the previous two chapters. In 
spite of their individual differences, all the aminides employed so far were based on π-
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deficient heterocycles, which facilitated the formation of the ylide via simple and 
general substitution reactions (Scheme 56). As a result, the catalysis products obtained 
presented a common 5,6-fused scaffold. Seeking to explore the boundaries of the 
developed nitrenoid approach, 5,5-fused imidazole systems were selected as next goal 
through the use of complementary π-rich heterocycles. However, considering the 
obstacles previously encountered due to the electronic differences between diazines and 
pyridine, the incorporation of five-membered rings in the gold-catalysis was expected to 
be accompanied by challenges in the preparation of both precursors and products. 
4.2 Results and discussion 
4.2.1 Synthesis of π-rich heteroaryl aminides 
In order to make a library of π-rich heteroaryl aminides, several halosubstituted azole 
derivatives were tested (Scheme 65). Thiazole 430 and isoxazole 432 systems were 
quickly discarded as feasible precursors due to the high electron density of the ring that 
hampered the conversion to the desired product either via SNAr or aminopalladation 
routes.  
In contrast, commercially available 2-chlorobenzoxa/thiazoles 434 were suitable 
substrates that efficiently reacted with N-aminopyridinium iodide 237 to give the 
corresponding aminides 436 and 437 in excellent yields. Based on these promising 
results, benzimidazole derivative 443 was also selected as an attractive motif for the 
future gold-catalysis.  
For its synthesis, o-phenylendiamine 438 was transformed into the cyclic urea 440 and 
subsequently converted to 2-chlorobenzimidazole 441 by treatment with phosphoryl 
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chloride (Scheme 65 – Bottom). Following the protection with mesyl chloride, aminide 
443 was isolated in a workable 37% yield. Attempts into forming the aminide derivative 
from the Boc- or benzoyl-protected benzimidazole were unreactive even under more 
forcing conditions, leading to degradation of the materials.  
 
Scheme 65: Synthesis of azole-based aminides 
Similarly to the diazine-based systems, the pyridinium N-(benzazole) aminides were 
bench-stable, bright yellow solids. Crystals of the three compounds were analysed 
through X–ray (data was obtained and solved by Dr Louise Male. Ellipsoids drawn at 
50% probability. Hydrogen atoms omitted. Figure 7–8). There was little difference in 
the key bond lengths or angles across the series. In the three structures the pyridinium 
ring was almost coplanar with the fused azole system, with a smaller deviation in the 
benzoxazole derivative 436. Analogously to the data reported in the literature for other 
diazine-based aminides,
53
 in solid state there seem to be an intramolecular hydrogen 
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bonding between the endocyclic nitrogen (N1) and the hydrogen atoms in 2-position of 
the pyridine ring. 
  
Figure 7: X-Ray structure of 436. N2–N3: 1.37(8) Å, N2–C3: 1.34(1) Å, C3–N1: 1.31(8) Å, N2–C3–
N1: 135.8º, N3–N2–C3–N1: -4.1º 
  
Figure 8: X-Ray structure of 437. N2–N3: 1.38(4) Å, N2–C3: 1.34(1) Å, C3–N1: 1.31(5) Å, N2–C3–
N1: 133.8º, N3–N2–C3–N1: 0.5º 
 
Figure 9: X-Ray structure of 443. N3–N4: 1.37(5) Å, N3–C7: 1.33(7) Å, C7–N1: 1.32(0) Å, N2–C3–
N1: 134.5º, N3–N2–C3–N1: 1.1º 
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4.2.2 Formation of 5,5-fused scaffolds 
The use of these π-rich aminides under gold-catalysis was investigated. In a preliminary 
test, benzoxazole-substituted system 436 was combined with ynamide 264 and gold(I) 
complex 227 following the original conditions developed in Chapter 2 for the synthesis 
of imidazo-fused heterocycles (Scheme 66 – Eq. 1). After 24 hours of reaction 
imidazo[2,1-b]benzoxazole 444 had been formed, although most of the starting material 
remained unreacted. Use of more forcing conditions in either m-xylene
34a
 or 1,2-DCB 
aided in the conversion to the fused system. Due to the higher boiling point of these 
solvents, after reaction completion the mixtures were directly purified through flash 
chromatography and therefore, all the given yields are from the isolated product.  
In light of previous results where gold(III) precatalyst PicAuCl2 enhanced the rate of 
cyclisation to the five-membered ring, this complex was subsequently introduced in the 
present screening. Gratifyingly, the yield of isolated product was almost duplicated over 
the same period of time at 90 ºC in 1,4-dioxane. Reaction in 1,2-DCB gave slightly 
lower amounts of products at the same temperature but on increase to 125 ºC, 
imidazo[2,1-b]benzoxazole 444 was isolated in a higher 84% yield after only 6 hours. It 
is worth noticing that the reaction afforded the same yield when no precautions were 
taken to exclude air or moisture (opened flask and non-dried solvent). As expected, no 
reactivity was observed in absence of catalyst or when zinc triflate (recently unveiled as 
surrogate of gold in some transformations)
110
 was employed. 
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Scheme 66: Survey for the reaction with π-rich heteroaryl aminides. Yields given as isolated 
product after chromatography. 
a 
Reaction performed in an opened-flask with non-dried solvent 
Analogously, imidazo[2,1-a]benzothiazole derivative 445 was isolated in excellent yield 
after 8 hours at 125 ºC using PicAuCl2 complex (Scheme 66 – Eq. 2). A considerable 
drop in the yield was observed when the reaction was performed in 1,4-dioxane at 90 
ºC. Hence, 1,2-DCB at 125 ºC were selected as general conditions for the formation of 
the 5,5-fused systems. 
While protected benzimidazole derivative 443 also underwent a formal [3+2]-dipolar 
cyclisation to deliver the desired imidazo[1,2-a]benzimidazole 446, it was found to be 
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substantially less reactive than the other annulated aminides giving large recoveries of 
unreacted ynamide (Eq. 3). Only the more forcing conditions yielded some product, in 
spite of the longer reaction times.  
A plausible explanation for the lower reactivity of the benzimidazole derivative 443 
could be assigned to a higher aromaticity of this system when compared with the 
benzoxazole 436 and benzothiazole aminides 437. Attending to the proposed 
mechanism (Scheme 67), a bis-heteroatom 4π-electrocyclisation from vinyl gold 
carbenoid intermediate 447 seems the most likely pathway considering the better result 
obtained with electrophilic gold species. As seen in chapter 3, the ring-forming stage 
(448→449) was indicated to be the turnover-limiting step of the reaction and therefore, 
a less favourable loss of aromaticity in the conjugated heterocycle would reduce the 
reactivity of the aminide. 
 
Scheme 67: Proposed mechanism for the gold-catalysed synthesis of fused 
imidazobenzoheterocycles 
Combining the crystallographic data and HOMA (Harmonic Oscillator Model of 
Aromaticity) index for benzazole heterocyclic motifs, Karolak-Wojciechowka and 
collaborators determined that the aromaticity for the parent series follows the order: 
benzoxazole < benzothiazole < benzoimidazole.
111
 While the study does not take into 
account the N-protecting group in the benzoimidazole (i.e. the authors acknowledge that 
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the effect of the N-substituent in the electronegativity of the heteroatom can 
significantly change the parameters), this trend would be consistent with the 
experimental observations for the current reaction.  
The reactivity profile observed for these aminides could also be derived from the more 
π-rich character of benzazole rings in comparison with diazine/pyridine-substituted 
systems. A higher nucleophilicity of the endocyclic nitrogen might lead to stronger 
intramolecular hydrogen bonding with the α-protons of the pyridine group (as reported 
by Alvarez-Builla and collaborators).
99
 To some extent, this could lock an unreactive 
conformation where exocyclic and endocyclic nitrogen atoms point in opposite 
directions of the plane (as seen in the crystal structures in Figure 7-3). Use of more 
forcing conditions (1,2-DCB at 125 ºC) would reduce this interaction aiding in the 
cyclisation step. Alternatively, the more π-rich character of the aminide/product might 
be favouring its coordination to the gold complex, reducing the effective concentration 
of catalytic species.  
4.2.3 Reactivity towards ynamides 
Once benzazole-based aminides were established as valid nucleophilic nitrenoids in the 
formal [3+2]-dipolar cycloaddition, the more reactive benzoxazole 436 and 
benzothiazole derivatives 437 were reacted with different gold-activated ynamides. 
Scheme 68 presents some of the examples synthesised to test the scope of the 
methodology. This table of substrates was prepared in collaboration with Elsa Martínez 
Arce (E.M.A.) and Dr. Raju Jannapureddy (R.J.), both members of the Davies Group 
(compounds obtained by them are indicated in the Scheme). 
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Both aminides had a similar behaviour and gave comparable good yields when 
combined with the same ynamide, although the reactions with benzothiazole derivative 
437 were generally slower. Mesyl, tosyl and phosphoryl protected ynamides were well 
tolerated and in most of the cases the reaction reached completion after a few hours 
451-458. While these conditions allowed the installation of stereogenic centres adjacent 
to the tricyclic scaffold (456 and 457), the ynamide precursor was quickly degraded at 
125 ºC. Switching to 1,4-dioxane 90 ºC improved the yield at expenses of longer 
reaction times. 
 
Scheme 68: Synthesis of fused imidazobenzoxazoles/thiazoles from different ynamides. 
a
 Reaction 
performed in 1,4-dioxane at 90 ºC. 
b
 Example prepared by E.M.A. 
c
 Example prepared by R.J. 
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The synthesis of imidazo[2,1-b]benzothiazole 455 was also performed at larger scale 
giving 1.1 grams of the fused heterocycle. The 1,2-dichlorobenzene employed for this 
scaled-up reaction (25 mL) was removed through distillation under reduced pressure 
before purification of the residue through flash chromatography, affording the desired 
compound. After full characterisation, 455 was redissolved in CHCl3, transferred to a 10 
mL flask and loosely capped with a Teflon stopper to allow a slow evaporation of the 
solvent. After one month, 455 had crystallised into a white needle-like solid shown in 
Figure 10.  
 
Figure 10: Crystals of imidazo[2,1-b]benzothiazole 455 grown after the gram scale reaction 
Generally good yields were obtained independently of the electronic differences 
between ynamides, allowing even the introduction of versatile carboxylic ester 461 and 
heteroaromatics such as furan 459 and thiophene 460 at C-3. Highly reactive 
enynamides were also tolerated, although at 125 ˚C the ynamide quickly degraded 
affording 462 in 35% yield. By switching the conditions to 1,4-dioxane at 90 ºC the 
yield was highly improved to 78% after 4 hours. Interestingly, on formation 462 crashed 
out in the solution and once the reaction mixture reached room temperature was readily 
purified by filtration and washing with cold diethyl ether. 2-Amino-3-thioether 
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derivative 465 was obtained as a single regioisomer despite the presence of a second 
nominal directing group in the ynamide.
34b
 Similarly, N-indole derivative 466 was 
obtained in good yield although at slower rate.  
In contrast, alkyl-substituted ynamides gave complex reaction mixtures difficult to 
separate using either set of conditions (Scheme 69). These mixtures would be again (cf. 
Scheme 42) consistent with 1,2–C,H insertion pathways that drastically reduced the 
formation of the desired product, with the exception of cyclopropyl-ynamide 279 which 
successfully underwent the cyclisation to give the corresponding fused heterocycles 463 
and 464.  
 
Scheme 69: Reaction of aminide 437 with alkyl-substituted ynamide. Complex mixtures obtained. 
a
 
Yield calculated by
1
H-NMR against a known quantity of internal standard  
4.2.4 Routes for the synthesis of functionalised benzazole aminides 
The introduction of more varied functionality in the catalysis product was subsequently 
pursued. In an attempt to prepare iodine-substituted aminides for a posterior 
functionalization step using cross coupling reactions (following the synthetic procedure 
in Scheme 57), aminide 436 was treated with N-iodosuccinimide in DMF (Scheme 70). 
These conditions led to an inseparable mixture of unreacted material and regioisomers 
from the halogenation in different positions of the fused benzene ring. Similar 
selectivity challenges were encountered by other members of the group when trying to 
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functionalise the 2-chlorobenzoxa/thiazole precursor prior to the formation of the 
aminide. 
 
Scheme 70: Failed sequence for the functionalization of benzazole aminides  
Thus, it was decided to assemble 2-halobenzazole rings bearing a preinstalled 
substituent. Following a literature procedure,
112
 2,5-dichlorobenzoxazole 470 was 
synthesised by chlorination of 2-mercapto derivative 471 using a mixture of POCl3 and 
PCl5 (Scheme 71). While aminide 472 was subsequently obtained in good yield by 
reaction of 471 with N- aminopyridinium iodide 237, the low efficiency and hazards of 
the chlorination step (use of toxic, harmful and corrosive reagents) were highly 
undesirable. 
 
Scheme 71: Synthesis of chloro-substituted aminide 472  
Therefore, 2-methylthio benzazoles 475 were selected as synthetic equivalents of 2-
halobenzazole 434 in the formation of heteroaryl aminide (Scheme 72). Both 
benzoxazole and benzothiazole thioether derivatives 475 were readily accessed from 
commercially available substituted o-halo or o-hydroxy aromatic amines 473 following 
a general and straightforward sequence:
113
 heating in either carbon disulfide and base in 
ethanol (method A) or sodium ethyl xanthate (method B) formed the annulated thiol 474 
which precipitated in the solution after allowing it to cool down to room temperature. 
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These compounds were successfully treated with methyl iodide to form the 
corresponding thioether derivative 475 which in most of the cases rapidly underwent 
aminide formation. Using this synthethic protocol other members of the group were able 
to prepare several aminides bearing halogen atoms (F, Cl and Br) and nitro groups 
attached to 4-,5- and 7-positions of the fused benzene ring in good yields. 
 
Scheme 72: Strategy for the preparation of functionalised N-(heteroaryl) aminides from thioether 
derivatives.  
 
Scheme 73: Top: Synthesis of fluoro-substituted aminide 480; Bottom: Mechanism for the TCT-
promoted oxidation of sulfides to sulfones 
Interestingly, 6-fluro-substituted thioether 479 resulted insufficiently reactive in the 
substitution step and the compound degraded before formation of the corresponding 
aminide 480 was detected (Scheme 73 – Top). In order to enhance its electrophilicity, 
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479 was oxidised to sulfone 481 by reaction with H2O2. 481 smoothly reacted with N-
aminopyridinium iodide 237 in a subsequent step to give the desired aminide 480. 
Cyanuric chloride (2,4,6-trichloro[1,3,5]triazine, TCT) is proposed to promote the 
oxidation of 479 by forming an electrophilic peroxide intermediate 484 that is attacked 
by sulfide 483 (Scheme 73 – Bottom).114 The resulting sulfoxide 485 can be reoxidised 
with intermediate 486 from the addition of a second molecule of H2O2, giving sulfone 
488.  
 
Scheme 74: Synthesis of fused aza-analogues 
The synthetic protocol in Scheme 72 was also applied to hydroxyl- and halo-substituted 
aminopyridines 489-492 giving the corresponding thioethers 497-500 (Scheme 74). 
These sulfides smoothly reacted with N-aminopyridinium iodide 237 affording novel 
fused aza-analogues 501-504 in good yields. Similarly to previous aminides, these 
compounds were bright yellow crystalline solids.  
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All these structures were tested in combination with various aminides under the 
standard conditions (1,2-DCB at 125 ºC), revealing a similar behaviour to aminides 436 
and 437 (Scheme 75). Both 5-chloro 472 and 6-fluoro-substituted derivatives 480 
rapidly underwent formation of the desired fused heterocycles 505-507.  
 
Scheme 75: Use of halo-substituted aminides in the synthesis of fused imidazobenzoxa/thiazoles. 
a 
Reaction performed in 1,4-dioxane at 90 ºC 
Considering the challenges previously encountered in the reaction with enynamides 
(462 in Scheme 68), 1,4-dioxane at 90 ºC was directly employed in the synthesis of 507 
which was rapidly formed in 75% yield after 1 hour. 
Likewise, pyridine-fused aminides 501-504 led to novel tri-hetero-fused scaffolds 508-
513 (Scheme 76), although in this case the profile of the reaction was significantly 
affected by the position of the nitrogen in the six-membered ring. The 4- and 7- aza-
analogues 502 and 501 quickly afforded excellent yields of the corresponding 
heterocycles 508-510. In contrast, the reaction with 5- analogue 503 reached completion 
only after eight hours 511, and 6-aza derivative 504 was even less reactive, giving 
relatively low yields of 512 and 513 after prolonged heating independently of the 
ynamide used. 
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Scheme 76: Use of aza-analogues in the synthesis of fused imidazobenzoxa/thiazoles: 
a 
Reaction 
performed in 1,4-dioxane at 90 ºC 
The reason for this trend could originate from the coordination of the metal with the 
nitrogen atoms of the fused pyridine ring in these aminides, reducing the concentration 
of active catalyst to interact with the ynamide. Nitrogen atoms in 4- and 6-position 
would be more basic due to the conjugative effect of the exocyclic nitrogen in the 
aminide system. However, inductive and steric effects in 4 and 7-position could be 
destabilising the N–Au complex. As a result, aminides 501 and 502 were very reactive 
while the reaction with 504 did not progress further after few minutes. A nitrogen atom 
in 5-position would be less basic than in 6- giving a less stabilised metal complex. 
Nevertheless, 503 is more sterically accessible to the metal than 501 and 502 which 
could explain the sluggish reaction obtained with aminide 503. 
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4.2.5 Confirmation of the structure of vinyl substituted derivatives 
As discussed in Scheme 67, the formation of fused imidazoheterocycle 450 is proposed 
to follow a formal [3+2]-dipolar cycloaddition process analogous to the described for 
the reaction with diazine-based aminides. On gold-activation of the ynamide, the 
aminide 435 regioselectively attacks on the π-system giving vinyl gold carbenoid 447. 
This intermediate would undergo a bis-heteroaryl 4π-electrocyclisation simultaneous to 
the elimination of the pyridine leaving group to form 449. A final deaurative 
aromatisation step affords the desired fused heterocycle 450. With the exception of 
ynamides bearing an alkyl chain that afforded complex mixtures (Scheme 69), all the 
systems tested were highly reactive and selectively gave the fused benzoheterocycle. 
Particularly, enynamides were similarly found to be suitable substrates for the 
cycloaddition process although milder conditions (1,4-dioxane at 90 ºC) were required 
in those cases in order to afford good yields of the corresponding products 462, 507 and 
510.  
 
Scheme 77: Synthesis of 2-aminopyrroles through gold-catalysed aza-Nazarov cyclisation of 
enynamides and azides 
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Interestingly, Shu et al. have recently reported a gold-catalysed azide-based 
intermolecular nitrene transfer reaction onto enynamides 514 (Scheme 77).
115
 Under 
their reported conditions enynamides undergo an alternative aza-Nazarov pathway to 
furnish valuable 2-aminopyrrole derivatives 516. Similarly to the reaction with 
aminides, the mechanism would be initiated with the attack of the nucleophilic nitrenoid 
into the gold-activated triple bond 517. Subsequent extrusion of N2 leads to the α-imino 
gold carbene 518/518’. This species undergoes a 4π-electrocyclisation giving 
intermediate 519 which after protodemetallation affords pyrrole 520. 
At this point of the studies detailed in this thesis, it was considered that the reaction 
between aminides (either diazine/pyridine- or benzazole-based) and enynamides could 
potentially be giving the corresponding aza-Nazarov product 520 in place of the desired 
fused imidazoheterocycle as both compounds are isomers (e.g. as indicated in Scheme 
78 using aminide 436).  
 
Scheme 78: Potential alternative pathway from the reaction with enynamides 
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Direct analysis of 462 could not be used to unambiguously confirm the structure of the 
isolated compound, although resonances for the pyrrole fragment were not seen in the 
expected range (Figure 11). The aromatic region of the spectrum was too complex due 
to overlapping of the signals which difficulted the identification of individual 
resonances (Apendix 1.1 – p.194). 
 
Figure 11: Reported values for the 
1
H-NMR shifts of the characteristic pyrrole protons in aza-
Nazarov product 527
115
 
A better resolved spectrum was obtained for chloro-substituted analogue 507. Attending 
to the coupling constants every peak could be matched to the corresponding proton in 
the scaffold (Figure 12; Full assignment in Appendix 1.2 – p.198). More importantly, 
the olefinic signals were identified through the large J value (
3
Jtrans = 16.6 Hz) 
confirming the formation of the imidazo[2,1-b]benzoxazole system 507.  
2D-NMR spectroscopy experiments (HSQC and HMBC pulse sequences) allowed the 
carbocyclic skeleton of 507 to be fully assigned. Comparison of the 
13
C-spectra for 
compounds 462, 507 and 510 (Figure 13) showed a correlation between the peaks 
across the three molecules. 
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Figure 12: 
1
H-NMR spectrum of compound 507 and assignment of the resonances 
Despite the structural modifications in the core scaffold, the signals for the styryl 
fragment remained mostly unchanged. For instance, the olefinic peaks e and o 
consistently appeared around 131.0 and 113.0 ppm respectively. The correlation is 
maintained even in aza-derivative 510, where the presence of an extra nitrogen atom 
greatly affects the shifting of the surrounding carbons b and f. These values contrast 
with those reported for pyrrole derivatives (Scheme 77),
115
 where both resonances for 
the characteristic carbon atoms in 3- and 4-position of the five-membered ring 
consistently appear at approximately 108.0 ppm. Therefore, it was concluded that in the 
three cases, the desired imidazobenzoxazole system was the product of the catalysis. 
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Figure 13: Expansion comparing 
13
C-NMR spectra of compounds 462, 507 and 510 
Additionally, analysis of the 
1
H-NMR spectrum of styryl-substituted imidazo[1,2-
a]pyrimidine 299 obtained through the same methodology (Scheme 40) similarly 
displays resonances typical for olefinic protons with trans-configuration (
3
Jtrans = 16.7 
Hz) (Figure 14).  
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Figure 14: 
1
H-NMR spectrum of imidazo[1,2-a]pyrimidine 299 
Returning to the aza-Nazarov cyclisation (Scheme 77), Shu et al. proposed a mechanism 
involving the cyclisation from gold carbene intermediate 518, formed after the 
elimination of N2. Workable yields of product 516 were only obtained by employing σ-
donating ligand on the gold(I) complex (IPr and SIPr) (Scheme 77). This trend directly 
opposes to the studies detailed in this thesis, where electrophilic gold(I) phosphide 227 
and gold(III) precatalyst PicAuCl2 were found to be the most suitable complexes for 
catalysing the formal [3+2]-dipolar cycloaddition process. Thus, the cyclisation step is 
believed to precede from the vinyl gold carbenoid intermediate 447 with near-
synchronous elimination of the nucleofuge (Scheme 67).  
4.2.6 Reactivity of benzimidazole-based aminides 
Based on the good results obtained with aza-derivatives 501 and 502 (Scheme 76), it 
was proposed that an analogous pyridine-fused imidazole aminide might reduce the π-
density on the five-membered ring and therefore, be more reactive than the parent 
benzimidazole 443 (Scheme 66). 
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For its synthesis (Scheme 79), 2,3-diaminopyridine 528 was treated with carbon 
disulfide to form the thiol derivative 529. Sulfide formation lead to an inseparable 
mixture of tautomers 530 and 531 (1:1.5 ratio) that was directly taken into the next step. 
Protection with mesyl chloride gave preferentially 533, although in this case the mixture 
of isomers could be separated through flash chromatography. Sulfide 533 resulted 
unreactive under aminide-forming conditions and had to be oxidised to the sulfone 534 
by treatment with mCPBA. 534 Was unstable and decomposed during the purification. 
Thus, the substitution with N-aminopyridinium iodide 237 was immediately performed 
once the oxidation was completed.  
 
Scheme 79: Synthesis and reactivity of aza-analogue 535. Conditions A: PicAuCl2 (5 mol%+ 
additional 5 mol% after 20 h) in 1,2-DCB at 125 ºC for 24 h 
Aminide 535 was isolated as a pure bench-stable solid, although in low yield after the 
two consecutive reactions. Unfortunately, no reactivity was achieved when it was 
treated with ynamide 264 under the standard conditions (1,2-DCB at 125 ºC). After 24 
hours no progress was detected and most of the starting material remained unreacted in 
spite of the addition of an extra 5 mol% of catalyst.  
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This may be again attributed to the formation of an aminide-metal complex, 
sequestering gold away from ynamide. The stabilisation of this complex may be related 
with a higher basicity of the pyridine nitrogen atom due to the more π-rich character of 
the imidazole system. 
Considering the apparent inefficiency in the reaction with benzimidazole-based 
aminides, caffeine derivate 538 was selected as potentially attractive substrate (Scheme 
80). It was expected that the presence of an electron-withdrawing 1,3-dimethyluracil 
group in 538 would reduce the π-density of the xanthine system. Thus, the stabilisation 
of an unproductive aminide-metal complex would be less favoured or even restricted by 
the N-methyl groups, giving an improved reactivity in comparison with aminides 443 
and 536.  
To test this hypothesis, 8-caffeine 537 was selected as precursor in the synthesis of 
aminide 538. Reported conditions for the selective bromination at C-8 gave inconsistent 
low yields of 537.
116
 The reaction was repeated using both freshly recrystallised and 
aged NBS, the latter giving an improved outcome probably derived from the presence of 
highly reactive molecular bromine in it. 537 Smoothly underwent substitution with 237 
to form aminide 538 as a bright orange solid (Scheme 80). This aminide successfully 
reacted with different electron rich/poor ynamides to form the desired cyclisation 
adducts 539-541 in good yields. Milder conditions (1,4-dioxane at 90 ºC) were however 
required as 538 degraded on prolonged heating at 125 ºC. This structures appear to be 
the first synthesised examples of functionalised fused imidazo[1,2-e]purine derivatives. 
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Scheme 80: Synthesis and reactivity of caffeine-based aminide 538 
4.3 Conclusions 
The formal [3+2]-dipolar cycloaddition reaction between pyridinium N-heteroaryl 
aminides and ynamides has been adapted to cover a wider group of aza-heterocycles. 
Novel polysubstituted imidazo[2,1-b]benzothiazoles and imidazo[2,1-b]benzoxazoles 
scaffolds have been synthesised through the use of π-rich aminides. These systems 
required more forcing conditions to enhance the formation of the 5,5,6-fused 
framework, probably in order to reduce the unproductive metal-aminide interaction.  
An alternative route for the synthesis of more complex π-rich N-heteroaryl aminides has 
been developed, employing sulfide-substituted heterocycles as direct precursors. This 
method allows the formation of halo– and nitro–functionalised ylides as well as novel 
fused pyridineoxazole/thiazole derivatives that have been successfully applied in the 
gold catalysis.  
The strategy tolerates the introduction of orthogonal functionality that may be 
selectively exploited for further manipulation and diversification. Additionally, the 
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synthesis of imidazo[2,1-b]benzothiazole 455 could be performed at gram-scale with no 
detriment in the yield. 
Aminides based on the benzimidazole system resulted less reactive, leading to 
incomplete reactions. This trend may be associated with the more π-rich character of the 
heterocycles, favouring the stabilisation of a metal-aminide complex. Nevertheless, 
workable yields of imidazo[1,2-a]benzoimidazole 446 could be isolated. In comparison, 
reaction with caffeine system 538 proved to be a more efficient process, probably due to 
the lower π-density of the xanthine ring that allowed the preparation of unprecedented 
substituted imidazo[1,2-e]purine derivatives. 
Considering all the structures obtained in the present investigation, future work to 
further develop this synthetic strategy could focus on several areas. Altering the nature 
of the aminide would lead to different and otherwise difficult to access fused imidazole 
scaffold. Alternatively, considering the recent advent of azides in the intermolecular 
formation of α-imino gold carbene intermediates (e.g. Scheme 23, Scheme 24 and 
Scheme 77), it would be interesting to prepare aza-heteroaryl azides analogous to the 
aminides detailed in this thesis and compare the outcome of the gold catalysis. 
The research presented in this thesis describes the development of a new type of 
reactivity that has been successfully adapted for the synthesis of fourteen classes of 
novel structures in a modular and convergent fashion. The compounds synthesised 
across this investigation are based on biologically relevant frameworks. Thus, they have 
been requested and submitted to industrial partners to be tested against several disease 
targets. 
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5.1. General information 
Commercially available chemicals/reagents were purchased from major suppliers 
(Aldrich, Fisher, Acros, Alfa Aesar, Fluorochem or VWR) and used without further 
purification unless otherwise stated. For all reactions carried out under inert atmosphere, 
solvents were purified using a PureSolv-MD solvent purification system and transferred 
under nitrogen except for DMF, 1,4-dioxane and 1,2-dichlorobenzene which were dried 
over activated 4 Å molecular sieves. For reactions above room temperature pre-heated 
paraffin oil baths or Asynt DrySyn heating blocks on stirrer hotplates were employed 
with temperature control via external probe. The following cooling baths were 
used: -10–0 ºC (ice/NaCl) and -78 ºC (dry ice/acetone). Reactions were monitored by 
thin layer chromatography using Merck silica gel 60 F254 (aluminium support) TLC 
plates which were developed using standard visualizing agents: UV fluorescence (254 
nm), potassium permanganate/Δ or vanillin/Δ. Flash column chromatography was 
performed using Merk Geduran Si 60 (40-63 μm) silica gel as the stationary phase. 
Melting points were measured in open capillaries using Stuart Scientific melting point 
apparatus and are uncorrected. Specific rotations were determined using a PolAAr 2001 
instrument and are given as follows:     
  (in deg dm
-1
cm
3
g
-1
), c (in g/100 mL), solvent 
used. All 
1
H NMR and 
13
C NMR spectroscopic experiments were recorded using 
Bruker AVIII400 (
1
H = 400 MHz, 
13
C = 101 MHz) or AVIII300 (
1
H = 300 MHz, 
13
C = 
75 MHz) spectrometers at 300 K, in commercial, TMS free, deuterated solvents. 
13
C 
NMR spectra were recorded using either the UDEFT or the PENDANT pulse sequences 
from the Bruker standard pulse program library. 2D COSY, HSQC and HMBC spectra 
were recorded in order to assist with NMR assignment when necessary. Spectra were 
processed using MestReNova software. Chemical shifts (δ) are given in ppm and 
Chapter 5 
106 
 
coupling constants (J) are quoted in Hz to one decimal place. The spectra were 
calibrated using the solvent peaks relative to the TMS scale (CDCl3: δC ≡ 77.16 ppm; 
residual CHCl3 in CDCl3: δH ≡ 7.26 ppm; DMSO-d6: δC ≡ 39.52 ppm; residual DMSO 
in DMSO-d6: δH ≡ 2.50 ppm). Spectral data for 
1
H NMR spectroscopy is reported as 
follows: Chemical shift (multiplicity, coupling constant, number of protons); and for 
13
C 
NMR spectroscopy: Chemical shift (multiplicity and coupling constant if needed, 
assignment). The following abbreviations were used for multiplicity in 
1
H NMR: s 
(singlet), d (doublet), t (triplet), q (quadruplet), dd (doublet of doublets), td (triplet of 
doublets), quin (quintuplet), br. (broad), m (multiplet), app. (apparent). Infra-red spectra 
were recorded neat on a Perkin-Elmer Spectrum 100 FTIR spectrometer. Wavelengths 
(ν) are reported in cm-1. HRMS (EI or ES): Waters LCT, Time of Flight. HRMS was 
obtained using leucine enkephalin as lock-mass. 
5.2 Precursors for Chapters 2 and 3 
5.2.1 Preparation of ynamides and indolylalkynes 
General Procedure 1 (GP1) 
 
Following the method reported by Evano and co-workers,
59
 a 10-25 mL flask was 
charged with sulfonamide (1.0 eq.), 1,1-dibromo-1-alkene (1.5 eq.), Cs2CO3 (4.0 eq.) 
and CuI (12 mol%). The flask was fitted with a rubber septum, evacuated under high 
vacuum and backfilled with argon (this operation was repeated three times). Dry DMF 
[0.5 M relative to the amount of sulfonamide] and N,N’-dimethylethylenediamine (19 
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mol%) were then added and the mixture was stirred at 60 ºC until complete 
consumption of the starting sulfonamide was observed by TLC. The reaction was 
diluted with water, extracted with diethyl ether and the combined organic layers were 
washed with brine, dried over MgSO4, filtered and concentrated. The crude residue was 
purified by flash chromatography over silica gel. 
General Procedure 2 (GP2) 
 
Following the method reported by Stahl and co-workers,
60
 CuCl2 (20 mol%), 
sulfonamide (5.0 eq.) and Na2CO3 (2.0 eq.) were added to a 500 mL three-necked 
round-bottomed flask. The flask was purged with oxygen for 15 min and a solution of 
pyridine (2.0 eq.) in dry toluene [0.2 M relative to the amount of alkyne] was added. A 
balloon filled with oxygen was connected to the flask and the stirred mixture was heated 
at 70 ºC. After 15 min, a solution of alkyne (1.0 eq.) in dry toluene (0.2 M) was added 
by syringe pump over 4 h. The mixture was stirred at 70 ºC for another 4 h and allowed 
to cool to rt. The reaction mixture was filtered through a plug of silica gel, washed with 
ethyl acetate and concentrated. The crude residue was purified by flash chromatography 
over silica gel. 
General Procedure 3 (GP3) 
 
Following the method reported by Hsung and co-workers,
117
 CuSO4∙5H2O (10 mol%), 
1,10-phenanthroline (20 mol%), K2CO3 (2.0 eq.) and the corresponding sulfonamide 
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(1.0 eq.) were added to a round-bottomed flask and flushed with argon for 15 min. 
Bromoalkyne (1.3 eq.) and dry toluene [1 mL/mmol of sulfonamide] were then added 
and the reaction mixture was allowed to react at 70 ºC until complete consumption of 
the starting sulfonamide was observed by TLC. The reaction mixture was filtered over a 
plug of silica gel, washed with ethyl acetate and concentrated. The crude residue was 
purified by flash chromatography over silica gel. 
N-Methyl-N-(phenylethynyl)methanesulfonamide (264) 
Following GP1 using N-methylmethanesulfonamide (0.82 g, 7.4 
mmol) and (2,2-dibromovinyl)benzene (1.63 g, 9.0 mmol). After 
purification by flash chromatography [hexane:ethyl acetate (7:3)] 
ynamide 264 was obtained as a pale yellow solid (1.51 g, 97% yield). 
1
H NMR (300 
MHz, CDCl3) δ 7.46–7.37 (m, 2H), 7.36–7.27 (m, 3H), 3.30 (s, 3H), 3.13 (s, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 131.7 (2×CH), 128.5 (2×CH), 128.2 (CH), 122.5 (C), 83.2 
(C), 69.6 (C), 39.3 (CH3), 36.9 (CH3); IR νmax/cm
-1
 2241, 1347, 1320, 1155, 1107, 957, 
763. Analytical data matches that reported in the literature.
118
 
N-Phenyl-N-(phenylethynyl)methanesulfonamide (265) 
Following GP2 using N-phenylmethanesulfonamide (1.29 g, 7.5 mmol) 
and phenylacetylene (0.18 mL, 1.5 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (7:3)] ynamide 265 was obtained 
as a pale yellow solid (300.3 mg, 74% yield). 
1
H NMR (300 MHz, CDCl3) δ 7.64–7.55 
(m, 2H), 7.51–7.28 (m, 8H), 3.17 (s, 3H); 13C NMR (101 MHz, CDCl3) 138.7 (C), 
131.6 (2×CH), 129.5 (2×CH), 128.3 (CH), 128.3 (2×CH), 128.2 (CH), 125.6 (2×CH), 
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122.3 (C), 82.0 (C), 71.0 (C), 36.8 (CH3); IR νmax/cm
-1
 3078, 3009, 2928, 2243, 1588, 
1482, 1365, 1156, 962. Analytical data matches that reported in the literature.
75
 
N-Benzyl-N-(phenylethynyl)methanesulfonamide (266) 
Following GP1 using N-benzylmethanesulfonamide (0.36 g, 2.0 
mmol) and (2,2-dibromovinyl)benzene (0.54 g, 3.1 mmol). After 
purification by flash chromatography [hexane:ethyl acetate (4:1)] 
ynamide 266 was obtained as a pale yellow solid (473.5 mg, 83% yield). 
1
H NMR (300 
MHz, CDCl3) δ 7.60–7.15 (m, 10H), 4.68 (s, 2H), 2.90 (s, 3H); 
13
C NMR (101 MHz, 
CDCl3) δ 134.5 (C), 131.3 (2×CH), 129.0 (2×CH), 128.8 (2×CH), 128.7 (C), 128.3 
(2×CH), 128.0 (CH), 122.4 (CH), 82.0 (C), 71.6 (C), 55.9 (CH2), 38.9 (CH3); IR 
νmax/cm
-1
 3056, 3036, 2926, 2235, 1498, 1457, 1349, 1156. Analytical data matches that 
reported in the literature.
75
  
N-Allyl-N-(phenylethynyl)methanesulfonamide (267) 
Following GP1 using N-allylmethanesulfonamide (180.1 mg, 1.3 mmol) 
and (2,2-dibromovinyl)benzene (525.0 mg, 2.0 mmol). After purification 
by flash chromatography [hexane:ethyl acetate (9:1)] ynamide 267 was 
isolated as a pale yellow solid (202.3 mg, 64%); 
1
H NMR (300 MHz, CDCl3) δ 7.48–
7.35 (m, 2H), 7.34–7.26 (m, 3H), 6.00 (ddt, J = 16.6, 10.1, 6.4 Hz, 1H), 5.44 (app. dq, J 
= 16.6, 1.3 Hz, 1H), 5.38 (app. dq, J = 10.1, 1.3 Hz, 1H), 4.17 (app. dt, J = 6.4, 1.3 Hz, 
2H), 3.14 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 131.6 (CH), 131.0 (CH), 128.4 
(2×CH), 128.2 (2×CH), 122.6 (C), 120.7 (CH2), 81.7 (C), 71.3 (C), 54.5 (CH2), 39.1 
(CH3); IR νmax/cm
-1
 3032, 2933, 2238, 1441, 1348, 1158, 1106, 1025. Analytical data 
matches that reported in the literature.
75
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Diethyl methyl(phenylethynyl)phosphoramidate (268) 
Following GP3 using diethyl methylphosphoramidate (0.84 g, 5.0 
mmol) and (bromoethynyl)benzene (1.08 g, 6.0 mmol). After 
purification by flash chromatography [hexane:ethyl acetate (1:4)] ynamide 268 was 
isolated as a pale yellow solid (0.87 g, 65%); 
1
H NMR (300 MHz, CDCl3) δ 7.39–7.32 
(m, 2H), 7.32–7.23 (m, 3H), 4.29–4.15 (m, 4H), 3.17 (d, J = 7.9 Hz, 3H), 1.41 (td, J = 
7.1. 1.0 Hz, 6H); 
13
C NMR (101 MHz, CDCl3) δ 131.1 (2×CH), 128.3 (2×CH), 127.1 
(CH), 123.9 (C), 87.3 (d, JC-P = 4.4 Hz, C), 64.0 (d, JC-P = 5.6 Hz, 2×CH2), 63.8 (d, JC-P 
= 5.1 Hz, C), 39.0 (d, JC-P = 5.7 Hz, CH3), 16.2 (d, JC-P = 6.8 Hz, 2×CH3); IR νmax/cm
-1
 
2983, 2236, 1442, 1350, 1269, 1115, 991, 795. Analytical data matches that reported in 
the literature.
34b
 
N-(4-Methoxybenzyl)-N-((3-nitrophenyl)ethynyl)methanesulfonamide (269) 
Following GP1 using N-(4-methoxyphenyl)-
methanesulfonamide (0.43 mg, 2.0 mmol) and 1,1-dibromo-
2-(3-nitrophenyl)ethene (0.86 mg, 2.8 mmol). After 
purification by flash chromatography [hexane:ethyl acetate (4:1)] ynamide 269 was 
isolated as a white solid (366.8 mg, 51%); mp: 90–92 ºC; 1H NMR (300 MHz, CDCl3) δ 
8.17 (app. t, J = 1.7 Hz, 1H), 8.16–8.11 (m, 1H), 7.65 (app. dt, J = 8.0, 1.7 Hz, 1H), 
7.49 (app. t, J = 8.0 Hz, 1H), 7.43 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 4.71 (s, 
2H), 3.86 (s, 3H), 2.98 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 160.2 (C), 148.1 (CH), 
136.6 (C), 130.5 (2×CH), 129.3 (CH), 126.1 (CH), 125.7 (CH), 124.6 (C), 122.4 (C), 
114.3 (2×CH), 84.7 (C), 70.1 (C), 55.6 (CH2), 55.3 (CH3), 39.5 (CH3); IR νmax/cm
-1 
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3106, 3008, 2929, 2230, 1514, 1349, 1158, 965, 757; HR-MS (ES-TOF): m/z: calcd. for 
C17H17N2O5S: 361.0858 found 361.0853 [M+H]
+ 
N-((4-Methoxyphenyl)ethynyl)-N-phenylmethanesulfonamide (270) 
Following GP2 using N-phenylmethanesulfonamide (1.85 g, 10.9 
mmol) and 1-ethynyl-4-methoxybenzene (0.24 g, 1.8 mmol). After 
purification by flash chromatography [hexane:ethyl acetate (17:1)] 
ynamide 270 was isolated as a white solid (346.9 mg, 65%); mp: 92–94 ºC; 1H NMR 
(300 MHz, CDCl3) δ 7.58 (d, J = 7.9 Hz, 2H), 7.50–7.31 (m, 5H), 6.85 (d, J = 7.9 Hz, 
2H), 3.82 (s, 3H), 3.16 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 159.8 (C), 138.9 (C), 
133.6 (2×CH), 129.5 (2×CH), 128.2 (CH), 125.6 (2×CH), 114.1 (C), 114.0 (2×CH), 
80.6 (C), 70.7 (C), 55.3 (CH3), 36.7 (CH3); IR νmax/cm
-1
 3155, 3028, 2933, 2257, 1496, 
1287, 1161, 963, 752; HR-MS (ES-TOF): m/z: calcd. for C16H15NO3NaS: 324.0670 
found 324.0678 [M+Na]
+
. 
N-Benzyl-N-((2-bromophenyl)ethynyl)methanesulfonamide (271) 
Following GP1 using N-benzylmethanesulfonamide (326 mg, 1.80 
mmol) and 1,1-dibromo-2-(2-bromophenyl)ethene (0.90 g, 2.7 
mmol). After purification by flash chromatography [hexane:ethyl 
acetate (4:1)] ynamide 271 was isolated as an orange solid (130.3 mg, 20%); mp: 90–92 
ºC; 
1
H NMR (300 MHz, CDCl3) δ 7.59–7.52 (m, 3H), 7.45–7.34 (m, 4H), 7.22 (dd, J = 
7.7, 1.2 Hz, 1H), 7.13 (app. td, J = 7.7, 1.7 Hz, 1H), 4.75 (s, 2H), 2.96 (s, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 134.4 (C), 132.7 (CH), 132.3 (CH), 129.1 (2×CH), 128.9 
(CH), 128.9 (2×CH), 128.8 (CH), 127.0 (CH), 125.0 (C), 124.8 (C), 86.5 (C), 70.9 (C), 
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56.0 (CH2), 39.3 (CH3); IR νmax/cm
-1
 3059, 3029, 2235, 1411, 1347, 1155, 1050, 962; 
HR-MS (ES-TOF): m/z: calcd. for C16H15NO2S
79
Br: 364.0007 found 364.0000 [M+H]
+
. 
N-([1,1'-Biphenyl]-2-ylethynyl)-N-phenylmethanesulfonamide (272) 
Following GP1 using N-phenylmethanesulfonamide (182.2 mg, 1.1 
mmol) and 1,1-dibromo-2-(2-biphenyl)ethene (450.0 mg, 1.4 mmol). 
After purification by flash chromatography [hexane:ethyl acetate (4:1)] 
ynamide 272 was isolated as a white solid (114.4 mg, 30%); mp: 96–98 ºC; 1H NMR 
(300 MHz, CDCl3) δ 7.61–7.52 (m, 3H), 7.47–7.27 (m, 11H), 2.81 (s, 3H); 
13
C NMR 
(101 MHz, CDCl3) δ 143.9 (C), 140.9 (C), 138.6 (C), 132.7 (CH), 129.3 (CH), 129.3 
(2×CH), 129.3 (2×CH), 128.3 (CH), 128.1 (2×CH), 128.1 (CH), 127.4 (CH), 127.2 
(CH), 125.5 (2×CH), 120.9 (C), 84.5 (C), 70.9 (C), 36.4 (CH3); IR νmax/cm
-1 
3077, 3021, 
3004, 2953, 2236, 1589, 1360, 1166, 957, 756; HR-MS (ES-TOF): m/z: calcd. for 
C21H17NO2NaS: 370.0878 found 370.0874 [M+Na]
+
. 
3-([1,1'-Biphenyl]-2-ylethynyl)oxazolidin-2-one (273) 
Following GP1 using oxazolidin-2-one (0.13 g, 1.5 mmol) and 1,1-
dibromo-2-(2-biphenyl)ethene (0.76 g, 2.3 mmol). After purification by 
flash chromatography [hexane:ethyl acetate (4:1)] ynamide 273 was 
isolated as a white solid (170.1 mg, 43%); mp: 94–96 ºC; 1H-NMR (300 MHz, CDCl3) 
δ 7.64–7.52 (m, 3H), 7.48–7.26 (m, 6H), 4.41 (app. t, J = 7.8 Hz, 2H), 3.80 (app. t, J = 
7.8 Hz, 2H); 
13
C-NMR (101 MHz, CDCl3) δ 155.6 (C), 143.5 (C), 140.5 (C), 132.5 
(CH), 129.4 (CH), 129.3 (2×CH), 128.3 (CH), 128.0 (2×CH), 127.5 (CH), 127.1 (CH), 
120.6 (C), 81.8 (C), 71.2 (C), 63.0 (CH2), 46.6 (CH2); IR νmax/cm
-1 
3066, 2983, 2252, 
Chapter 5 
113 
 
1762, 1477, 1197, 1164, 1029, 949, 745; HR-MS (ES-TOF): m/z: calcd. for C17H14NO2: 
264.1025 found 264.1031 [M+H]
+
. 
N-(Phenyl)-N-(thiophen-2-ylethynyl)methanesulfonamide (274) 
Following GP1 using N-phenylmethanesulfonamide (0.29 g, 1.7 mmol) 
and 1,1-dibromo-2-thiophenylethene (0.69 g, 2.6 mmol). After 
purification by flash chromatography [hexane:ethyl acetate (4:1)] 
ynamide 274 was isolated as a white solid (188.9 mg, 40%); mp: 66–68 ºC; 1H NMR 
(300 MHz, CDCl3) δ 7.62–7.55 (m, 2H), 7.51–7.43 (m, 2H), 7.43–7.36 (m, 1H), 7.33 
(dd, J = 5.2, 1.1 Hz, 1H), 7.30 (dd, J = 3.7, 1.1 Hz, 1H), 7.01 (dd, J = 5.2, 3.7 Hz, 1H), 
3.20 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 138.6 (CH), 133.5 (C), 129.6 (2×CH), 
128.5 (CH), 128.2 (CH), 127.1 (CH), 125.6 (2×CH), 122.2 (C), 85.4 (C), 64.4 (C), 37.2 
(CH3); IR νmax/cm
-1 
3102, 3026, 2933, 2233, 1490, 1367, 1166, 960, 777; HR-MS (ES-
TOF): m/z: calcd. for C13H12NO2S2: 278.0214 found 278.0221 [M+H]
+
. 
N-(4-Methoxybenzyl)-N-(thiophen -2-ylethynyl)methanesulfonamide (275) 
Following GP1 using N-(4-methoxyphenyl)-methane-
sulfonamide (0.43 g, 2.0 mmol) and 1,1-dibromo-2-
thiophenylethene (0.78 g, 2.9 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (4:1)] ynamide 275 was isolated as a white solid 
(529.1 mg, 82%); mp: 64–66 ºC; 1H NMR (300 MHz, CDCl3) δ 7.43 (d, J = 8.7 Hz, 
2H), 7.30 (dd, J = 5.2, 1.1 Hz, 1H), 7.22 (dd, J = 3.6, 1.1 Hz, 1H), 7.00 (dd, J = 5.2, 3.6 
Hz, 1H), 6.95 (d, J = 8.7 Hz, 2H), 4.68 (s, 2H), 3.85 (s, 3H), 2.92 (s, 3H); 
13
C NMR 
(101 MHz, CDCl3) δ 160.0 (C), 133.2 (C), 130.5 (2×CH), 128.0 (CH), 127.0 (CH), 
126.5 (CH), 122.5 (C), 114.2 (2×CH), 85.6 (C), 64.9 (C), 55.8 (CH3), 55.3 (CH2), 39.3 
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(CH3); IR νmax/cm
-1 
3106, 3007, 2964, 2229, 1514, 1348, 1159, 965, 758; HR-MS (ES-
TOF): m/z: calcd. for C15H15NO3NaS2: 344.0391 found 344.0392 [M+Na]
+
. 
N-(4-Methoxybenzyl)-N-(furan-2-ylethynyl)methanesulfonamide (276) 
Following GP1 using N-(4-methoxyphenyl)-methane-
sulfonamide (0.43 g, 2.0 mmol) and 1,1-dibromo-2-furanylethene 
(0.71 g, 2.8 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (4:1)] ynamide 276 was isolated as a white solid (371.1 mg, 60%); 
mp: 54–56 ºC; 1H NMR (300 MHz, CDCl3) δ 7.45–7.39 (m, 3H), 6.94 (d, J = 8.7 Hz, 
2H), 6.65 (dd, J = 3.4, 0.7 Hz, 1H), 6.42 (dd, J = 3.4, 1.9 Hz, 1H), 4.69 (s, 2H), 3.85 (s, 
3H), 2.92 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 160.0 (C), 144.2 (C), 136.5 (C), 130.5 
(2×CH), 126.5 (CH), 117.5 (CH), 114.2 (2×CH), 111.1 (CH), 86.3 (C), 62.4 (C), 55.8 
(CH3), 55.3 (CH2), 39.4 (CH3); IR νmax/cm
-1 
3147, 3015, 2932, 2226, 1512, 1348, 1154, 
948, 764; HR-MS (ES-TOF): m/z: calcd. for C15H15NO4NaS: 328.0619 found 328.0610 
[M+Na]
+
. 
N-((1-Acetyl-1H-indol-3-yl)ethynyl)-N-phenylmethanesulfonamide (277) 
Following GP2 using N-phenylmethanesulfonamide (1.03 g, 6.0 
mmol) and 1-(3-ethynyl-1H-indol-1-yl)ethen-1-one (0.18 mg, 1.0 
mmol). After purification by flash chromatography [toluene:ethyl 
acetate (95:5)] ynamide 277 was isolated as a white solid (96.3 mg, 27%); mp: 142–144 
ºC; 
1
H NMR (300 MHz, CDCl3) δ 8.42 (d, J = 8.0 Hz, 1H), 7.73–7.57 (m, 4H), 7.54–
7.30 (m, 5H), 3.21 (s, 3H), 2.64 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 168.3 (C), 
138.8 (C), 135.1 (C), 130.7 (C), 129.8 (2×CH), 128.6 (CH), 128.5 (CH), 126.3 (CH), 
125.7 (2×CH), 124.4 (CH), 120.0 (CH), 116.8 (CH), 104.3 (C), 85.8 (C), 62.8 (C), 37.2 
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(CH3), 24.0 (CH3); IR νmax/cm
-1
 3155, 3028, 2933, 1716, 1491, 1348, 1283, 1052, 996, 
818, 742; HR-MS (ES-TOF): m/z: calcd. for C19H16N2O3NaS: 375.0779 found 
375.0782 [M+Na]
+
. 
(E)-N-Benzyl-N-(4-phenylbut-3-en-1-yn-1-yl)methanesulfonamide (278) 
 Following GP1 using N-benzylmethanesulfonamide (0.32 g, 1.7 
mmol) and (E)-(4,4-dibromobuta-1,3-dien-1-yl)benzene (0.72 mg, 
2.6 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (7:3)] ynamide 278 was isolated as a white 
solid (367.2 mg, 69%); mp: 84–86 ºC; 1H NMR (300 MHz, CDCl3) δ 7.57–7.22 (m, 10 
H), 6.84 (d, J = 16.2 Hz, 1H), 6.24 (d, J = 16.2 Hz, 1H), 4.68 (s, 2H), 2.92 (s, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 140.0 (CH), 136.3 (C), 134.5 (C), 128.9 (2×CH), 128.9 
(2×CH), 128.8 (CH), 128.7 (2×CH), 128.5 (CH), 126.1 (2×CH), 107.2 (CH), 83.9 (C), 
71.2 (C), 55.9 (CH2), 39.1 (CH3); IR νmax/cm
-1
 3059, 3026, 2929, 2221, 1494, 1351, 
1161, 946, 746; HR-MS (ES-TOF): m/z: calcd. for C18H17NO2NaS: 334.0878 found 
334.0883 [M+Na]
+
. 
N-(Cyclopropylethynyl)-N-phenylmethanesulfonamide (279) 
Following GP2 using N-phenylmethanesulfonamide (1.26 g, 7.4 mmol) 
and cyclopropylacetylene (120.0 µL, 1.5 mmol). After purification by 
flash chromatography [hexane:ethyl acetate (9:1)] ynamide 279 was 
isolated as a white solid (303.7 mg, 88%); mp: 62–64 ºC; 1H NMR (300 MHz, CDCl3) δ 
7.51–745 (m, 2H), 7.44–7.36 (m, 2H), 7.35–7.29 (m, 1H), 3.07 (s, 3H), 1.38 (tt, J = 8.0, 
4.9 Hz, 1H), 0.87–0.70 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 139.3 (C), 129.5 
(2×CH), 128.1 (CH), 125.6 (2×CH), 75.3 (C), 68.8 (C), 36.5 (CH3), 9.0 (2×CH2), -0.6; 
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IR νmax/cm
-1
 3157, 3014, 2933, 2220, 1715, 1490, 1348, 1283, 1157, 965, 779; HR-MS 
(ES-TOF): m/z: calcd. for C12H14NO2S: 236.0745 found 236.0746 [M+H]
+
. 
N-Benzyl-N-(hex-1-yn-1-yl)methanesulfonamide (280) 
 Following GP3 using N-benzylmethanesulfonamide (0.43 g, 2.4 mmol) 
and (bromoethynyl)benzene (0.47 g, 3.1 mmol). After purification by 
flash chromatography [hexane:ethyl acetate (9:1)] ynamide 280 was 
obtained as a colourless oil (628.8 mg, 99% yield). 
1
H NMR (300 MHz, CDCl3) δ 7.48–
7.33 (m, 5H), 4.57 (s, 2H), 2.86 (s, 3H), 2.26 (t, J = 6.9 Hz, 2H), 1.52–1.25 (m, 4H), 
0.88 (t, J = 7.2 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 134.8 (C), 128.9 (2×CH), 128.6 
(2×CH), 128.5 (CH), 72.9 (C), 71.4 (C), 55.6 (CH2), 38.2 (CH3), 30.9 (CH2), 21.8 
(CH2), 18.1 (CH2), 13.5 (CH3); IR νmax/cm
-1
 2957, 2932, 2254, 1684, 1456, 1351, 1159, 
1026. Analytical data matches that reported in the literature.
75 
N-Benzyl-N-(5-chloropent-1-yn-1-yl)methanesulfonamide (281) 
Following GP3 using N-benzylmethanesulfonamide (0.38 g, 2.0 mmol) 
and 1-bromo-5-chloropent-1-yne (0.45 mg, 2.5 mmol). After purification 
by flash chromatography [hexane:ethyl acetate (4:1)] ynamide 281 was 
isolated as a colourless oil (534.0 mg, 92%); 
1
H NMR (300 MHz, CDCl3) δ 7.49–7.32 
(m, 5H), 4.58 (s, 2H), 3.51 (t, J = 6.6 Hz, 2H), 2.89 (s, 3H), 2.47 (t, J = 6.6 Hz, 2H), 
1.89 (app. quin, J = 6.6 Hz, 2H); 
13
C NMR (101 MHz, CDCl3) δ 134.6 (C), 128.9 
(2×CH), 128.8 (2×CH), 128.7 (CH), 73.9 (C), 69.5 (C), 55.5 (CH2), 43.5 (CH2), 38.4 
(CH3), 31.3 (CH2), 15.9 (CH2); IR νmax/cm
-1
 3104, 3046, 2927, 2255, 1484, 1348, 1217, 
1154, 960, 754; HR-MS (ES-TOF): m/z: calcd. for C13H17ClNO2S: 286.0679, found: 
286.0678 [M+H]
+
. 
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(S)-(+)-N-Benzyl-N-(4,8-dimethylnon-7-en-1-yn-1-yl)methanesulfonamide (282) 
Following GP1 using N-benzylmethanesulfonamide (0.26 g, 1.4 
mmol) and (S)-1,1-dibromo-3,7-dimethylocta-1,6-diene (0.63 g, 2.1 
mmol). After purification by flash chromatography [hexane:ethyl 
acetate (85:5)] ynamide 282 was isolated as a colourless oil (412.4 mg, 87%);     
    
10.7 (c 1.31, CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 7.52-7.34 (m, 5H), 5.08 (t, J = 8.5 
Hz, 1H), 4.60 (s, 2H), 2.88 (s, 3H), 2.25 (dd, J = 16.6, 5.6 Hz, 1H), 2.17 (dd, J = 16.6, 
6.6 Hz, 1H), 2.05–1.89 (m, 2H), 1.70 (s, 3H), 1.67–1.54 (m, 4H), 1.45–1.29 (m, 1H), 
1.28–1.11 (m, 1H), 0.92 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 134.8 (C), 
131.4 (C), 128.9 (2×CH), 128.7 (2×CH), 128.5 (CH), 124.4 (CH), 73.8 (C), 70.1 (C), 
55.6 (CH2), 38.3 (CH3), 36.0 (CH2), 32.3 (CH), 25.7 (CH3), 25.7 (CH2), 25.5 (CH2), 
19.4 (CH3), 17.7 (CH3); IR νmax/cm
-1
 2967, 2925, 2255, 1682, 1493, 1351, 1325, 1151, 
967, 761; HR-MS (ES-TOF): m/z: calcd. for C19H28NO2S: 334.1841, found: 334.1831 
[M+H]
+
. 
N-(4-(Benzo[d][1,3]dioxol-5-yl)-3-methylbut-1-yn-1-yl)-N-benzylmethanesulfonamide 
(283) 
Following GP1 using N-benzylmethanesulfonamide (0.23 g, 1.3 
mmol) and 5-(4,4-dibromo-2-methylbut-3-en-1-yl)benzo[d][1,3]-
dioxole (0.64, 1.9 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (4:1)] ynamide 283 was isolated as a colourless 
oil (370.6 mg, 69%); 
1
H NMR (300 MHz, CDCl3) δ 7.43–7.31 (m, 5H), 6.71 (d, J = 7.9 
Hz, 1H), 6.69 (d, J = 1.5 Hz, 1H), 6.61 (dd, J = 7.9, 1.5 Hz, 1H), 5.94–5.91 (m, 2H), 
4.64-4.46 (m, 2H), 2.84–2.69 (m, 4H), 2.66–2.60 (m, 2H), 1.18 (d, J = 6.7 Hz, 3H); 13C 
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NMR (101 MHz, CDCl3) δ 147.4 (C), 146.0 (C), 134.7 (C), 133.4 (C), 129.0 (2×CH), 
128.7 (2×CH), 128.6 (CH), 122.2 (CH), 109.7 (CH), 107.9 (CH), 100.8 (CH2), 74.9 (C), 
74.4 (C), 55.6 (CH2), 42.8 (CH2), 38.2 (CH3), 28.1 (CH), 20.8 (CH3); IR νmax/cm
-1
 3026, 
2970, 2930, 2250, 1488, 1351, 1245, 1158, 1036, 793; HR-MS (ES-TOF): m/z: calcd. 
for C20H22NO4S: 372.1270, found: 372.1274 [M+H]
+
. 
3-(Cyclopropylethynyl)-1H-indole (312a) 
Following the literature procedure,
34a
 using 3-iodoindole (0.49 mg, 2.0 
mmol) and cyclopropyl acetylene (0.50 mL, 5.9 mmol). After 
purification by flash chromatography [hexane:toluene (9:1)] 
alkynylindole 312a was isolated as a dark brown solid (289.5 mg, 80%); 
1
H NMR (300 
MHz, CDCl3) δ 8.09 (br., 1H), 7.73 (dd, J = 7.6, 1.3 Hz, 1H), 7.40–7.36 (m, 1H), 7.35 
(d, J = 2.6 Hz, 1H), 7.26–7.24 (m, 1H), 7.22 (dd, J = 8.2, 1.5 Hz, 1H), 1.58–1.50 (m, 
1H), 0.92–0.80 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 135.3 (C), 129.0 (C), 127.4 
(CH), 123.0 (CH), 120.6 (CH), 120.1 (CH), 111.3 (CH), 99.5 (C), 94.8 (C), 68.6 (C), 
8.8 (2×CH2), 0.5 (CH); IR νmax/cm
-1
 23380, 1607, 1485, 1432, 1174, 930, 830, 736. 
Analytical data matches that reported in the literature.
34a
 
3-(Phenylethynyl)-1H-indole (312b) 
Following the literature procedure,
34a
 using 3-iodoindole (1.21 g, 5.0 
mmol) and phenyl acetylene (0.71 mL, 6.0 mmol). After purification 
by flash chromatography [hexane:toluene (9:1)] alkynylindole 312b 
was isolated as a brown solid (759.4 mg, 70%); 
1
H NMR (300 MHz, DMSO-d6) δ 11.58 
(br., 1H), 7.78 (d, J = 2.7 Hz, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.57–7.51 (m, 2H), 7.47–
7.30 (m, 4H), 7.24–7.01 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 135.5 (C), 130.8 
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(2CH), 129.7 (CH), 128.5 (2CH), 128.1 (C), 127.7 (C), 123.9 (CH), 122.4 (CH), 
120.1 (CH), 119.0 (CH), 112.2 (CH), 96.1 (C), 90.6 (C), 84.4 (C); IR νmax/cm
-1
 3386, 
2214, 1484, 1421, 1456, 1333, 1236, 1100, 819. Analytical data matches that reported 
in the literature.
34a
  
5.2.2 Preparation of pyridinium N-(heteroaryl)aminides 
General Procedure 4 (GP4) 
 
Following the method reported by Alvarez-Builla and co-workers,
103
 potassium 
carbonate (2.8 eq.) was added to a solution of N-aminopyridinium iodide (1.0 eq.) in 
acetonitrile [0.2 M relative to the amount of N-aminopyridinium iodide] and the 
reaction mixture was stirred for 45 min. at rt to give a purple solution. The 
corresponding haloheterocycle (1.04 eq.) was added to the reaction mixture and heated 
under reflux for the indicated amount of time. After this time the solvent was 
evaporated under reduced pressure and the residue redissolved in CH2Cl2 and washed 
with NaOH (2.5 M). The combined organic layers were dried with MgSO4, filtered off 
and the solvent removed under reduced pressure, purifying the resulting compound by 
flash chromatography over silica gel using the indicated eluent. 
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General Procedure 5 (GP5) 
 
Following and adaptation of GP4 where the solvent was replaced for methanol and the 
mixture was stirred at rt for the indicated amount of time. 
General Procedure 6 (GP6) 
 
Following the method reported by Alvarez-Builla and co-workers,
119
 N-iodosuccinimide 
(1.1 eq.) was added to a stirred solution of the corresponding aminide (1.0 eq.) in DMF 
[0.2 M relative to the amount of aminide]. The reaction mixture was stirred at 50 ºC for 
5 h. Once the starting material was consumed (detected by TLC), the mixture was 
extracted with CH2Cl2 and washed with brine. The combined organic layers were dried 
with MgSO4, filtered off and the solvent removed under reduced pressure, purifying the 
resulting compound by flash chromatography over silica gel using the indicated eluent. 
General Procedure 7 (GP7) 
 
Following the method reported by Alvarez-Builla and co-workers,
104
 aminide (1.0 eq.), 
the corresponding boronic acid (1.5 eq.) and K2CO3 (10.0 eq.) were combined in a 
toluene/ethanol mixture [4:1, 15 mL/mmol of aminide]. Pd(PPh3)4 (5 mol%) was added 
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and the mixture was stirred under argon at 80 ºC for 4.5 h. Once the starting material 
was consumed (detected by TLC), the solution was filtered and concentrated under 
reduced pressure. The crude residue was purified by flash chromatography over silica 
gel using the indicated eluent. 
N-(Pyrimidin-2-yl)pyridinium aminide (239) 
Following GP4 using N-aminopyridinium iodide (0.40 g, 1.8 mmol), 2-
chloropyrimidine (0.21 g, 1.9 mmol) and potassium carbonate (0.70 g, 
5.0 mmol) for 4 h. After purification by flash chromatography [CH2Cl2:MeOH (98:2)] 
aminide 239 was isolated as a bright yellow solid (217.4 mg, 70%); mp: 152–154 ºC 
(lit.
53
 150-152 ºC); 
1
H NMR (300 MHz, CDCl3) δ 8.71 (dd, J = 6.9, 1.3 Hz, 2H), 8.20 
(tt, J = 7.8, 1.3 Hz, 1H), 8.11 (d, J = 4.8 Hz, 2H), 7.91 (dd, J = 7.8, 6.9 Hz, 2H), 6.38 (t, 
J = 4.8 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 169.4 (C), 159.2 (2×CH), 145.8 
(2×CH), 139.9 (CH), 128.8 (2×CH), 109.0 (CH). Analytical data matches that reported 
in the literature.
103
 
N-(Pyrazin-2-yl)pyridinium aminide (380) 
Following GP4 using N-aminopyridinium iodide (0.40 g, 1.8 mmol), 2-
chloropyrazine (0.21 g, 1.9 mmol) and potassium carbonate (0.70 g, 5.0 
mmol) for 4 h. After purification by flash chromatography [CH2Cl2:MeOH (9:1)] 
aminide 380 was isolated as a bright yellow solid (203.9 mg, 66%); mp: 159–161 ºC 
(lit.
53
 157-159 ºC); 
1
H NMR (300 MHz, CDCl3) δ 8.82 (dd, J = 7.0, 1.2 Hz, 2H), 8.21 (t, 
J = 7.8 Hz, 1H), 7.93 (dd, J = 7.8, 7.0 Hz, 2H), 7.86 (d, J = 1.5 Hz, 1H), 7.61 (dd, J = 
3.1, 1.5 Hz, 1H), 7.45 (d, J = 3.1 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 162.0 (C), 
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145.3 (2×CH), 141.9 (CH), 140.0 (CH), 136.8 (CH), 129.5 (CH), 128.9 (2×CH). 
Analytical data matches that reported in the literature.
103
 
N-(2-Chloropyrimidin-4-yl)pyridinium aminide (381) 
Following GP4 using N-aminopyridinium iodide (0.40 g, 1.8 mmol), 
2,4-dichloropyrimidine (0.21 g, 1.9 mmol) and potassium carbonate 
(0.70 g, 5.0 mmol) for 15 h. After purification by flash chromatography [AcOEt:MeOH 
(4:1)] aminide 381 was isolated as a bright yellow solid (333.0 mg, 79%); mp: 130–132 
ºC (lit.
103
 134-136 ºC); 
1
H NMR (300 MHz, CDCl3) δ 8.65 (dd, J = 6.9, 1.4 Hz, 2H), 
8.27 (t, J = 7.6 Hz, 1H), 7.94 (dd, J = 7.6, 6.9 Hz, 2H), 7.65 (d, J = 6.2 Hz, 1H), 6.25 (d, 
J = 6.2 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 168.9 (C), 160.8 (C), 153.8 (CH), 
145.5 (2×CH), 141.2 (CH), 128.6 (2×CH), 105.8 (CH). Analytical data matches that 
reported in the literature.
103
 
N-(6-Chloropyridazin-3-yl)pyridinium aminide (382) 
Following GP4 using N-aminopyridinium iodide (0.40 g, 1.8 mmol), 
and 3,6-dichloropyridazine (0.21 g, 1.9 mmol) and potassium 
carbonate (0.70 g, 5.0 mmol) for 15 h. After purification by flash chromatography 
[AcOEt:MeOH (3:2)] aminide 382 was isolated as a bright yellow solid (310.8 mg, 
84%); mp: 154–156 ºC (lit.103 154-155 ºC); 1H NMR (300 MHz, CDCl3) δ 8.79 (dd, J = 
6.9, 1.3 Hz, 2H), 8.22 (t, J = 7.8 Hz, 1H), 7.93 (dd, J = 7.8, 6.9 Hz, 2H), 7.18 (d, J = 9.4 
Hz, 1H), 6.83 (d, J = 9.4 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 164.9 (C), 145.5 
(2×CH), 144.8 (C), 140.3 (CH), 129.9 (CH), 128.9 (2×CH), 122.3 (CH). Analytical data 
matches that reported in the literature.
103
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N-(Pyridin-2-yl)pyridinium aminide (384) 
Following the method reported by Alvarez-Builla,
103
 a flame-dried flask 
was charged with N-aminopyridinium iodide (125.2 mg, 0.56 mmol), 2-
bromopyridine (37.0 µL, 0.37 mmol), sodium tert-butoxide (220.5 mg, 2.25 mmol) and 
BINAP (10.1 mg, 0.02 mmol). The mixture was flushed with argon for 10 min. Dry 
toluene [0.04 M relative to the amount of bromopyridine] and 
tris(dibenzylidenacetone)-palladium(0) (15.6 mg, 0.02 mmol) were added and the 
mixture heated under reflux for 24 h. After purification by flash chromatography 
[CH2Cl2:MeOH (95:5)] aminide 384 was isolated as a bright yellow solid (43.5 mg, 
69%); mp: 117–119 ºC (lit.53 115-116 ºC); 1H NMR (300 MHz, CDCl3) δ 9.07 (dd, J = 
5.6, 2.8 Hz, 2H), 7.90 (dd, J = 5.1, 1.2 Hz, 1H), 7.42–7.36 (m, 4H), 6.60 (d, J = 8.5 Hz, 
1H), 6.54–6.41 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 163.0 (C), 145.9 (CH), 139.1 
(2×CH), 136.8 (CH), 129.4 (CH), 125.5 (2×CH), 113.5 (CH), 112.4 (CH). Analytical 
data matches that reported in the literature.
53
 
N-(5-Iodopyrazin-2-yl)pyridinium aminide (385) 
Following GP6 using aminide 380 (242.3 mg, 1.4 mmol) and NIS 
(346.7 mg, 1.5 mmol) for 4 h. After purification by flash 
chromatography [CH2Cl2:MeOH (9:1)] aminide 380 was isolated as an orange solid 
(299.0 mg, 47%); mp: 133–135 ºC (lit.119 132-134 ºC); 1H NMR (300 MHz, CDCl3) δ 
9.03–8.96 (m, 2H), 7.89 (d, J = 1.4 Hz, 1H), 7.88 (d, J = 1.4 Hz, 1H), 7.78–7.68 (m, 
1H), 7.59 (app. t, J = 7.0 Hz, 2H); 
13
C NMR (101 MHz, CDCl3) δ 149.8 (C), 147.0 
(2×CH), 141.4 (CH), 139.2 (CH), 134.5 (CH), 126.3 (2×CH), 123.7 (C). Analytical data 
matches that reported in the literature.
119
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N-(5-Iodopyrimidin-2-yl)pyridinium aminide (386) 
 Following GP6 using aminide 239 (200.5 mg, 1.2 mmol) and NIS 
(286.2 mg, 1.3 mmol) for 4 h. After purification by flash 
chromatography [CH2Cl2:MeOH (9:1)] aminide 386 was isolated as a yellow solid 
(323.3 mg, 93%); 
1
H NMR (300 MHz, CDCl3) δ 8.80 (d, J = 5.6 Hz, 2H), 8.25 (s, 2H), 
7.80 (t, J = 7.3 Hz, 1H), 7.71–7.53 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 165.5 (C), 
162.4 (2×CH), 142.4 (2×CH), 134.6 (CH), 126.1 (2×CH), 72.6 (C); HRMS (ES-TOF): 
m/z: calcd. for C9H7N4
127
I: 298.9794, found: 298.9784 [M]
+
. Analytical data matches 
that reported in the literature.
119
 
N-(5-(3-Formylphenyl)pyrazin-2-yl)pyridinium aminide (388) 
Following GP7 using (3-formylphenyl)boronic acid (143.1 mg, 
0.9 mmol) and aminide 385 (189.8 mg, 0.6 mmol). After 
purification by flash chromatography [ethyl acetate:methanol 
(4:1)] aminide 388 was isolated as a bright yellow solid (135.2 mg, 63% at ~90% purity 
estimated by 
1
H NMR); mp: 126–128 ºC; 1H NMR (300 MHz, CDCl3) δ 10.10 (s, 1H), 
9.14 (d, J = 5.9 Hz, 2H), 8.38 (s, 1H), 8.28 (d, J = 1.2 Hz, 1H), 8.19 (d, J = 1.2 Hz, 1H), 
8.16 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.73 (app. t, J = 7.8 Hz, 1H), 7.66–
7.56 (m, 3H);
 13
C NMR (101 MHz, CDCl3) δ 192.6 (CH), 157.6 (C), 140.9 (C), 140.8 
(CH), 138.9 (C), 137.9 (CH), 137.8 (CH), 136.9 (2×CH), 133.3 (C), 130.6 (CH), 129.4 
(CH), 127.8 (CH), 126.5 (CH), 126.2 (2×CH); IR νmax/cm
-1
 3118, 3062, 3923, 1690, 
1467, 1395, 1145, 997, 750; HRMS (ES-TOF): m/z: calcd. for C16H13N4O: 277.1089, 
found: 277.1092 [M+H]
+
. 
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N-(5-(3-Fluorophenyl)pyrimidin-2-yl)pyridinium aminide (389) 
Following GP7 using (3-fluorophenyl)boronic acid (167.8 mg, 1.2 
mmol) and aminide 386 (239.0 mg, 0.8 mmol). After purification 
by flash chromatography [ethyl acetate:methanol (7:3)] aminide 
389 was isolated as a bright orange solid (137.5 mg, 79% at ~90% purity estimated by 
1
H NMR); mp: 152–154 ºC; 1H NMR (300 MHz, CDCl3) δ 8.88 (d, J = 6.8 Hz, 2H), 
8.45 (s, 2H), 7.76 (t, J = 6.8 Hz, 1H), 7.60 (app. t, J = 6.8 Hz, 2H), 7.40–7.29 (m, 1H), 
7.22 (d, J = 8.5 Hz, 1H), 7.14 (d, JH-F = 9.1 Hz, 1H), 6.95 (app. t, J = 8.5 Hz, 1H); 
13
C 
NMR (101 MHz, CDCl3) δ 165.8 (d, JC-F = 245.8 Hz, CF), 162.1 (C), 156.1 (2×CH), 
142.3 (2×CH), 138.7 (d, JC-F = 8.0 Hz, C), 134.3 (CH), 130.4 (d, JC-F = 8.5 Hz, CH), 
126.1 (2×CH), 120.7 (CH), 120.4 (C), 113.3 (d, JC-F = 20.2 Hz, CH), 111.9 (d, JC-F = 
22.0 Hz, CH); IR νmax/cm
-1
 3109, 3040, 3023, 1582, 1420, 1273, 1160, 864, 767; HRMS 
(ES-TOF): m/z: calcd. for C15H12N4F: 267.1047, found: 267.1045 [M+H]
+
. 
N-(5-(2-Bromopyridin-5-yl)pyrimidin-2-yl)pyridinium aminide (390) 
Following GP7 using (6-bromopyridin-3-yl)boronic acid (242.4 
mg, 1.2 mmol) and aminide 386 (239.6 mg, 0.8 mmol). After 
purification by flash chromatography [ethyl acetate:methanol (7:3)] aminide 390 was 
isolated as a bright yellow solid (191.1 mg, 73% at ~90% purity estimated by 
1
H NMR); 
mp: 221–222 ºC; 1H NMR (300 MHz, CDCl3) δ 8.82 (d, J = 6.9 Hz, 2H), 8.46 (d, J = 
2.5 Hz, 1H), 8.40 (s, 2H), 7.83 (t, J = 7.6 Hz, 1H), 7.68–7.57 (m, 3H), 7.48 (d, J = 8.3 
Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 167.3 (C), 155.9 (CH), 146.5 (CH), 142.7 
(2×CH), 139.7 (C), 135.0 (CH), 134.8 (CH), 131.7 (C), 128.1 (2×CH), 126.2 (2×CH), 
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116.8 (C); IR νmax/cm
-1
 3130, 3014, 1572, 1498, 1352, 1183, 1074, 957, 1052, 864, 795; 
HRMS (ES-TOF): m/z: calcd. for C14H11N5
79
Br: 328.0197, found: 328.0198 [M+H]
+
. 
N-(6-Chloropyridin-2-yl)pyridinium aminide (411) 
Following GP4 using N-aminopyridinium iodide (221.3 mg, 1.0 
mmol), 2,6-dichloropyridine (152.4 mg, 1.1 mmol) and potassium 
carbonate (386.6 mg, 2.1 mmol) for 6 h. After purification by flash chromatography 
[CH2Cl2:MeOH (8:2)] aminide 411 was isolated as a brown solid (130.7 mg, 65%); 
1
H 
NMR (300 MHz, CDCl3) δ 9.07–9.00 (m, 2H), 7.64–7.56 (m, 1H), 7.55–7.47 (m, 2H), 
7.32 (dd, J = 8.3, 7.3 Hz, 1H), 6.50 (dd, J = 8.3, 0.6 Hz, 1H), 6.46 (dd, J = 7.3, 0.6 Hz, 
1H); 
13
C NMR (101 MHz, CDCl3) δ 151.0 (C), 147.8 (C), 140.2 (CH), 138.8 (2×CH), 
131.9 (CH), 125.8 (2×CH), 110.8 (CH), 110.6 (CH); HRMS (ES-TOF): m/z: calcd. for 
C10H9N3Cl: 206.0485, found: 206.0483 [M+H]
+
. Data matches that reported in the 
literature.
54
 
This transformation was also performed following GP5, using N-aminopyridinium 
iodide (221.9 mg, 1.0 mmol), 2,6-dichloropyridine (152.5 mg, 1.1 mmol) and potassium 
carbonate (388.0 mg, 2.1 mmol) for 24 h to give aminide 411 (199.4 mg, 97%). 
N-(2-Chloroquinazolin-4-yl)pyridinium aminide (412) 
Following GP4 using N-aminopyridinium iodide (322.4 mg, 1.5 
mmol), 2,4-dichloroquinazoline (300.3 mg, 0.5 mmol) and potassium 
carbonate (563.8 mg, 4.1 mmol) for 24 h. After purification by flash chromatography 
[CH2Cl2:MeOH (95:5)] aminide 412 was isolated as a bright yellow solid (347.0 mg, 
90%); mp: 205–207 ºC; 1H NMR (300 MHz, CDCl3) δ 8.75 (dd, J = 6.9, 1.2 Hz, 2H), 
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8.18 (dd, J = 7.6, 1.5 Hz, 1H), 8.00 (t, J = 7.7 Hz, 1H), 7.80–7.71 (m, 2H), 7.66–7.54 
(m, 2H), 7.34 (ddd, J = 8.2, 6.1, 1.5 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 
13
C NMR 
(101 MHz, CDCl3) δ 164.7 (C), 158.0 (C), 151.0 (C), 143.5 (2×CH), 137.8 (CH), 132.4 
(CH), 126.6 (2×CH), 126.1 (CH), 125.1 (CH), 124.0 (CH), 116.1 (C); IR νmax/cm
-1
 
3096, 3012, 1569, 1481, 1430, 1352, 1261, 1150, 943; HRMS (ES-TOF): m/z: calcd. 
for C13H10N4Cl: 257.0594, found: 257.0600 [M+H]
+
. 
This transformation was also performed following GP5, using N-aminopyridinium 
iodide (320.6 mg, 1.5 mmol), 2,6-dichloropyridine (152.4 mg, 1.1 mmol) and potassium 
carbonate (388.9 mg, 2.1 mmol) for 3 h to give aminide 412 (369.8 mg, 99%). 
5.2.3 Preparation of 227 
Following a reported procedure,
34a
 a double-neck, round-
bottom flask covered with aluminium foil was charged with 
AgSbF6 (61.0 mg, 0.18 mmol) dissolved in MeCN (10 mL). Chloro[tris(2,4-di-tert-
butylphenyl)phosphite]gold (130.2 mg, 0.15 mmol) was added at room temperature to 
the reaction mixture forming a white suspension. The reaction mixture was stirred at 
room temperature overnight. The solvent was removed under reduced pressure and the 
white solid residue was redissolved in CH2Cl2 (15 mL). After filtration through a plug 
of silica, evaporation of the solvent and drying on the high vaccuum line for at least 3 
hours, the gold complex 227 was afforded as a white powder (126.6 mg, 80%); 
1
H 
NMR (300 MHz, CDCl3) δ 7.50–7.46 (m, 3H), 7.37 (dd, J = 8.5, 1.5 Hz, 3H), 7.25 (d, J 
= 8.5 Hz, 3H), 2.50 (s, 3H), 1.46 (s, 27H), 1.32 (s, 27H); 
13
C NMR (101 MHz, CDCl3) δ 
13
C NMR (101 MHz, CDCl3) δ 149.2 (3×C), 147.1 (3×C), 139.1 (3×C), 125.9 (3×CH), 
124.7 (3×CH), 119.2 (3×CH), 35.3 (3×C), 34.7 (3×C), 31.4 (9×CH3), 30.5 (9×CH3), 2.9 
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(CH3); One resonance for a quaternary carbon was not visible; IR νmax/cm
-1
 3096, 
3012, 1569, 1481, 1430, 1352, 1261, 1150, 943; Analytical data matches that reported 
in the literature.
34a
 
5.3 Cycloaddition products for Chapter 2 
General Procedure 8 (GP8) 
 
A heat gun-dried reaction tube was charged with the corresponding heterocyclic 
aminide (1.2 eq.), 227 (5 mol%) and solid ynamide (1.0 eq.) under an argon atmosphere 
before 1,4-dioxane [0.2 M relative to the amount of ynamide] was added. In cases when 
the ynamide was an oil it was prepared as a solution in 1,4-dioxane [0.2 M] and added 
to the aminide and catalyst. The mixture was stirred at 90 ºC until the reaction was 
either complete or appeared to be proceeding no further (24 h unless otherwise 
specified). Heating was removed and the reaction mixture allowed to cool down to rt 
before being filtered through a pad of silica gel (~1 cm) and washing with chloroform. 
The filtrate was concentrated under reduced pressure and the residue was purified by 
flash chromatography. 
General Procedure 9 (GP9) 
Following the same procedure as GP8 but using dichloro(2-pyridincarboxylato)gold(III) 
(PicAuCl2) (5 mol%) as catalyst. 
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General Procedure 10 (GP10)  
Following the same procedure as GP8 but using 1,2-DCB [0.2 M] as solvent and 
stirring at 120 °C until reaction was either complete or appeared to be proceeding no 
further. Heating was removed and the reaction mixture allowed to cool down to rt. The 
reaction mixture was directly placed onto a column of silica gel for purification by flash 
chromatography. 
Imidazo[1,2-a]pyrimidine 284 
Following GP8 using ynamide 264 (41.8 mg, 0.20 mmol) and aminide 
239 (41.4 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (3:7)] compound 284 was isolated as a white 
solid (53.2 mg, 88%); mp.185–186 oC; 1H NMR (300 MHz, CDCl3) δ 8.55 (dd, J = 4.1, 
2.0 Hz, 1H), 8.45 (dd, J = 6.9, 2.0 Hz, 1H), 7.62–7.58 (m, 2H), 7.48–7.41 (m, 2H), 
7.42–7.36 (m, 1H), 6.90 (dd, J = 6.9, 4.1 Hz, 1H), 3.25 (s, 3H), 3.25 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 150.6 (CH), 145.4 (C), 142.2 (C), 131.5 (CH), 129.4 (2×CH), 
129.3 (2×CH), 129.2 (CH), 126.1 (C), 119.7 (C), 109.6 (CH), 38.9 (CH3), 37.1 (CH3); 
IR νmax/cm
-1
 3086, 3012, 2984, 2853, 1624, 1502, 1379, 1237, 1145, 970, 766; HRMS 
(ES-TOF): m/z: calcd. for C14H15N4O2S: 303.0916, found: 303.0912 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 287 
Following GP8 using ynamide 265 (54.6 mg, 0.20 mmol) and aminide 
239 (41.5 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (3:7)] imidazopyrimidine 287 was isolated as a 
white solid (69.4 mg, 95%); mp. 225–226 oC; 1H NMR (300 MHz, CDCl3) δ 8.60 (dd, J 
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= 4.2 Hz, J = 2.0 Hz, 1H), 8.44 (dd, J = 6.9, 2.0 Hz, 1H), 7.58–7.40 (m, 7H), 7.30–7.18 
(m, 3H), 6.91 (dd, J = 6.9, 4.2 Hz, 1H), 3.44 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 
150.5 (CH), 145.2 (C), 141.6 (C), 140.4 (C), 131.4 (CH), 129.3 (CH), 129.2 (2×CH), 
129.2 (2×CH), 129.1 (2×CH), 127.9 (2×CH), 127.8 (CH), 125.8 (C), 120.2 (C), 109.6 
(CH), 38.9 (CH3); IR νmax/cm
-1
 3100, 3057, 3008, 2931, 1605, 1484, 1384, 1152, 963, 
746; HRMS (ES-TOF): m/z: calcd. for C19H17N4O2S: 365.1072, found: 365.1081 
[M+H]
+
. 
Imidazo[1,2-a]pyrimidine 288 
Following GP8 using ynamide 266 (57.0 mg, 0.20 mmol) and 
aminide 239 (41.4 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 288 was 
isolated as a white solid (68.3 mg, 89%); mp. 152–153 oC; 1H NMR (300 MHz, CDCl3) 
δ 8.57 (dd, J = 4.1, 2.0 Hz, 1H), 8.27 (dd, J = 6.9, 2.0 Hz, 1H), 7.43–7.32 (m, 3H), 
7.23–7.16 (m, 2H), 7.12–7.04 (m, 1H), 6.98–6.90 (m, 4H), 6.84 (dd, J = 6.9, 4.1 Hz, 
1H), 4.79 (s, 2H), 3.33 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 150.5 (CH), 145.4 (C), 
140.0 (C), 134.9 (C), 131.5 (CH), 129.5 (2×CH), 129.1 (2×CH), 129.1 (CH), 129.0 
(2×CH), 128.0 (2×CH), 127.6 (CH), 125.8 (C), 121.9 (C), 109.4 (CH), 55.3 (CH2), 38.4 
(CH3); IR νmax/cm
-1
 3097, 3062, 3028, 3001, 2925, 1624, 1504, 1388, 1334, 1154, 971; 
HRMS (ES-TOF): m/z: calcd. for C20H19N4O2S: 379.1229, found: 379.1224 [M+H]
+
. 
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Imidazo[1,2-a]pyrimidine 289 
Following GP8 using ynamide 267 (47.4 mg, 0.20 mmol) and aminide 
239 (41.4 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (3:7)] compound 289 was isolated as a white solid 
(37.9 mg, 59%); mp. 142–143 oC; 1H NMR (300 MHz, CDCl3) δ 8.59 (dd, J = 4.1, 2.0 
Hz, 1H), 8.44 (dd, J = 6.9, 2.0 Hz, 1H), 7.67–7.62 (m, 2H), 7.57–7.51 (m, 2H), 7.50–
7.44 (m, 1H), 6.91 (dd, J = 6.9, 4.1 Hz, 1H), 5.63 (ddt, J = 16.8, 10.1, 6.6 Hz, 1H), 5.03 
(app. dq, J = 16.8, 1.3 Hz, 1H), 4.95 (app. dq, J = 10.1, 1.3 Hz, 1H), 4.22 (app. dt, J = 
6.6, 1.3 Hz, 2H), 3.31 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 150.5 (CH), 145.3 (C), 
140.4 (C), 132.2 (CH), 131.1 (CH), 129.5 (2×CH), 129.3 (2×CH), 129.3 (CH), 126.1 
(C), 121.1 (C), 119.3 (CH2), 109.5 (CH), 54.3 (CH2), 39.0 (CH3); IR νmax/cm
-1
 3025, 
3010, 2924,2854, 1625, 1505, 1382, 1152, 972, 766; HRMS (ES-TOF): m/z: calcd. for 
C16H17N4O2S: 329.1079, found: 329.1072 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 290 
 Following GP8 using ynamide 268 (54.0 mg, 0.20 mmol) and 
aminide 239 (41.4 mg, 0.24 mmol). After purification by flash 
chromatography [ethyl acetate:MeOH (4:1)] compound 290 was 
isolated as a white solid (60.8 mg, 84%); mp. 167–169 oC; 1H NMR (400 MHz, CDCl3) 
δ 8.51 (dd, J = 4.1, 1.8 Hz, 1H), 8.33 (dd, J = 6.8, 1.8 Hz, 1H), 7.59 (d, J = 8.1 Hz, 2H), 
7.52 (app. t, J = 7.6 Hz, 2H), 7.44 (t, J = 7.3 Hz, 1H), 6.82 (dd, J = 6.8, 4.1 Hz, 1H), 
3.99 (app. quin, J = 7.2 Hz, 4H), 3.13 (d, J = 8.8 Hz, 3H), 1.23 (t, J = 7.1 Hz, 6H);
 13
C 
NMR (101 MHz, CDCl3) δ 149.3 (CH), 145.3 (C), 145.20 (d, JC-P = 5.3 Hz, C), 130.7 
(CH), 130.0 (2×CH), 129.1 (2×CH), 128.9 (CH), 127.6 (C), 116.7 (d, JC-P = 4.8 Hz, C), 
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108.9 (CH), 62.6 (d, JC-P = 4.8 Hz, 2×CH2), 37.3 (d, JC-P = 3.5 Hz, CH3), 16.10 (d, JC-P 
= 7.2 Hz, 2×CH3); IR νmax/cm
-1
 3029, 2982, 2924, 1620, 1555, 1447, 1342, 1150, 1026; 
HRMS (ES-TOF): m/z: calcd. for C17H21N4O3PNa: 383.1249, found: 383.1248 
[M+Na]
+
. 
Imidazo[1,2-a]pyrimidine 291 
 Following GP8 using ynamide 269 (72.5 mg, 0.20 mmol) 
and aminide 239 (41.4 mg, 0.24 mmol). After purification by 
flash chromatography [hexane:ethyl acetate (1:9)] compound 
291 was isolated as a white solid (68.8 mg, 77%); mp. 86–88 oC; 1H NMR (300 MHz, 
CDCl3) δ 8.66 (dd, J = 4.1, 2.0 Hz, 1H), 8.25 (dd, J = 6.9, 2.0 Hz, 1H), 8.23–8.20 (m, 
1H), 7.86 (app. dt, J = 7.9, 1.9 Hz, 1H), 7.66 (app. t, J = 1.9 Hz, 1H), 7.61 (app. t, J = 
7.9 Hz, 1H), 6.97 (dd, J = 6.9, 4.1 Hz, 1H), 6.84–6.78 (m, 2H), 6.48–6.40 (m, 2H), 4.70 
(s, 2H), 3.65 (s, 3H), 3.36 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 159.3 (C), 151.3 
(CH), 148.1 (C), 145.9 (C), 140.7 (C), 136.4 (CH), 131.2 (CH), 130.6 (2×CH), 130.3 
(CH), 127.6 (C), 126.4 (C), 123.6 (CH), 123.0 (CH), 119.9 (C), 113.2 (2×CH), 110.0 
(CH), 55.0 (CH3), 54.8 (CH2), 38.4 (CH3); IR νmax/cm
-1
 3096, 3078, 2969, 1613, 1524, 
1333, 1243, 1149, 808, 760; HRMS (ES-TOF): m/z: calcd. for C21H20N5O5S: 454.1182 
found: 454.1185 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 292 
 Following GP8 using ynamide 270 (58.2 mg, 0.20 mmol) and aminide 
239 (41.4 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (3:7)] compound 292 was isolated as a white solid 
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(65.2 mg, 83%); mp. 212–214 oC; 1H NMR (300 MHz, CDCl3) δ 8.59 (dd, J = 4.1, 2.0 
Hz, 1H), 8.40 (dd, J = 6.9, 2.0 Hz, 1H), 7.57–7.50 (m, 2H), 7.48 (d, J = 8.8 Hz, 2H), 
7.31–7.18 (m, 3H), 7.04 (d, J = 8.8 Hz, 2H), 6.89 (dd, J = 6.9, 4.1 Hz, 1H), 3.87 (s, 3H), 
3.44 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 160.3 (C), 150.3 (CH), 145.1 (C), 141.3 
(C), 140.5 (C), 131.4 (CH), 130.8 (2×CH), 129.1 (2×CH), 128.0 (2×CH), 127.8 (CH), 
120.3 (C), 117.9 (C), 114.7 (2×CH), 109.5 (CH), 55.4 (CH3), 38.9 (CH3); IR νmax/cm
-1
 
3023, 3007, 2957, 2927, 2851, 1618, 1577, 1503, 1486, 1389, 1347, 1298, 1245, 1147, 
1021, 965, 841, 753; HRMS (ES-TOF): m/z: calcd. for C20H19N4O3S: 395.1172, found: 
395.1178 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 293 
Following GP8 using ynamide 271 (72.8 mg, 0.20 mmol) and 
aminide 239 (41.7 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 293 was 
isolated as a white solid (47.3 mg, 51%); mp. 158–160 oC; 1H NMR (300 MHz, CDCl3) 
δ 8.63 (dd, J = 4.1, 2.0 Hz, 1H), 7.89 (dd, J = 6.8, 2.0 Hz, 1H), 7.52 (dd, J = 7.9, 1.1 Hz, 
1H), 7.47 (dd, J = 7.6, 1.7 Hz, 1H), 7.39 (app. td, J = 7.6, 1.1 Hz, 1H), 7.31 (app. td, J = 
7.9, 1.7 Hz, 1H), 7.18–7.15 (m, 1H), 7.09–7.03 (m, 4H), 6.90 (dd, J = 6.8, 4.1 Hz, 1H), 
4.91 (d, J = 13.7 Hz, 1H), 4.68 (d, J = 13.7 Hz, 1H), 3.32 (s, 3H); 
13
C NMR (101 MHz, 
CDCl3) δ 150.7 (CH), 145.5 (C), 141.1 (C), 135.1 (C), 135.0 (CH), 133.1 (CH), 132.8 
(CH), 131.2 (CH), 128.8 (2×CH), 128.3 (2×CH), 127.8 (CH), 127.8 (CH), 126.9 (C), 
124.9 (C), 120.6 (C), 109.0 (CH), 55.3 (CH2), 38.7 (CH3); IR νmax/cm
-1
 3027, 3001, 
2924, 2854, 1623, 1562, 1495, 1454, 1390, 1361, 1325, 1230, 1147, 1026, 968, 814, 
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755; HRMS (ES-TOF): m/z: calcd. for C20H18
79
BrN4O2S: 457.0334 found: 457.0336 
[M+H]
+
. 
Imidazo[1,2-a]pyrimidine 294 
Following GP8 using ynamide 272 (67.4 mg, 0.20 mmol) and 
aminide 239 (41.3 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 294 was 
isolated as a white solid (56.1 mg, 63%); mp. 64–65 oC; 1H NMR (300 MHz, CDCl3) δ 
8.38 (dd, J = 4.1, 2.0 Hz, 1H), 7.66 (dd, J = 7.4, 1.2 Hz, 1H), 7.60–7.44 (m, 6H), 7.36–
7.24 (m, 3H), 7.00 (app. t, J = 7.4 Hz, 1H), 6.93 (app. t, J = 7.7 Hz, 2H), 6.72 (d, J = 7.1 
Hz, 2H), 6.45 (dd, J = 6.9, 4.1 Hz, 1H), 3.51 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 
150.1 (CH), 144.8 (C), 142.3 (C), 141.6 (C), 140.3 (C), 139.8 (C), 133.5 (CH), 131.4 
(CH), 130.3 (2×CH), 129.2 (2×CH), 128.5 (2×CH), 128.3 (2×CH), 128.1 (CH), 128.0 
(CH), 127.6 (2×CH), 127.4 (CH), 123.7 (C), 120.2 (C), 108.5 (CH), 39.2 (CH3); IR 
νmax/cm
-1
 3066, 3023, 1620, 1491, 1427, 1379, 1345, 1154, 967, 741; HRMS (ES-TOF): 
m/z: calcd. for C25H21N4O2S: 441.1387, found: 441.1372 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 295 
Following GP8 using ynamide 273 (52.7 mg, 0.20 mmol) and 
aminide 239 (41.8 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (1:9)] and recrystallisation 
[chloroform-hexane] compound 295 was isolated as a white solid (49.6 mg, 70%); mp. 
206–207 oC; 1H NMR (300 MHz, CDCl3) δ 8.48 (dd, J = 4.2, 2.0 Hz, 1H), 8.20 (dd, J = 
6.9, 2.0 Hz, 1H), 7.62–7.42 (m, 4H), 7.21–7.16 (m, 3H), 7.15–7.09 (m, 2H), 6.76 (dd, J 
= 6.9, 4.2 Hz, 1H), 4.43–4.29 (m, 1H), 4.25–4.03 (m, 2H), 3.36–3.14 (m, 1H); 13C NMR 
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(101 MHz, CDCl3) δ 154.5 (C), 149.4 (CH), 145.4 (C), 142.0 (C), 140.9 (C), 139.5 (C), 
130.7 (CH), 130.7 (CH), 130.4 (CH), 129.8 (CH), 128.3 (2×CH), 128.2 (2×CH), 128.1 
(CH), 127.3 (CH), 125.9 (C), 113.4 (C), 108.8 (CH), 62.7 (CH2), 45.2 (CH2); IR 
νmax/cm
-1 
3090, 2992, 2914, 1757, 1681, 1568, 1439, 1419, 1203, 1156, 1068, 1026, 
787, 741; HRMS (ES-TOF): m/z: calcd. for C21H17N4O2: 357.1352, found: 357.1355 
[M+H]
+
. 
Imidazo[1,2-a]pyrimidine 296 
Following GP8 using ynamide 275 (62.4 mg, 0.19 mmol) and 
aminide 239 (40.2 mg, 0.23 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 296 was 
isolated as a yellow solid (58.4 mg, 73%); mp. 187–189 oC; 1H NMR (300 MHz, 
CDCl3) δ 8.55 (dd, J = 4.1, 2.0 Hz, 1H), 8.49 (dd, J = 6.9, 2.0 Hz, 1H), 7.46 (dd, J = 5.1, 
1.1 Hz, 1H), 7.20 (dd, J = 3.5, 1.1 Hz, 1H), 7.11 (dd, J = 5.1, 3.5 Hz, 1H), 7.00 (d, J = 
8.7 Hz, 2H), 6.92 (dd, J = 6.9, 4.1 Hz, 1H), 6.58 (d, J = 8.7 Hz, 2H), 4.77 (s, 2H), 3.69 
(s, 3H), 3.27 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 159.1 (C), 150.7 (CH), 145.6 (C), 
141.0 (C), 131.9 (CH), 130.3 (2×CH), 129.4 (CH), 127.9 (CH), 127.6 (CH), 126.9 (C), 
125.7 (C), 116.1 (C), 113.5 (2×CH), 109.7 (CH), 55.2 (CH3), 54.6 (CH2), 38.3 (CH3); 
IR νmax/cm
-1
 3116, 3071, 3013, 2955, 1611, 1509, 1244, 1152, 842, 799; HRMS (ES-
TOF): m/z calcd. for C19H19N4O3S2: 415.1049 found: 415.1054 [M+H]
+
. 
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Imidazo[1,2-a]pyrimidine 297 
Following GP8 using ynamide 276 (61.7 mg, 0.20 mmol) and 
aminide 239 (41.4 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 297 was 
isolated as a yellow solid (49.7 mg, 62%); mp. 210–212 oC; 1H NMR (300 MHz, 
CDCl3) δ 8.88 (dd, J = 7.0, 2.0 Hz, 1H), 8.58 (dd, J = 4.1, 2.0 Hz, 1H), 7.48 (d, J = 1.8 
Hz, 1H), 7.11 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 3.5 Hz, 1H), 6.94 (dd, J = 7.0, 4.1 Hz, 
1H), 6.62 (d, J = 8.7 Hz, 2H), 6.51 (dd, J = 3.5, 1.8 Hz, 1H), 4.86 (s, 2H), 3.69 (s, 3H), 
3.23 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 159.1 (C), 150.7 (CH), 145.2 (C), 142.2 
(CH), 141.8 (C), 139.9 (C), 133.7 (CH), 130.3 (2×CH), 126.9 (C), 123.6 (C), 113.5 
(2×CH), 111.9 (CH), 111.3 (CH), 109.7 (CH), 55.2 (CH3), 54.6 (CH2), 38.1 (CH3); IR 
νmax/cm
-1
 3101, 3072, 2932, 2228, 1622, 1505, 1338, 1156, 963, 761; HRMS (ES-TOF): 
m/z: calcd. for C19H18N4O4SNa: 421.0956 found: 421.0959 [M+Na]
+
. 
Imidazo[1,2-a]pyrimidine 298 
Following GP8 using ynamide 277 (70.5 mg, 0.20 mmol) and aminide 
239 (41.3 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (3:7)] compound 298 was isolated as a white 
solid (71.1 mg, 80%); mp. 228–230 oC; 1H NMR (300 MHz, CDCl3) δ 8.67 (dd, J = 4.0, 
2.0 Hz, 1H), 8.57 (d, J = 8.4 Hz, 1H), 8.24 (dd, J = 6.9, 2.0 Hz, 1H), 7.86 (s, 1H), 7.59–
7.54 (m, 2H), 7.43 (app. t, J = 7.8 Hz, 1H), 7.59–7.54 (m, 4H), 7.09 (d, J = 7.8 Hz, 1H), 
6.94 (dd, J = 6.9, 4.0 Hz, 1H), 3.43 (s, 3H), 2.70 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
168.7 (C), 150.7 (CH), 145.8 (C), 142.6 (C), 140.6 (C), 135.8 (C), 132.7 (CH), 129.2 
(2×CH), 127.9 (2×CH), 127.9 (CH), 127.6 (CH), 126.0 (CH), 124.3 (CH), 119.7 (CH), 
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117.4 (CH), 113.7 (C), 109.5 (CH), 107.0 (C), 38.9 (CH3), 24.0 (CH3); One resonance 
for a quaternary carbon was not visible. IR νmax/cm
-1
 3103, 3063, 3019, 2931, 1702, 
1626, 1493, 1373, 1225, 805, 763; HRMS (ES-TOF): m/z: calcd. for C23H20N5O3S: 
446.1284 found: 446.1287 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 299 
Following GP8 using ynamide 278 (62.2 mg, 0.20 mmol) and 
aminide 239 (41.3 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (2:8)] compound 299 was 
isolated as a pale yellow solid (73.1 mg, 90%); mp. 258–260 oC; 1H 
NMR (300 MHz, CDCl3) δ 8.55 (dd, J = 4.1, 1.9 Hz, 1H), 8.51 (dd, J = 6.9, 1.9 Hz, 
1H), 7.42–7.32 (m, 4H), 7.32–7.23 (m, 4H), 7.19–7.15 (m, 2H), 7.10 (d, J = 16.7 Hz, 
1H), 6.97 (dd, J = 6.9, 4.1 Hz, 1H), 6.80 (d, J = 16.7 Hz, 1H), 4.95 (s, 2H), 3.24 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 150.2 (CH), 145.6 (C), 141.0 (C), 136.6 (C), 135.3 (C), 
132.0 (CH), 131.5 (CH), 129.2 (2×CH), 128.7 (2×CH), 128.3 (CH), 128.3 (2×CH), 
128.0 (2×CH), 126.5 (2×CH), 126.5 (2×CH), 119.8 (C), 55.2 (CH2), 38.0 (CH3); IR 
νmax/cm
-1
 3136, 3063, 3003, 2922, 2851, 1618, 1495, 1452, 1395, 1242, 1154, 960; 
HRMS (ES-TOF): m/z: calcd. for C22H21N4O2S: 405.1385 found: 405.1390 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 300 
Following GP8 using ynamide 279 (47.3 mg, 0.20 mmol) and aminide 
239 (41.4 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (3:7)] compound 300 was isolated as a white solid 
(48.0 mg, 70%); mp. 182–183 oC; 1H NMR (300 MHz, CDCl3) δ 8.58 (dd, J = 4.1, 2.0 
Hz, 1H), 8.48 (dd, J = 6.8, 2.0 Hz, 1H), 7.73 (dd, J = 8.3, 1.1 Hz, 2H), 7.40–7.32 (m, 
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2H), 7.31–7.24 (m, 1H), 6.95 (dd, J = 6.8, 4.1 Hz, 1H), 3.39 (s, 3H), 1.62 (tt, J = 8.1, 
5.2 Hz, 1H), 1.12–1.02 (m, 2H), 0.95-0.87 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 
149.8 (CH), 144.6 (C), 142.5 (C), 140.6 (C), 131.5 (CH), 129.2 (2×CH), 128.0 (2×CH), 
127.7 (CH), 119.9 (C), 109.1 (CH), 38.8 (CH3), 5.1 (2×CH2), 2.3 (CH); IR νmax/cm
-1
 
3092, 3035, 2932, 2854, 1619, 1501, 1845, 1412, 1347, 1316, 1211, 1151, 960, 756; 
HRMS (ES-TOF): m/z: calcd. for C16H17N4O2S: 329.1072, found: 329.1075 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 301 
Following GP9 using ynamide 280 (64.5 mg, 0.20 mmol) and 
aminide 239 (41.4 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 301 was 
isolated as a yellow solid (47.9 mg, 67%); mp. 140–142oC; 1H NMR (300 MHz, CDCl3) 
δ 8.52 (dd, J = 4.1, 2.0 Hz, 1H), 8.11 (dd, J = 6.9, 2.0 Hz, 1H), 7.34–7.25 (m, 2H), 
7.24–7.16 (m, 3H), 6.87 (dd, J = 6.9, 4.1 Hz, 1H), 4.92 (s, 2H), 3.17 (s, 3H), 2.64 (t, J = 
8.0 Hz, 2H), 1.11 (app. quin, J = 8.0 Hz, 2H), 1.02–0.88 (m, 2H), 0.77 (t, J = 7.1 Hz, 
3H); 
13
C NMR (101 MHz, CDCl3) δ 149.4 (CH), 145.2 (C), 139.1 (C), 136.0 (C), 131.3 
(CH), 129.4 (2×CH), 128.3 (2×CH), 127.9 (CH), 122.6 (C), 108.8 (CH), 54.7 (CH2), 
37.4 (CH3), 28.7 (CH2), 22.7 (CH2), 21.8 (CH2), 13.7 (CH3); IR νmax/cm
-1
 3103, 3034, 
2930, 1526, 1338, 1296, 1157, 959, 820, 744; HRMS (ES-TOF): m/z: calcd. for 
C18H23N4O2S: 359.1542 found: 359.1542 [M+H]
+
. 
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Imidazo[1,2-a]pyrimidine 307 
Following GP9 using ynamide 281 (59.1 mg, 0.21 mmol) and 
aminide 239 (43.3 mg, 0.25 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 307 was 
isolated as a yellow solid (49.3 mg, 62%); mp. 134–138 oC; 1H NMR (300 MHz, 
CDCl3) δ 8.55 (dd, J = 4.1, 2.0 Hz, 1H), 8.23 (dd, J = 6.9, 2.0 Hz, 1H), 7.33–7.17 (m, 
5H), 6.91 (dd, J = 6.9, 4.1 Hz, 1H), 4.91 (s, 2H), 3.25–3.12 (m, 5H), 2.81 (t, J = 7.6 Hz, 
2H), 1.60–1.45 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 149.8 (CH), 145.3 (C), 139.7 
(C), 135.9 (C), 131.3 (CH), 129.5 (2×CH), 128.5 (2×CH), 128.1 (CH), 120.7 (C), 109.1 
(CH), 54.6 (CH2), 44.4 (CH2), 37.4 (CH3), 29.5 (CH2), 18.9 (CH2); IR νmax/cm
-1
 3106, 
2955, 2930, 2865, 1620, 1502, 1342, 1157, 1053, 731; HRMS (ES-TOF): m/z: calcd. 
for C17H20ClN4O2S: 379.0995 found: 379.0993 [M+H]
+
. 
(S)-(–)-Imidazo[1,2-a]pyrimidine 308 
Following GP9 using ynamide 282 (67.7 mg, 0.20 mmol) and 
aminide 239 (41.6 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 308 
was isolated as a yellow oil (67.8 mg, 80%);     
    -25.8 (c 1.24, CHCl3); 
1
H-NMR 
(300 MHz, CDCl3) δ 8.59–8.52 (m, 1H), 8.17 (dd, J = 6.9, 1.9 Hz, 1H), 7.39–7.30 (m, 
2H), 7.25–7.19 (m, 3H), 6.89 (dd, J = 6.9, 4.1 Hz, 1H), 5.02–4.91 (m, 3H), 3.13 (s, 3H), 
2.73 (dd, J = 15.3, 6.1, 1H), 2.48 (dd, J = 15.3, 6.1, 1H), 1.97–1.84 (m, 1H), 1.84–1.72 
(m, 1H), 1.68 (s, 3H), 1.58 (s, 3H), 1.47–1.29 (m, 2H), 1.08–0.93 (m, 1H), 0.38 (d, J = 
6.6, 3H); 
13
C NMR (101 MHz, CDCl3) δ 149.3 (CH), 145.1 (C), 140.2 (C), 135.8 (C), 
131.5 (C), 131.4 (CH), 129.8 (2×CH), 128.4 (2×CH), 128.0 (CH), 124.4 (CH), 121.5 
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(C), 108.8 (CH), 54.7 (CH2), 37.2 (CH3), 36.8 (CH2), 31.5 (CH), 29.2 (CH2), 25.7 
(CH3), 25.4 (CH2), 19.1 (CH3), 17.7 (CH3); IR νmax/cm
-1
 2960, 2924, 2854, 1620, 1562, 
1500, 1335, 1152, 1026, 697; HRMS (ES-TOF): m/z: calcd. for C23H31N4O2S: 427.2168 
found: 427.2179 [M+H]
+
. 
rac-Imidazo[1,2-a]pyrimidine 309 
Following GP8 using ynamide 282 (75.7 mg, 0.20 mmol) and 
aminide 239 (41.2 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 309 
was isolated as a white solid (74.2 mg, 81%); mp. 194–196 oC; 1H NMR (300 MHz, 
CDCl3) δ 8.51 (dd, J = 4.1, 1.9 Hz, 1H), 7.92 (dd, J = 7.0, 1.9 Hz, 1H), 7.38-7.15 (m, 
5H), 6.75 (dd, J = 7.0, 4.1 Hz, 1H), 6.70–6.62 (m, 1H), 6.49–6.39 (m, 2H), 5.90 (s, 2H), 
5.04–4.83 (m, 2H), 3.42–3.27 (m, 1H), 3.22 (s, 3H), 2.58–2.46 (m, 2H), 0.98 (d, J = 7.3 
Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 149.5 (CH), 147.7 (C), 146.2 (C), 145.1 (C), 
138.6 (C), 135.6 (C), 133.1 (C), 132.3 (CH), 129.7 (2×CH), 128.5 (2×CH), 128.1 (CH), 
125.6 (C), 122.1 (CH), 109.5 (CH), 108.5 (CH), 108.2 (CH), 100.8 (CH2), 55.0 (CH2), 
39.7 (CH2), 37.5 (CH3), 31.4 (CH), 15.2 (CH3); IR νmax/cm
-1
 2983, 2924, 2855, 1623, 
1559, 1502, 1491, 1328, 1248, 1150, 1037, 969, 762; HRMS (ES-TOF): m/z: calcd. for 
C24H25N4O4S: 465.1591 found: 465.1597 [M+H]
+
. 
This transformation was also performed on larger scale using ynamide 282 (1.12 g, 2.93 
mmol), PicAuCl2 (22.1 mg, 2 mol%) and aminide 239 (608.8 mg, 3.52 mmol), 
affording 309 (991.8 mg, 61%) after 6 h. 
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Imidazo[1,2-a]pyrimidine 313 
Following G10 using alkynylindole 312a (36.1 mg, 0.20 mmol) and 
aminide 239 (41.3 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 313 was isolated as a yellow 
solid (38.7 mg, 71%); mp. 258–260 oC; 1H NMR (300 MHz, DMSO-D6) δ 11.22 (br., 
1H), 8.63 (dd, J = 6.7, 1.9 Hz, 1H), 8.29–8.17 (m, 2H), 7.65 (d, J = 2.6 Hz, 1H), 7.21 (d, 
J = 7.5 Hz, 1H), 6.98–6.80 (m, 3H), 1.95–1.82 (m, 1H), 1.05–0.90 (m, 2H), 0.38–0.21 
(m, 2H); 
13
C NMR (101 MHz, DMSO D6) δ 148.4 (CH), 147.1 (C), 141.8 (C), 136.5 
(C), 132.3 (CH), 126.7 (C), 126.0 (CH), 122.2 (CH), 122.0 (CH), 119.8 (CH), 117.4 
(C), 111.9 (CH), 109.3 (C), 108.5 (CH), 7.9 (2×CH2), 4.0 (CH); IR νmax/cm
-1
 3147, 
3106, 2919, 2851, 1610, 1580, 1491, 1344, 1227, 765; HRMS (ES-TOF): m/z: calcd. 
for C17H15N4: 275.1297 found: 275.1300 [M+H]
+
. 
5.4 Cycloaddition products for Chapter 3 
Imidazo[1,2-a]pyrazine 393 
Following GP8 using ynamide 265 (54.4 mg, 0.20 mmol) and 
aminide 388 (67.2 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (7:3)] compound 393 
was isolated as a white solid (79.2 mg, 84%); mp. 200–202 oC; 1H NMR (400 MHz, 
CDCl3) δ 10.10 (s, 1H), 9.26 (d, J = 1.4 Hz, 1H), 8.46 (d, J = 1.4 Hz, 1H), 8.38 (app. t, J 
= 1.6 Hz, 1H), 8.18 (app. dt, J = 7.6, 1.6 Hz, 1H), 7.93 (app. dt, J = 7.6, 1.6 Hz, 1H), 
7.65 (app. t, J = 7.6 Hz, 1H), 7.61–7.50 (m, 5H), 7.48–7.42 (m, 2H), 7.33–7.22 (m, 3H), 
3.45 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 192.0 (CH), 143.4 (CH), 142.9 (C), 140.1 
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(C), 139.4 (C), 137.3 (C), 137.0 (C), 136.5 (C), 132.2 (CH), 130.1 (CH), 129.9 (CH), 
129.8 (CH), 129.5 (2×CH), 129.4 (2×CH), 129.2 (2×CH), 128.0 (CH), 127.9 (2×CH), 
127.3 (CH), 125.5 (C), 123.4 (C), 113.0 (CH), 39.1 (CH3); IR νmax/cm
-1
 3020, 2936, 
1699, 1482, 1380, 1345, 1154, 965, 750; HRMS (ES-TOF): m/z: calcd. for 
C26H21N4O3S: 469.1334, found: 469.1336 [M+H]
+
. 
Imidazo[1,2-a]pyrazine 394 
Following GP10 using alkynylindole 312a (36.0 mg, 0.20 mmol) and 
aminide 380 (41.5 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 394 was 
isolated as a yellow solid (20.4 mg, 38%); mp. 224–226 oC; 1H NMR (300 MHz, 
CDCl3) δ 9.09 (d, J = 1.1 Hz, 1H), 8.62 (br, 1H), 8.47–8.40 (m, 1H), 8.21 (dd, J = 4.5, 
2.0 Hz, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.73 (d, J = 2.0 Hz, 1H), 7.49–7.38 (m, 1H), 
7.34–7.19 (m, 2H), 2.06–1.96 (m, 1H), 1.22–1.11 (m, 2H), 0.68–0.58 (m, 2H); 13C 
NMR (101 MHz, CDCl3) δ 142.7 (C), 142.5 (CH), 139.8 (C), 136.1 (C), 129.1 (CH), 
126.5 (C), 124.8 (CH), 122.6 (CH), 121.7 (CH), 121.0 (C), 120.7 (CH), 116.5 (CH), 
111.1 (CH), 110.2 (C), 7.2 (2×CH2), 3.8 (CH); IR νmax/cm
-1
 3150, 3120, 2931, 2863, 
1618, 1576, 1492, 1380, 1117, 760; HRMS (ES-TOF): m/z: calcd. for C17H15N4: 
275.1297 found: 275.1293 [M+H]
+
. 
Imidazo[1,2-a]pyrazine 395 
Following GP8 using ynamide 270 (48.2 mg, 0.20 mmol) and aminide 
380 (41.4 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (7:3)] compound 395 was isolated as a white solid 
(55.6 mg, 71%); mp. 206–208 oC; 1H NMR (300 MHz, CDCl3) δ 9.13 (s, 1H), 8.03 (d, J 
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= 4.7 Hz, 1H), 7.90 (d, J = 4.7 Hz, 1H), 7.50–7.41 (m, 4H), 7.33–7.23 (m, 3H), 7.08–
7.00 (m, 2H), 3.89 (s, 3H), 3.42 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 160.6 (C), 
143.6 (C), 142.2 (C), 140.1 (CH), 137.0 (C), 130.7 (2×CH), 129.8 (CH), 129.2 (2×CH), 
127.9 (CH), 127.8 (2×CH), 122.9 (CH), 117.5 (C), 116.7 (C), 114.8 (2×CH), 55.4 
(CH3), 39.1 (CH3); IR νmax/cm
-1
 3021, 2925, 2842, 1608, 1498, 1483, 1349, 1159, 969, 
759; HRMS (ES-TOF): m/z: calcd. for C20H19N4O3S: 395.1178, found: 395.1184 
[M+H]
+
. 
Imidazo[1,2-a]pyrazine 396 
Following GP8 using ynamide 264 (42.5 mg, 0.20 mmol) and aminide 
380 (41.5 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (1:9)] compound 396 was isolated as a white solid 
(50.4 mg, 83%); mp. 128–130 oC; 1H NMR (300 MHz, CDCl3) δ 9.06 (d, J = 1.4 Hz, 
1H), 8.11 (dd, J = 4.7, 1.4 Hz, 1H), 7.91 (d, J = 4.7 Hz, 1H), 7.66 (d, J = 7.8 Hz, 2H), 
7.60–7.46 (m, 3H), 3.25 (s, 3H), 3.25 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 144.0 
(CH), 142.7 (C), 137.4 (C), 130.4 (CH), 129.7 (CH), 129.5 (2×CH), 129.1 (2×CH), 
125.9 (C), 122.1 (C), 116.6 (CH), 38.8 (CH3), 37.3 (CH3); IR νmax/cm
-1
 3060, 3030, 
2928, 1620, 1489, 1472, 1380, 1154, 967, 742; HRMS (ES-TOF): m/z: calcd. for 
C14H15N4O2S: 303.0916, found: 303.0920 [M+H]
+
. 
Imidazo[1,2-c]pyrimidine 397 
Following GP8 using ynamide 274 (55.4 mg, 0.20 mmol) and aminide 
381 (49.6 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (8:2)] compound 397 was isolated as a white 
solid (46.9 mg, 58%); mp. 148-150 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.91 (d, J = 6.3 
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Hz, 1H), 7.57-7.53 (m, 2H), 7.29–7.26 (m, 5H), 7.11–7.07 (m, 2H), 3.34 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 145.5 (C), 145.0 (C), 140.2 (C), 139.8 (C), 139.5 (CH), 
137.6 (C), 133.9 (CH), 129.8 (CH), 129.1 (2×CH), 128.2 (2×CH), 128.1 (CH), 126.6 
(CH), 126.3 (C), 111.7 (CH), 39.5 (CH3); IR νmax/cm
-1
 3088, 3015, 2927, 1616, 1473, 
1426, 1345, 1154, 966, 762; HRMS (ES-TOF): m/z: calcd. for C17H14ClN4O2S2: 
405.0247 found: 405.0240 [M+H]
+
. 
Imidazo[1,2-c]pyrimidine 398 
Following GP8 using ynamide 265 (54.4 mg, 0.20 mmol) and aminide 
381 (50.2 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (3:7)] compound 398 was isolated as a white solid 
(60.3 mg, 75%); mp. 104-106 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.87 (d, J = 6.3 Hz, 
1H), 7.54 (d, J = 6.3 Hz, 1H), 7.49–7.41 (m, 1H), 7.40–7.32 (m, 2H), 7.29–7.15 (m, 
7H), 3.31 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 144.1 (C), 143.4 (C), 140.0 (C), 138.9 
(CH), 137.4 (C), 132.2 (2×CH), 129.4 (CH), 129.1 (2×CH), 128.0 (2×CH), 127.9 (CH), 
127.6 (2×CH), 127.4 (C), 121.9 (C), 111.7 (CH), 39.4 (CH3); IR νmax/cm
-1
 3068, 3023, 
2929, 1616, 1586, 1484, 1377, 1155, 817, 762; HRMS (ES-TOF): m/z: calcd. for 
C19H16ClN4O2S: 399.0682 found: 399.0687 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 399 
Following GP8 using ynamide 264 (42.4 mg, 0.20 mmol) and 
aminide 286 (72.1 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 399 was 
isolated as a white solid (73.2 mg, 85%); mp. 213–214 oC; 1H NMR (300 MHz, CDCl3) 
δ 8.67 (d, J = 2.3 Hz, 1H), 8.66 (d, J = 2.3 Hz, 1H), 7.67-7.62 (m, 2H), 7.62–7.54 (m, 
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2H), 7.54–7.48 (m, 1H), 3.25 (s, 3H), 3.25 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
155.1 (CH), 143.4 (C), 142.4 (C), 135.6 (CH), 129.7 (CH), 129.6 (2×CH), 129.3 
(2×CH), 125.9 (C), 119.7 (C), 74.7 (C), 38.8 (CH3), 37.1 (CH3); IR νmax/cm
-1
 3061, 
3020, 2934, 1620, 1491, 1472, 1379, 1345, 1154, 968, 742; HRMS (ES-TOF): m/z: 
calcd. for C14H14N4O2SI: 428.9882, found: 428.9877 [M+H]
+
. 
Imidazo[1,2-a]pyrimidine 400 
Following GP10 using alkynylindole 312b (43.2 mg, 0.20 
mmol) and aminide 390 (79.8 mg, 0.24 mmol). After 
purification by flash chromatography [hexane:ethyl acetate 
(1:9)] compound 400 was isolated as a yellow solid (46.1 mg, 50%); mp. 220–222oC; 
1
H NMR (400 MHz, DMSO-D6) δ 11.28 (br., 1H), 8.90 (d, J = 2.5 Hz, 1H), 8.81 (d, J = 
2.4 Hz, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.15 (dd, J = 8.3, 2.5 Hz, 1H), 8.11 (d, J = 7.7 Hz, 
1H), 7.76 (d, J = 8.3 Hz, 1H), 7.71 – 7.52 (m, 5H), 7.41 (d, J = 7.7 Hz, 1H), 7.17 (d, J = 
2.5 Hz, 1H), 7.13 (app. t, J = 7.7 Hz, 1H), 7.03 (app. t, J = 7.7 Hz, 1H); 
13
C NMR (101 
MHz, DMSO- D6) δ 149.1 (CH), 148.4 (CH), 147.3 (C), 142.0 (C), 141.3 (C), 138.5 
(CH), 136.5 (C), 131.1 (2×CH), 130.5 (C), 130.1 (2×CH), 129.5 (CH), 129.1 (C), 129.0 
(CH), 128.5 (CH), 126.3 (C), 125.0 (CH), 122.1 (CH), 121.9 (CH), 120.0 (CH), 118.2 
(C), 118.1 (C), 112.0 (CH), 109.1 (C); IR νmax/cm
-1
 3155, 3103, 3048, 2973, 2920, 
1617, 1561, 1451, 1219, 1091, 737; HRMS (ES-TOF): m/z: calcd. for C25H17
79
BrN5: 
466.0667 found: 466.0675 [M+H]
+
. 
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Imidazo[1,2-a]pyrimidine 401 
Following GP8 using ynamide 264 (42.1 mg, 0.20 mmol) and 
aminide 390 (79.5 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (7:3)] compound 401 
was isolated as a white solid (57.0 mg, 62%); mp. 182–184 oC; 1H NMR (300 MHz, 
CDCl3) δ 8.81 (d, J = 2.5 Hz, 1H), 8.61 (d, J = 2.5 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 
7.76–7.69 (m, 3H), 7.68–7.50 (m, 4H), 3.31 (s, 3H), 3.31 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 149.4 (CH), 148.1 (CH), 144.7 (C), 143.2 (C), 142.7 (C), 136.9 (CH), 129.7 
(2×CH), 129.6 (CH), 129.3 (2×CH), 128.7 (CH), 128.5 (CH), 125.7 (C), 120.4 (C), 
120.0 (C), 38.9 (CH3), 37.1 (CH3); One resonance for a quaternary carbon was not 
visible. IR νmax/cm
-1
 3083, 3022, 2934, 1623, 1583, 1488, 1452, 1377, 1155, 811, 764; 
HRMS (ES-TOF): m/z: calcd. for C19H17
79
BrN5O2S: 458.0284 found: 458.0286 
[M+H]
+
.  
Imidazo[1,2-a]pyrimidine 402 
Following GP8 using ynamide 265 (54.2 mg, 0.20 mmol) and 
aminide 389 (64.2 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 402 was 
isolated as a white solid (70.4 mg, 80%); mp. 193–195 oC; 1H NMR (300 MHz, CDCl3) 
δ 8.84 (d, J = 2.5 Hz, 1H), 8.53 (d, J = 2.5 Hz, 1H), 7.62–7.41 (m, 8H), 7.32–7.21 (m, 
4H), 7.21–7.10 (m, 2H), 3.46 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.3 (d, JC-F = 
248.1 Hz, CF), 150.3 (CH), 144.7 (C), 142.4 (C), 140.4 (C), 136.0 (d, JC-F = 7.5 Hz, C), 
131.2 (d, JC-F = 8.4 Hz, CH), 129.5 (CH), 129.4 (2×CH), 129.4 (2×CH), 129.1 (2×CH), 
128.3 (CH), 128.0 (2×CH), 127.9 (CH), 125.5 (C), 123.2 (C), 122.8 (CH), 120.7 (C), 
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115.8 (d, JC-F = 21.0 Hz, CH), 114.2 (d, JC-F = 22.6 Hz, CH), 39.0 (CH3); IR νmax/cm
-1
 
3083, 3067, 3023, 2929, 1614, 1585, 1487, 1383, 1155, 867, 762; HRMS (ES-TOF): 
m/z: calcd. for C25H20N4O2SF: 459.1295, found: 459.1299 [M+H]
+
. 
Imidazo[1,2-a]pyridine 403 
Following GP9 using ynamide 265 (54.3 mg, 0.20 mmol) and aminide 
384 (41.5 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (3:7)] compound 403 was isolated as a yellow 
solid (46.9 mg, 65%); mp. 196–198 oC; 1H NMR (300 MHz, CDCl3) δ 8.13 (d, J = 6.9 
Hz, 1H), 7.65 (d, J = 9.1 Hz, 1H), 7.59–7.38 (m, 7H), 7.32–7.15 (m, 4H), 6.80 (app. td, 
J = 6.9, 1.0 Hz, 1H), 3.42 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 142.3 (C), 140.8 (C), 
140.4 (C), 129.5 (2×CH), 129.0 (2×CH), 129.0 (2×CH), 128.9 (CH), 127.6 (2×CH), 
127.4 (CH), 127.1 (C), 125.2 (CH), 123.8 (CH), 121.4 (C), 118.1 (CH), 113.0 (CH), 
39.1 (CH3); IR νmax/cm
-1
 3096, 3028, 2928, 1612, 1587, 1490, 1378, 1149, 803, 769; 
HRMS (ES-TOF): m/z: calcd. for C20H18N3O2S: 364.1120 found: 364.1123 [M+H]
+
. 
Imidazo[1,2-a]pyridine 404 
Following GP8 using ynamide 279 (47.3 mg, 0.20 mmol) and aminide 
384 (41.4 mg, 0.24 mmol). After purification by flash chromatography 
[hexane:ethyl acetate (1:1)] compound 404 was isolated as a white solid 
(35.5 mg, 51%); mp. 192–194 oC; 1H NMR (300 MHz, CDCl3) δ 8.19 (d, J = 6.9 Hz, 
1H), 7.74–7.64 (m, 2H), 7.58 (d, J = 9.1 Hz, 1H), 7.42–7.31 (m, 2H), 7.30–7.18 (m, 
2H), 6.88 (app. td, J = 6.9 Hz, 1H), 3.36 (s, 3H), 1.67–1.55 (m, 1H), 1.11–0.99 (m, 2H), 
0.94–0.84 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 141.5 (C), 141.0 (C), 140.6 (C), 
129.1 (2×CH), 127.5 (2×CH), 127.3 (CH), 124.6 (CH), 123.9 (CH), 120.9 (C), 117.7 
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(CH), 112.6 (CH), 39.0 (CH3), 5.0 (2×CH2), 2.8 (CH); IR νmax/cm
-1
 3105, 3047, 2927, 
1574, 1412, 1348, 1154, 996, 960, 754; HRMS (ES-TOF): m/z: calcd. for C17H18N3O2S: 
328.1123 found: 328.1128 [M+H]
+
. 
Imidazo[1,2-b]pyridazine 405 
Following GP8 using ynamide 264 (42.4 mg, 0.20 mmol) and 
aminide 382 (50.4 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 405 was 
isolated as a white solid (55.4 mg, 82%); mp. 222-224 
o
C; 
1
H NMR (300 MHz, CDCl3) 
δ 8.02–7.95 (m, 2H), 7.87 (d, J = 9.4 Hz, 1H), 7.58–7.49 (m, 2H), 7.49–7.40 (m, 1H), 
7.15 (d, J = 9.4 Hz, 1H), 3.26 (s, 3H), 3.26 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
147.3 (C), 142.0 (C), 134.9 (C), 129.1 (CH), 128.8 (2×CH), 128.7 (2×CH), 126.9 (CH), 
126.0 (C), 124.5 (C), 119.6 (CH), 38.6 (CH3), 37.7 (CH3); IR νmax/cm
-1
 3096, 3030, 
2942, 1578, 1490, 1396, 1241, 1148, 894, 769; HRMS (ES-TOF): m/z: calcd. for 
C14H14ClN4O2S: 337.0526 found: 337. 0529 [M+H]
+
. 
Imidazo[1,2-b]pyridazine 406 
Following GP10 using alkynylindole 312b (43.4 mg, 0.20 mmol) 
and aminide 382 (49.6 mg, 0.24 mmol). After purification by 
flash chromatography [hexane:ethyl acetate (1:1)] compound 406 
was isolated as a yellow solid (48.9 mg, 71%); mp. 206–208oC; 1H NMR (300 MHz, 
DMSO-D6) δ 11.31 (br., 1H), 8.27 (d, J = 9.4 Hz, 1H), 8.08 (d, J = 7.9 Hz, 1H), 7.69–
7.48 (m, 5H), 7.41 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 9.4 Hz, 1H), 7.18 (d, J = 2.7 Hz, 
1H), 7.13 (app. t, J = 7.9 Hz, 1H), 7.02 (app. t, J = 8.0 Hz, 1H); 
13
C NMR (101 MHz, 
DMSO-D6) δ 145.2 (C), 141.0 (C), 137.0 (C), 136.1 (C), 130.4 (2×CH), 128.9 (2×CH), 
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128.7 (CH), 126.4 (C), 125.7 (CH), 124.5 (C), 123.3 (CH), 121.7 (C), 121.2 (CH), 
119.5 (CH), 118.0 (CH), 111.6 (CH), 108.5 (C), 79.1 (CH); IR νmax/cm
-1
 3174, 3100, 
3070, 3008, 1588, 1444, 1218, 808, 745; HRMS (ES-TOF): m/z: calcd. for C20H14ClN4: 
345.0907 found: 345.0908 [M+H]
+
. 
Imidazo[1,2-b]pyridazine 407 
Following GP8 using ynamide 278 (62.2 mg, 0.20 mmol) and 
aminide 382 (50.4 mg, 0.24 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (1:4)] compound 407 was 
isolated as a white solid (73.1 mg, 83%); mp. 204-206 
o
C; 
1
H NMR (300 MHz, CDCl3) 
δ 7.85 (d, J = 16.7 Hz, 1H), 7.84 (d, J = 9.4 Hz, 1H), 7.48 (d, J = 7.1 Hz, 2H), 7.36 (app. 
t, J = 7.1 Hz, 2H), 7.33–7.27 (m, 3H), 7.24–7.15 (m, 3H), 7.10 (d, J = 9.4 Hz, 1H), 7.04 
(d, J = 16.7 Hz, 1H), 4.94 (s, 2H), 3.19 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 147.3 
(C), 140.7 (C), 137.2 (C), 135.5 (C), 135.2 (C), 132.1 (CH), 129.0 (2×CH), 128.6 
(2×CH), 128.5 (2×CH), 128.2 (CH), 128.1 (CH), 126.9 (2×CH), 126.5 (CH), 125.1 (C), 
119.1 (CH), 111.7 (CH), 55.2 (CH2), 38.3 (CH3); IR νmax/cm
-1
 3103, 3034, 2929, 1527, 
1338, 1296, 1157, 966, 820, 744; HRMS (ES-TOF): m/z: calcd. for C22H20ClN4O2S: 
439.0995 found: 439.0991 [M+H]
+
. 
Imidazo[1,2-c]pyrimidine 408 
Following GP9 using ynamide 264 (42.4 mg, 0.20 mmol) and aminide 
381 (50.4 mg, 0.24 mmol) for 1.5 h. After purification by flash 
chromatography [hexane:ethyl acetate (3:7)] compound 408 was 
isolated as a white solid (64.2 mg, 95%); mp. 110–112 oC; 1H NMR (300 MHz, CDCl3) 
δ 7.87 (d, J = 6.3 Hz, 1H), 7.54–7.44 (m, 6H), 3.15 (s, 3H), 3.13 (s, 3H); 13C NMR (101 
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MHz, CDCl3) δ 144.1 (C), 143.5 (C), 139.1 (CH), 137.5 (C), 132.2 (2×CH), 129.6 
(CH), 127.8 (2×CH), 127.5 (C), 121.9 (C), 111.5 (CH), 38.5 (CH3), 37.8 (CH3); IR 
νmax/cm
-1
 2929, 1617, 1566, 1478, 1342, 1263, 1150, 964, 911; HRMS (ES-TOF): m/z: 
calcd. for C14H14N4O2SCl: 337.0526 found: 337.0538 [M+H]
+
. 
Imidazo[1,2-a]pyridine 417 
Following GP9 using ynamide 264 (42.0 mg, 0.20 mmol) and aminide 
411 (49.5 mg, 0.24 mmol) for 24 h. After purification by flash 
chromatography [hexane:ethyl acetate (1:4)] compound 417 was 
isolated as a white solid (47.2 mg, 70%); mp. 178–180 oC; 1H NMR (300 MHz, CDCl3) 
δ 7.59 (dd, J = 9.0, 1.1 Hz, 1H), 7.56–7.50 (m, 2H), 7.49–7.42 (m, 3H), 7.22 (dd, J = 
9.0, 7.3 Hz, 1H), 6.88 (dd, J = 7.3, 1.1 Hz, 1H), 3.19 (s, 3H), 3.17 (s, 3H); 
13
C NMR 
(101 MHz, CDCl3) δ 144.1 (C), 142.2 (C), 132.2 (2×CH), 129.0 (CH), 128.8 (C), 127.6 
(C), 127.4 (2×CH), 125.1 (CH), 116.4 (CH), 114.6 (CH), 38.7 (CH3), 37.6 (CH3); One 
resonance for a quaternary carbon was not visible. IR νmax/cm
-1
 3071, 3005, 2922, 
1630, 1561, 1488, 1338, 1146, 1098, 957; HRMS (ES-TOF): m/z: calcd. for 
C15H15N3O2SCl: 336.0574 found: 336.0573 [M+H]
+
. 
Imidazo[1,2-c]quinazoline 418 
Following GP9 using ynamide 264 (41.6 mg, 0.20 mmol) and aminide 
412 (62.0 mg, 0.24 mmol) for 18 h. After purification by flash 
chromatography [hexane:ethyl acetate (7:3)] compound 418 was 
isolated as a white solid (56.8 mg, 73%); mp. 267–269 oC; 1H NMR 
(300 MHz, CDCl3) δ 8.50 (dd, J = 7.3, 1.8 Hz, 1H), 7.87 (dd, J = 7.5, 1.4 Hz, 1H), 7.73 
(app. td, J = 7.3, 1.4 Hz, 1H), 7.67 (app. td, J = 7.5, 1.8 Hz, 1H), 7.58–7.51 (m, 2H), 
Chapter 5 
151 
 
7.51–7.45 (m, 3H), 3.22 (s, 3H), 3.17 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 142.7 (C), 
141.6 (C), 140.4 (C), 134.6 (C), 132.0 (2×CH), 131.0 (CH), 129.5 (CH), 128.8 (CH), 
127.9 (2×CH), 127.8 (C), 127.5 (CH), 124.1 (C), 123.0 (CH), 118.2 (C), 38.7 (CH3), 
37.9 (CH3); IR νmax/cm
-1
 2927, 1618, 1603, 1368, 1341, 1251, 1151, 949; HRMS (ES-
TOF): m/z: calcd. for C18H16N4O2SCl: 387.0682 found: 387.0678 [M+H]
+
. 
Imidazo[1,2-c]pyrimidine 423 
Following GP9 using ynamide 278 (200.1 mg, 0.64 mmol) and 
aminide 381 (159.8 mg, 0.72 mmol). After purification by flash 
chromatography [hexane:ethyl acetate (3:2)] compound 423 was 
isolated as a white solid (234.8 mg, 84%); mp. 150–152 oC; 1H NMR 
(400 MHz, CDCl3) δ 7.79 (d, J = 6.3 Hz, 1H), 7.41–7.36 (m, 5H), 7.36–7.29 (m, 1H), 
7.25–7.20 (m, 1H), 7.19–7.12 (m, 4H), 7.00 (d, J = 16.2 Hz, 1H), 6.95 (d, J = 16.2 Hz, 
1H), 4.82 (s, 2H), 3.23 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 144.1 (C), 140.7 (C), 
139.1 (CH), 137.6 (C), 136.6 (C), 135.9 (CH), 134.7 (C), 129.4 (2×CH), 128.7 (2×CH), 
128.4 (CH), 128.3 (2×CH), 128.1 (CH), 126.9 (2×CH), 122.7 (C), 113.0 (CH), 111.5 
(CH), 55.1 (CH2), 38.7 (CH3); IR νmax/cm
-1
 3031, 2924, 1621, 1478, 1344, 1217, 1150, 
1052, 967; HRMS (ES-TOF): m/z: calcd. for C22H19N4O2SClNa: 461.0811 found: 
461.0815 [M+Na]
+
. 
  
Chapter 5 
152 
 
Aminide 424 
 Following GP5 using N-aminopyridinium iodide (87.0 mg, 
0.39 mmol) and imidazo[1,2-c]pyrimidine 423 (180.6 mg, 0.41 
mmol) and potassium carbonate (150.1 mg, 1.09 mmol) for 3 
h. After purification by flash chromatography [CH2Cl2:MeOH 
(9:1)] aminide 424 was isolated as a bright orange solid (190.2 mg, 98%); mp: 266–268 
ºC; 
1
H NMR (400 MHz, CDCl3) δ 8.76 (d, J = 6.1 Hz, 2H), 7.97 (d, J = 16.6 Hz, 1H), 
7.88 (t, J = 7.7 Hz, 1H), 7.66 (app. t, J = 7.2 Hz, 2H), 7.38 (d, J = 7.4 Hz, 2H), 7.36–
7.26 (m, 5H), 7.24–7.16 (m, 5H), 6.56 (d, J = 6.3 Hz, 1H), 4.91 (s, 2H), 3.26 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 155.2 (C), 145.4 (C), 143.4 (2×CH), 140.5 (CH), 138.6 
(C), 138.2 (C), 136.5 (CH), 135.6 (C), 129.5 (2×CH), 129.1 (CH), 128.3 (2×CH), 128.1 
(2×CH), 127.8 (CH), 126.8 (CH), 126.6 (2×CH), 126.5 (2×CH), 121.9 (C), 117.8 (CH), 
99.3 (CH), 55.0 (CH2), 38.7 (CH3); IR νmax/cm
-1
 3130, 3014, 1572, 1498, 1352, 1183, 
1074, 957, 1052, 864, 795; HRMS (ES-TOF): m/z: calcd. for C27H25N6O2S: 497.1760, 
found: 497.1758 [M+H]
+
. 
5.4 Precursors for Chapter 4 
5.4.1 Preparation of ynamides 
Ynamides 537 (Dr Raju Jannapureddy, UoB), 542 and 543 (Joshua Priest, UoB) were 
prepared and characterised by other members of the Davies Group.  
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(R)-N-(1-Phenylethyl)-N-(phenylethynyl)methanesulfonamide (538) 
Following GP3 using (R)-N-(1-Phenylethyl)methanesulfonamide 
(1.00 g, 5.0 mmol) and (bromoethynyl)benzene (10.8 g, 6.0 mmol). 
After purification by flash chromatography [hexane:ethyl acetate 
(9:1)] ynamide 538 was isolated as a white solid (0.79 g, 53%); mp: 60–62 ºC (lit.34b 
62–64 ºC); 1H NMR (300 MHz, CDCl3) δ 7.56–7.50 (m, 2H), 7.47–7.29 (m, 8H), 5.23 
(q, J = 7.1 Hz, 1H), 2.75 (s, 3H), 1.78 (d, J = 7.1 Hz, 3H); IR νmax/cm
-1
 2988, 2924, 
2236, 1354, 1162, 962, 798, 694; Analytical data matches that reported in the 
literature.
34b
 
(E)-N-Methyl-N-(4-phenylbut-3-en-1-yn-1-yl)methanesulfonamide (539) 
Following GP3 using N-methylmethanesulfonamide (0.57 g, 5.1 
mmol) and (E)-(4-bromobut-1-en-3-yn-1-yl)benzene (1.19 g, 6.3 
mmol). After purification by flash chromatography [hexane:ethyl 
acetate (4:1)] ynamide 539 was isolated as a yellow solid (691.3 mg, 60%); 
1
H NMR 
(300 MHz, CDCl3) δ 7.36–7.25 (m, 5H), 6.87 (d, J = 16.0 Hz, 1H), 6.22 (d, J = 16.0 Hz, 
1H), 3.24 (s, 3H), 3.08 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 140.1 (CH), 136.2 (C), 
128.7 (2×CH), 128.5 (CH), 126.1 (2×CH), 107.1 (CH), 84.9 (C), 69.1 (C), 39.2 (CH3), 
36.9 (CH3); IR νmax/cm
-1
 3034, 2941, 2250, 1431, 1279, 1160, 964, 755; Analytical data 
matches that reported in the literature.
120
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N-Benzyl-N-(thiophen-2-ylethynyl)methanesulfonamide (540) 
Following GP1 using N-benzylmethanesulfonamide (0.26 g, 1.3 
mmol) and 2-(2,2-dibromovinyl)thiophene (0.54 g, 2.0 mmol). After 
purification by flash chromatography [hexane:ethyl acetate (9:1)] 
ynamide 540 was isolated as a pale yellow solid (342.0 mg, 87%); mp: 72–74 ºC; 1H 
NMR (300 MHz, CDCl3) δ 7.49–7.46 (m, 2H), 7.43–7.37 (m, 3H), 7.28 (dd, J = 5.2, 1.1 
Hz, 1H), 7.19 (dd, J = 3.6, 1.1 Hz, 1H), 6.97 (dd, J = 5.2, 3.6 Hz, 1H), 4.72 (s, 2H), 2.93 
(s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 134.6 (CH), 133.4 (C), 129.1 (2×CH), 129.0 
(2×CH), 128.9 (CH), 128.2 (CH), 127.2 (CH), 122.6 (C), 85.7 (C), 65.0 (C), 56.2 (CH2), 
39.4 (CH3); IR νmax/cm
-1
 3016, 1363, 1215, 1163, 1007, 962, 748; HR-MS (EI-TOF): 
m/z: calcd. for C14H13NO2S2: 291.0388 found: 291.0386 [M]
+
. 
Ethyl 3-((4-methyl-N-phenylphenyl)sulfonamido)propiolate (541) 
Following a reported procedure,
34b
 n-BuLi (7.80 mL, 8.3 mmol) was 
added dropwise to a solution of N-(2,2-dichlorovinyl)-4-methyl-N-
phenylbenzenesulfonamide (1.29 g, 3.8 mmol) in THF (60 mL) at -78 
ºC. After stirring for 30 min. at -78 ºC the reaction mixture was allowed to reach -40 ºC 
and stirred for additional 30 min. Ethyl 2-chloroacetate (1.44 mL, 15.1 mmol) was 
added and the mixture moved to an ice-cooled bath for 30 min. The mixture was poured 
into a satured aqueous solution of NH4Cl (100 mL) and extracted with ethyl acetate 
(3×50 mL), dried over MgSO4, filtered-off and concentrated under reduced pressure. 
After purification by flash chromatography [hexane:ethyl acetate (4:1)] ynamide 541 
was isolated as a white solid (0.82 g, 63%); mp: 117–119 ºC (lit.34b 117–119 ºC); 1H 
NMR (300 MHz, CDCl3) δ 7.63 (d, J = 8.3 Hz, 2H), 7.39–7.29 (m, 5H), 7.23–7.16 (m, 
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2H), 4.23 (q, J = 7.1 Hz, 2H), 2.45 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H); IR νmax/cm
-1
 2966, 
2856, 2212, 1702, 1607, 1592, 1515, 1379, 1236, 1119; Analytical data matches that 
reported in the literature.
34b
 
5.4.2 Preparation of precursors for the formation of aminides 
General Procedure 11 (GP11) 
 
Adapted from literature procedures.
113a,113d,121
 A mixture of 2-halo(hetero)aryl amine 
(1.0 eq.) and potassium ethyl xanthate (2.2 eq.) in DMF or EtOH [1.55 M relative to the 
amount of 2-halo(hetero)aryl amine] was stirred at the indicated temperature for the 
given time. Subsequently, the mixture was allowed to cool to room temperature. Water 
(10 mL) and HCl(aq) [1 M, 20 mL] were then added, precipitating a solid. The 
suspension was stirred for an additional 30 min, and then filtered off. The resulting cake 
was washed with water before being dissolved in ethyl acetate, dried over MgSO4, 
filtered off and concentrated under reduced pressure to afford the desired product which 
was used without further purification in the next step. 
General Procedure 12 (GP12) 
 
Adapted from literature procedures.
113a,122 
Ground potassium hydroxide (1.5 eq.) was 
added to a solution of the corresponding 2-hydroxy(hetero)aryl amine (1.0 eq.) in 
ethanol [0.5 M relative to the amount of 2-hydroxy(hetero)aryl amine]. Carbon disulfide 
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(8.0 eq.) was added and the reaction mixture stirred at reflux for the given time. 
Subsequently, the solution was allowed to cool to room temperature and the solvent was 
removed under reduced pressure. The residue was dissolved in water and neutralised 
with acetic acid, precipitating a solid. This was filtered off and the resulting cake was 
washed with water, dissolved in ethyl acetate, dried over MgSO4, filtered off and 
concentrated under reduced pressure, to afford the desired product which was used 
without further purification in the next step. 
General Procedure 13 (GP13) 
 
Adapted from literature procedures.
113d,122 
A mixture of benzo(thia/oxa)zole-2-thiol or 
aza-analogue (1.0 eq.) in dry THF [0.25 M] was cooled down into an ice-bath before the 
portionwise addition of sodium hydride (60% in mineral oil, 1.1 eq.) or potassium 
carbonate (1.1 eq.) over 10 min. The reaction mixture was stirred for 30 min, before the 
dropwise addition of methyl iodide (1.2 eq.). The cooling bath was removed and the 
solution stirred for 8 h at room temperature. The mixture was quenched with NH4Cl(aq) 
(sat.), and the resulting mixture was extracted with ethyl acetate (2×15 mL), washed 
with brine (10 mL), dried over MgSO4, filtered off and concentrated under reduced 
pressure to afford the desired product which was used without further purification in the 
next step unless otherwise specified. 
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2-Chloro-1-(methylsulfonyl)-1H-benzo[d]imidazole (442) 
A suspension of 2-chlorobenzimidazole (0.40 g, 2.6 mmol) and sodium 
carbonate (0.41 g, 3.9 mmol) in dry DMF (5 mL) was stirred at 0 ºC for 5 
min before the dropwise addition of mesyl chloride (0.22 mL, 2.9 mmol). The mixture 
was stirred at room temperature for 2 h. Water (5 mL) was then added precipitating a 
white solid that was filtered off and washed with water (10 mL). The air-dried residue 
was purified by flash chromatography [hexane:ethyl acetate (4:1)], to afford compound 
442 as a white solid (348.1 mg, 58%); mp. 138–140 oC; 1H NMR (300 MHz, CDCl3) δ 
7.98–7.91 (m, 1H), 7.77–7.70 (m, 1H), 7.47–7.38 (m, 2H), 3.43 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 140.8 (C), 137.9 (C), 133.7 (C), 125.8 (CH), 125.4 (CH), 120.1 (CH), 
113.6 (CH), 42.7 (CH3); IR νmax/cm
-1
 3000, 2917, 1500, 1446, 1371, 1229, 1143, 1038, 
967; HRMS (ES-TOF): m/z: calcd. for C8H8N2O2SCl: 230.9995 found: 230.9987 
[M+H]
+
.  
2,5-Dichlorobenzo[d]oxazole (471) 
Following a literature procedure,
112
 a suspension of 5-chloro-2-
mercaptobenzoxazole (0.50 g, 2.7 mmol) in POCl3 (2.20 mL, 24.0 
mmol) was stirred at room temperature for 5 min. PCl5 (0.66 g, 3.2 mmol) and CH2Cl2 
(2.2 mL) were then added and the reaction mixture was stirred for 1.5 h. The mixture 
was slowly quenched over an ice-cooled solution of Na2CO3 (sat.) until no further gas 
was evolved. The mixture was extracted with CH2Cl2 (2×20 mL) and the combined 
organic extracts were washed with brine (10 mL), dried over MgSO4, filtered off and 
concentrated under reduced pressure. Compound 471 was isolated after flash 
chromatography [hexane:CH2Cl2 (7:3)] as a white solid (100.5 mg, 20%); 
1
H NMR (300 
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MHz, CDCl3) δ 7.67 (d, J = 2.1 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 7.34 (dd, J = 8.8, 
2.1 Hz, 1H);
 13
C NMR (101 MHz, CDCl3) δ 152.3 (C), 150.1 (C), 142.1 (C), 130.8 (C), 
125.9 (CH), 119.8 (CH), 111.2 (CH); IR νmax/cm
-1
 3150, 3053, 1767, 1619, 1478, 1298, 
1259, 1151; HRMS (EI-TOF): m/z: calcd. for C7H3NOCl2: 186.9592 found: 186.9593 
[M]
+
. Analytical data matches that reported in the literature.
123
 
6-Fluoro-2-mercaptobenzothiazole (478) 
Following GP11, using 2,4-difluoroaniline (1.01 mL, 10.0 mmol) and 
potassium ethyl xanthate (3.5 g, 22.0 mmol) in DMF (6.5 mL) at 95 ºC 
for 4 h. Compound 478 was isolated as a pale pink solid (1.54 g, 83%); 
mp. 218–220 oC; 1H NMR (300 MHz, DMSO-d6) δ 13.82 (s, 1H), 7.66 (ddd, J = 8.4, 
2.2, 0.6 Hz, 1H), 7.31–7.24 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 190.4 (C), 
159.6 (d, JC-F = 241.3 Hz, C), 138.5 (C), 131.2 (d, JC-F = 11.1 Hz, C), 115.2 (d, JC-F = 
24.6 Hz, CH), 113.8 (d, JC-F = 8.9 Hz, CH), 109.3 (d, JC-F = 27.7 Hz, CH). Analytical 
data matches that reported in the literature.
121
  
6-Fluoro-2-(methylthio)benzo[d]thiazole (479) 
 Following GP13, compound 478 (1.64 g, 8.1 mmol), methyl iodide 
(0.60 mL, 8.9 mmol) and sodium hydride (0.36 g, 9.7 mmol) in dry 
THF (32 mL) for 9 h. Compound 479 was isolated as an orange solid 
(1.60 g, 99%); 
1
H NMR (300 MHz, DMSO-d6) δ 7.96 (dd, J = 8.7, 2.7 Hz, 1H), 7.86 
(dd, J = 8.9, 4.9 Hz, 1H), 7.33 (app. td, J = 9.0, 2.7 Hz, 1H), 2.79 (s, 3H);
 13
C NMR 
(101 MHz, DMSO-d6) δ 168.3 (C), 159.4 (d, JC-F = 241.8 Hz, C), 150.2 (C), 136.2 (d, 
JC-F = 12.0 Hz, C), 122.5 (d, JC-F = 9.4 Hz, CH), 115.0 (d, JC-F = 24.6 Hz, CH), 108.9 (d, 
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JC-F = 27.6 Hz, CH), 16.0 (CH3); IR νmax/cm
-1
 2924, 1853, 1596, 1567, 1441, 1189, 
1005, 903, 809. Analytical data matches that reported in the literature.
113d
 
6-Fluoro-2-(methylsulfonyl)benzo[d]thiazole (481) 
Following a literature procedure,
114
 H2O2(aq) (30%, 0.16 mL, 2.0 
mmol) was added over a mixture of compound 479 (200.1 mg, 1.0 
mmol) and cyanuric chloride (184.4 mg, 1.0 mmol) in acetonitrile (5 
mL). The mixture was stirred at room temperature for 5 h. Water (10 mL) was then 
added to the mixture followed by extraction with ethyl acetate (4×5 mL). The combined 
organic extracts were dried over MgSO4, filtered and concentrated under reduced 
pressure. Purification by flash chromatography [hexane:ethyl acetate (7:3)] afforded 
compound 481 as a white solid (123.5 mg, 53%); mp. 134–136 oC; 1H NMR (300 MHz, 
CDCl3) δ 8.01 (dd, J = 9.0, 4.7 Hz, 1H), 7.69 (dd, J = 7.9, 2.5 Hz, 1H), 7.31 (app. td, J = 
8.9, 2.5 Hz, 1H), 3.07 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 178.0 (C), 160.9 (d, JC-F = 
248.9 Hz, C), 159.7 (C), 150.5 (C), 137.2 (d, JC-F = 11.2 Hz, C), 125.2 (d, JC-F = 9.6 Hz, 
CH), 116.1 (d, JC-F = 25.1 Hz, CH), 108.6 (d, JC-F = 26.9 Hz, CH), 43.2 (CH3); IR 
νmax/cm
-1
 3062, 1600, 1503, 1468, 1449, 1187, 761; HRMS (ES-TOF): m/z: calcd. for 
C8H7NO2FS2: 231.9902 found: 231.9907 [M+H]
+
. 
Thiazolo[5,4-b]pyridine-2-thiol (493) 
Following GP11, 3-amino-2-chloropyridine (1.28 g, 10.0 mmol) and 
potassium ethyl xanthate (3.5 g, 21.9 mmol) were stirred in DMF (6.5 mL) 
at 130 ºC for 24 h, to afford compound 493 as a beige solid (1.55 g, 92%); 
1
H NMR 
(300 MHz, DMSO-d6) δ 13.95 (br., 1H), 8.41 (dd, J = 4.8, 1.4 Hz, 1H), 7.63 (dd, J = 
8.2, 1.4 Hz, 1H), 7.43 (dd, J = 8.2, 4.8 Hz, 1H);
 13
C NMR (101 MHz, DMSO-d6) δ 
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189.2 (C), 151.8 (C), 146.1 (CH), 136.7 (C), 122.8 (CH), 119.9 (CH); IR νmax/cm
-1
 
3080, 2536, 1594, 1520, 1391, 1300, 1029; Analytical data matches that reported in the 
literature.
122
 
2-(Methylthio)thiazolo[5,4-b]pyridine (497) 
Following GP13, compound 493 (1.20 g, 7.1 mmol), methyl iodide 
(0.53 mL, 8.6 mmol) and sodium hydride (0.31 g, 7.9 mmol) were 
stirred in dry THF (32 mL) for 24 h, affording compound 497 as an orange solid (1.15 
g, 88%); 
1
H NMR (300 MHz, DMSO-d6) δ 8.49 (dd, J = 4.7, 1.5 Hz, 1H), 8.22 (dd, J = 
8.2, 1.5 Hz, 1H), 7.53 (dd, J = 8.2, 4.7 Hz, 1H), 2.81 (s, 3H);
 13
C NMR (101 MHz, 
DMSO) δ 169.4 (C), 158.2 (C), 146.4 (C), 146.3 (CH), 128.5 (CH), 122.3 (CH), 15.5 
(CH3); IR νmax/cm
-1
 3049, 2922, 2852, 1552, 1433, 1374, 1216, 1006; Analytical data 
matches that reported in the literature.
122
 
Oxazolo[4,5-b]pyridine-2-thiol (494) 
Following GP12, 2-amino-3-hyridoxypyridine (2.20 g, 20.0 mmol), 
potassium hydroxide (2.00 g, 29.0 mmol) and carbon disulfide (9.60 mL, 
160.0 mmol) in ethanol (40 mL) were stirred under reflux for 8 h to afford compound 
494 as a beige solid (2.12 g, 70%); mp. 254–256 oC; 1H NMR (300 MHz, DMSO-d6) δ 
14.53 (br., 1H), 8.23 (dd, J = 5.2, 1.3 Hz, 1H), 7.88 (dd, J = 8.1, 1.3 Hz, 1H), 7.27 (dd, J 
= 8.1, 5.2 Hz, 1H);
 13
C NMR (101 MHz, DMSO-d6) δ 181.8 (C), 147.5 (C), 144.7 (CH), 
142.1 (C), 119.6 (CH), 117.5 (CH); IR νmax/cm
-1
 3048–2570 (br), 1631, 1607, 1481, 
1430, 1366; 1248, 1134. Analytical data matches that reported in the literature.
122
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2-(Methylthio)oxazolo[4,5-b]pyridine (498) 
Following a modification of GP13, compound 494 (2.00 g, 13.2 mmol), 
methyl iodide (0.98 mL, 15.8 mmol) and potassium carbonate (1.8 g, 
13.2 mmol) were stirred in dry DMF (33 mL) for 1 h. After purification by flash 
chromatography [hexane:ethyl acetate (3:2)] compound 498 was isolated as a white 
solid (1.73 g, 79%); mp. 55–57 oC; 1H NMR (300 MHz, CDCl3) δ 8.41 (dd, J = 5.0, 1.4 
Hz, 1H), 7.65 (dd, J = 8.1, 1.4 Hz, 1H), 7.13 (dd, J = 8.1, 5.0 Hz, 1H), 2.77 (s, 3H);
 13
C 
NMR (101 MHz, CDCl3) δ 170.3 (C), 156.1 (C), 145.8 (CH), 144.2 (C), 118.8 (CH), 
117.1 (CH), 14.7 (CH3); IR νmax/cm
-1
 3065, 2929, 1617, 1493, 1400, 1250, 1125, 1093. 
Analytical data matches that reported in the literature.
122
 
Thiazolo[4,5-c]pyridine-2-thiol (495) 
Following GP11 using 3-amino-4-chloropyridine (0.50 g, 3.9 mmol) and 
potassium ethyl xanthate (1.34 g, 8.6 mmol) were stirred in DMF (2.5 mL) 
at 130 ºC for 24 h, to afford compound 495 as a brown solid (337.8 mg, 52%); mp. 280 
o
C (degradation); 
1
H NMR (300 MHz, DMSO-d6) δ 11.86 (br., 1H), 8.62 (s, 1H), 8.49 
(d, J = 5.7 Hz, 1H), 8.05 (d, J = 5.7 Hz, 1H);
 13
C NMR (101 MHz, DMSO-d6) δ 144.4 
(C), 140.3 (CH), 140.3 (CH), 131.4 (C), 131.3 (C), 118.5 (CH); IR νmax/cm
-1
 3087, 
1527, 1452, 1289, 1029, 814; HRMS (ES-TOF): m/z: calcd. for C6H5N2S2: 168.9894 
found: 168.9891 [M+H]
+
. 
2-(Methylthio)thiazolo[4,5-c]pyridine (499) 
Following GP13, compound 495 (280.5 mg, 1.7 mmol), methyl iodide 
(0.12 mL, 2.1 mmol) and sodium hydride (73.5 mg, 1.8 mmol) were 
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stirred in dry THF (7 mL) for 5 h. Purification by flash chromatography [hexane:ethyl 
acetate (1:1)] afforded compound 499 as a white solid (172.2 mg, 57%); mp. 87–89 oC; 
1
H NMR (300 MHz, CDCl3) δ 9.14 (d, J = 0.7 Hz, 1H), 8.43 (d, J = 5.4 Hz, 1H), 7.71 
(dd, J = 5.4, 0.7 Hz, 1H), 2.83 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 169.9 (C), 150.1 
(C), 143.6 (C), 143.2 (CH), 143.1 (CH), 116.1 (CH), 16.1 (CH3); IR νmax/cm
-1
 2996, 
1572, 1456, 1438, 1415, 978; HRMS (EI-TOF): m/z: calcd. for C7H6N2S2: 181.9972 
found: 181.9967 [M]
+
. 
Thiazolo[5,4-c]pyridine-2-thiol (496) 
Following GP11 using 4-amino-3-fluoropyridine (0.40 g, 3.6 mmol) and 
potassium ethyl xanthate (1.30 g, 7.9 mmol) were stirred in DMF (2.3 mL) 
at 130 ºC for 6 h, to afford compound 496 as a yellow solid (590.2 mg, 98%); mp. 305 
ºC (degradation) (lit.
122
 >290 ºC); 
1
H NMR (300 MHz, DMSO-d6) δ 14.25 (br., 1H), 
8.82 (d, J = 0.8 Hz 1H), 8.40 (d, J = 6.1 Hz, 1H), 7.45 (dd, J = 6.1, 0.8 Hz, 1H);
 
IR 
νmax/cm
-1
 3077, 3029, 1607, 1513, 1448, 1399, 1320, 1246, 1040. Analytical data 
matches that reported in the literature.
122
 
2-(Methylthio)thiazolo[5,4-c]pyridine (500) 
Following GP13, compound 496 (0.40 g, 1.8 mmol), methyl iodide 
(0.13 mL, 2.1 mmol) and sodium hydride (86.4 mg, 2.1 mmol) were 
stirred in dry THF (7 mL) for 5 h, to afford compound 500 as a white solid (139.0 mg, 
45%); mp. 162–164 oC; 1H NMR (300 MHz, CDCl3) δ 9.02 (d, J = 0.7 Hz, 1H), 8.57 (d, 
J = 5.6 Hz, 1H), 7.73 (dd, J = 5.6, 0.7 Hz, 1H), 2.83 (s, 3H);
 13
C NMR (101 MHz, 
CDCl3) δ 174.9 (C), 158.2 (C), 146.0 (CH), 143.0 (CH), 132.4 (C), 115.7 (CH), 16.1 
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(CH3); IR νmax/cm
-1
 2916, 1578, 1427, 1397, 1006, 978; HRMS (EI-TOF): m/z: calcd. 
for C7H6N2S2: 181.9972 found: 181.9970 [M]
+
. 
3H-Imidazo[4,5-b]pyridine-2-thiol (529) 
Following and adaptation of GP12, 2,3-diaminopyridine (1.01 g, 9.2 
mmol), potassium hydroxide (0.74 g, 13.3 mmol) and carbon disulfide 
(4.4 ml, 73.3 mmol) in EtOH (18 mL) were stirred under reflux for 5 h, to afford 
compound 529 as brown solid (1.11 g, 80%); mp. 310–312 oC (lit.124 315–316 ºC); 1H 
NMR (300 MHz, DMSO-d6) δ 13.13 (br., 1H), 12.73 (br., 1H), 8.10 (dd, J = 5.0, 1.4 
Hz, 1H), 7.48 (dd, J = 7.9, 1.4 Hz, 1H), 7.13 (dd, J = 7.9, 5.1 Hz, 1H); 
13
C NMR (101 
MHz, DMSO-d6) δ 170.3 (C), 146.9 (C), 142.8 (CH), 125.9 (C), 118.6 (CH), 116.7 
(CH). Analytical data matches the reported in the literature.
125
 
1-(methylsulfonyl)-2-(methylthio)-1H-imidazo[4,5-b]pyridine (533) 
 
A mixture of 529 (0.96 g, 6.3 mmol), methyl iodide (0.39 mL, 6.3 mmol) and N,N-
diisopropylethylamine (1.09 mL, 6.3 mmol) in acetone (3.2 mL) was sonicated for 5 
minutes, leading to the dissolution of the thiol and immediate precipitation of the 
product as a white solid. This was extracted with ethyl acetate (20 mL) and washed with 
brine (2×10 mL). The solution was dried over MgSO4, filtered off and concentrated 
under reduced pressure. The residue was recrystallized in ethyl acetate affording the 
product as a mixture of tautomers 530 and 531 (1 : 1.5). Beige solid (514.0 mg, 49%); 
mp. 211–213 oC (lit.124 210–212 ºC); 1H NMR (300 MHz, DMSO-d6) δ 13.14 and 12.78 
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(br., 1H), 8.17 (m, 1H), 7.98–7.67 (m, 1H), 7.27–7.05 (m, 1H), 2.71 (s, 3H); IR νmax/cm
-
1
 3067, 2978, 2931, 1513, 1457, 1393, 1298, 1271, 950. Analytical data matches that 
reported in the literature.
125
 
 
Part of the mixture obtained in the previous step (250.2 mg, 1.5 mmol) was taken into a 
flame-dried flask. Mesyl chloride (0.18 mL, 2.3 mmol), N,N-diisopropylethylamine 
(0.39 mL, 2.3 mmol), 4-dimethylaminopyridine (9 mg, 0.1 mmol) and DMF (3 mL) 
were sequentially added and the resulting mixture was stirred at room temperature for 
24 h. The reaction mixture was diluted with brine (5 mL) and extracted with ethyl 
acetate (2×10 mL). The organic phases were combined, dried over MgSO4, filtered off 
and concentrated under reduced pressure, affording a mixture of regioisomers 532 and 
533 (1 : 5.6) that were separated by flash chromatography [hexane:ethyl acetate (1:1)]. 
Compound 532: White solid (30.3 mg, 8%). mp. 140–142 oC; 1H NMR 
(300 MHz, CDCl3) δ 8.28 (dd, J = 4.9, 1.5 Hz, 1H), 7.84 (dd, J = 8.0, 1.5 
Hz, 1H), 7.22 (dd, J = 8.0, 4.9 Hz, 1H), 3.56 (s, 3H), 2.65 (s, 3H);
 13
C NMR (101 MHz, 
CDCl3) δ 155.5 (C), 148.0 (C), 143.6 (CH), 135.6 (C), 126.0 (CH), 120.4 (CH), 42.4 
(CH3), 14.9 (CH3); IR νmax/cm
-1
 3020, 2989, 2910, 1597, 1439, 1402, 1353, 1227, 1151, 
1032. HRMS (ES-TOF): m/z: calcd. for C8H10N3O2S2: 244.0214 found: 244.0215 
[M+H]
+
.  
Compound 533: White solid (164.5 mg, 45%). mp. 166–168 oC; 1H NMR 
(300 MHz, CDCl3) δ 
1
H NMR (300 MHz, CDCl3) δ 8.45 (dd, J = 4.9, 1.5 
Hz, 1H), 8.03 (dd, J = 8.1, 1.5 Hz, 1H), 7.16 (dd, J = 8.1, 4.9 Hz, 1H), 3.23 (s, 3H), 2.76 
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(s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 157.6 (C), 155.3 (C), 146.5 (CH), 127.1 (C), 
120.5 (CH), 118.9 (CH), 41.2 (CH3), 15.5 (CH3); IR νmax/cm
-1
 3014, 2997, 2905, 1599, 
1461, 1394, 1361, 1320, 1210, 1145, 1035. HRMS (ES-TOF): m/z: calcd. for 
C8H10N3O2S2: 244.0214 found: 244.0216 [M+H]
+
. 
1,2-bis(methylsulfonyl)-1H-imidazo[4,5-b]pyridine (534) 
m-Chloroperbenzoic acid (70%, 353.5 mg, 2.1 mmol,) was added into 
an ice-cooled solution of 533 (200.7 mg, 0.8 mmol) in CH2Cl2 (4 mL). 
The mixture was stirred at room temperature for 40 min. Then, washed with a satured 
aqueous solution of Na2S2O3 (10 mL), and concentrated under reduced pressure. The 
resulting product was directly taken into the aminide-forming step due to its quick 
degradation over time. 
8-Bromocaffeine (537) 
Following the reported procedure,
126
 caffeine (0.97 g, 5.0 mmol) and 
aged NBS (1.78 g, 10.0 mmol) were combined and dissolved in dry 
CH2Cl2 (30 mL). Water was then added and the resulting mixture was 
vigorously stirred at room temperature for 5 days. The mixture was then washed with 
NaOH [2 M] (100 mL) followed by water (2×50 mL). The organic phase was dried over 
MgSO4, filtered off, concentrated under reduced pressure and purified by flash 
chromatography [hexane:ethyl acetate (1:1)] to afford compound 537 as a white solid 
(1.1 g, 80%); mp. 194–196 oC; 1H NMR (300 MHz, CDCl3) δ 3.97 (s, 3H), 3.56 (s, 3H), 
3.40 (s, 3H);
 
IR νmax/cm
-1
 2953, 1701, 1653, 1448, 1341, 972, 743. Analytical data 
matches that reported in the literature.
126
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5.4.3 Preparation of aminides 
General Procedure 14 (GP14) 
 
Following a modification of GP5 a mixture of N-aminopyridinium iodide (1.0 eq.) and 
potassium carbonate (2.8 eq.) in methanol [0.1 M relative to the amount of N-
aminopyridinium iodide] was stirred at room temperature for 30 min until a permanent 
purple suspension appeared. The corresponding 2-halobenzoheterocycle (1.04 eq.) was 
added and the reaction mixture was stirred at room temperature for the indicated period 
of time. The solvent was removed under reduced pressure and the residue redissolved in 
CH2Cl2 and washed with a solution of NaOH [2.5 M]. The aqueous phase was extracted 
with CH2Cl2 and the combined organic phases were dried over MgSO4, filtered off and 
the solvent removed under reduced pressure. The residue was purified by flash 
chromatography over silica gel. 
General Procedure 15 (GP15) 
 
Following an adaptation of GP14, a mixture of N-aminopyridinium iodide (1.0 eq.) and 
potassium carbonate (2.8 eq.) in methanol [0.1 M relative to the amount of N-
aminopyridinium iodide] was stirred at room temperature for 30 min until a permanent 
purple suspension appeared. The corresponding 2-methylthiobenzo(thio/oxa)zole (1.04 
eq.) was added and the reaction mixture was stirred at room temperature for the 
indicated period of time. The solvent was removed under reduced pressure and the 
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residue dissolved in CH2Cl2 and washed with a solution of NaOH [2.5 M]. The aqueous 
phase was extracted with CH2Cl2 and the combined organic phases were dried over 
MgSO4, filtered off and the solvent removed under reduced pressure. The residue was 
purified by flash chromatography over silica gel. 
Pyridinium N-(benzo[d]oxazol-2-yl) amide (436) 
Following GP14 using N-aminopyridinium iodide (0.40 g, 2.0 mmol), 
2-chlorobenzoxazole (0.23 mL, 2.1 mmol) and potassium carbonate 
(0.80 g, 5.6 mmol) for 16 h. After purification by flash chromatography 
[CH2Cl2:methanol (95:5)] aminide 436 was isolated as a bright yellow solid (405.2 mg, 
96%); mp. 200–202 oC; 1H NMR (300 MHz, CDCl3) δ 9.60–9.54 (m, 2H), 7.63–7.53 
(m, 3H), 7.35 (dd, J = 7.7, 0.9 Hz, 1H), 7.29 (dd, J = 7.5, 1.1 Hz, 1H), 7.15 (app. td, J = 
7.5, 0.9 Hz, 1H), 7.04 (app. td, J = 7.7, 1.1 Hz, 1H);
 13
C NMR (101 MHz, CDCl3) δ 
166.1 (C), 147.4 (C), 143.5 (C), 138.6 (2×CH), 131.3 (CH), 126.1 (2×CH), 123.1 (CH), 
120.8 (CH), 115.3 (CH), 108.5 (CH); IR νmax/cm
-1
 3069, 3046, 1626, 1604, 1526, 1469, 
1300, 1236, 1192, 1002; HRMS (ES-TOF): m/z: calcd. for C12H9N3ONa: 234.0643 
found: 234.0641 [M+Na]
+
. 
Pyridinium N-(benzo[d]thiazol-2-yl) amide (437) 
Following GP14 using N-aminopyridinium iodide (0.40 g, 2.0 mmol), 
2-chlorobenzoxothiazole (0.30 mL, 2.1 mmol) and potassium 
carbonate (0.80 g, 5.6 mmol) for 16 h. After purification by flash chromatography 
[CH2Cl2:methanol (95:5)] aminide 437 was isolated as a bright yellow solid (434.4 mg, 
95%); mp. 174–176 oC; 1H NMR (300 MHz, CDCl3) δ 9.64–9.55 (m, 2H), 7.62–7.41 
(m, 5H), 7.30–7.18 (m, 1H), 7.03 (app. td, J = 7.6, 1.1 Hz, 1H); 13C NMR (101 MHz, 
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CDCl3) δ 172.3 (C), 153.3 (C), 138.3 (2×CH), 131.0 (C), 131.0 (CH), 125.9 (2×CH), 
125.3 (CH), 121.2 (CH), 120.5 (CH), 118.0 (CH); IR νmax/cm
-1
 3070, 3050, 1590, 1551, 
1467, 1351, 1290, 1193, 1012, 754; HRMS (ES-TOF): m/z: calcd. for C12H10N3OS: 
228.0595 found: 228.0598 [M+H]
+
. 
Pyridinium N-(1-(Methylsulfonyl)-1H-benzo[d]imidazol-2-yl) amide (443) 
Following GP14 using N-aminopyridinium iodide (278.5 mg, 1.3 
mmol), compound 442 (301.2 mg, 1.3 mmol) and potassium 
carbonate (483.7 mg, 3.5 mmol) for 17 h. After purification by flash chromatography 
[CH2Cl2:methanol (95:5)] aminide 443 was isolated as a bright yellow solid (105.3 mg, 
37%); mp. 135–137 oC; 1H NMR (300 MHz, CDCl3) δ 9.51–9.44 (m, 2H), 7.82 (dd, J = 
8.2, 1.3 Hz, 1H), 7.68–7.52 (m, 3H), 7.29 (dd, J = 7.7, 1.2 Hz, 1H), 7.16 (app. td, J = 
7.7, 1.3 Hz, 1H), 7.02 (app. td, J = 8.2, 1.2 Hz, 1H), 3.53 (s, 3H);
 13
C NMR (101 MHz, 
CDCl3) δ 157.1 (C), 142.7 (C), 139.7 (2×CH), 132.2 (CH), 131.4 (C), 126.0 (2×CH), 
123.8 (CH), 120.7 (CH), 115.6 (CH), 112.5 (CH), 41.4 (CH3); IR νmax/cm
-1
 3018, 1601, 
1523, 1466, 1352, 1282, 1214, 746, 667; HRMS (ES-TOF): m/z: calcd. for 
C13H13N4O2S: 289.0759 found: 289.0748 [M+H]
+
. 
Pyridinium N-(5-Chlorobenzo[d]oxazol-2-yl) amide (472) 
Following GP14 using N-aminopyridinium iodide (248.2 mg, 1.1 
mmol), compound 471 (231.3 mg, 1.2 mmol) and potassium 
carbonate (464.4 mg, 3.4 mmol) for 16 h. After purification by flash chromatography 
[CH2Cl2:methanol (95:5)] aminide 472 was isolated as a bright yellow solid (208.6 mg, 
76%); mp. 218–220 oC; 1H NMR (300 MHz, CDCl3) δ 9.49 (dd, J = 6.9, 1.3 Hz, 2H), 
7.69–7.55 (m, 3H), 7.26 (br., 1H), 7.14 (d, J = 8.3 Hz, 1H), 6.96 (dd, J = 8.3, 2.1 Hz, 
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1H);
 13
C NMR (101 MHz, CDCl3) δ 167.2 (C), 146.2 (C), 145.0 (C), 139.0 (CH), 132.1 
(CH), 128.3 (C), 126.2 (2×CH), 120.3 (2×CH), 115.3 (CH), 108.9 (CH); IR νmax/cm
-1
 
3061, 3039, 1603, 1519, 1453, 1188; HRMS (ES-TOF): m/z: calcd. for C12H9N3OCl: 
246.0434 found: 246.0432 [M+H]
+
. 
Pyridinium N-(6-fluorobenzo[d]thiazol-2-yl) amide (480) 
Following GP15 using N-aminopyridinium iodide (73.0 mg, 0.33 
mmol), compound 481 (80.2 mg, 0.35 mmol) and potassium 
carbonate (129.3 mg, 0.93 mmol) for 16 h. After purification by flash 
chromatography [CH2Cl2:methanol (95:5)] aminide 480 was isolated as a bright yellow 
solid (63.6 mg, 74%); mp. 168–170 oC; 1H NMR (300 MHz, CDCl3) δ 9.63–9.55 (m, 
2H), 7.59–7.49 (m, 3H), 7.36 (dd, J = 8.9, 4.8 Hz, 1H), 7.28 (dd, J = 8.3, 2.7 Hz, 1H), 
6.94 (app. td, J = 9.0, 2.7 Hz, 1H);
 13
C NMR (101 MHz, CDCl3) δ 171.9 (C), 158.1 (d, 
JC-F = 239.1 Hz, C), 149.8 (C), 138.2 (2×CH), 131.8 (d, JC-F = 10.2 Hz, C), 130.9 (CH), 
125.9 (2×CH), 118.2 (d, JC-F = 8.6 Hz, CH), 112.6 (d, JC-F = 23.6 Hz, CH), 107.2 (d, JC-
F = 26.8 Hz, CH); IR νmax/cm
-1
 3062, 3034, 1600, 1503, 1468, 1448, 1188; HRMS (ES-
TOF): m/z: calcd. for C12H9N3SF: 246.0501 found: 246.0503 [M+H]
+
. 
Pyridinium N-(thiazolo[5,4-b]pyridin-2-yl) amide (501) 
Following GP15 using N-aminopyridinium iodide (235.0 mg, 1.10 
mmol), compound 497 (200.6 mg, 1.04 mmol) and potassium 
carbonate (410.5 mg, 3.01 mmol) for 24 h. After purification by flash chromatography 
[CH2Cl2:methanol (95:5)] aminide 501 was isolated as a bright yellow solid (193.7 mg, 
80%); mp. 194–196 oC; 1H NMR (300 MHz, CDCl3) δ 9.49 (dd, J = 7.1, 1.2 Hz, 2H), 
8.10 (dd, J = 4.8, 1.5 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.61–7.55 (m, 2H), 7.51 (dd, J = 
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8.0, 1.5 Hz, 1H), 7.11 (dd, J = 8.0, 4.8 Hz, 1H);
 13
C NMR (101 MHz, CDCl3) δ 171.8 
(C), 156.0 (C), 147.6 (C), 141.7 (CH), 139.5 (2×CH), 132.8 (CH), 126.1 (2×CH), 122.7 
(CH), 120.5 (CH); IR νmax/cm
-1
 3109, 3069, 1573, 1550, 1467, 1141; HRMS (ES-TOF): 
m/z: calcd. for C11H9N4S: 229.0548 found: 229.0551 [M+H]
+
. 
Pyridinium N-(oxazolo[4,5-b]pyridin-2-yl) amide (502) 
Following GP15 using N-aminopyridinium iodide (222.0 mg, 1.01 
mmol), compound 498 (173.2 mg, 1.05 mmol) and potassium 
carbonate (389.8 mg, 2.82 mmol) for 22 h. After purification by flash chromatography 
[CH2Cl2:methanol (9:1)] aminide 502 was isolated as a yellow solid (168.3 mg, 79%); 
mp. 189–191 oC; 1H NMR (300 MHz, CDCl3) δ 9.55 (dd, J = 7.1, 1.2 Hz, 2H), 8.14 (dd, 
J = 5.2, 1.4 Hz, 1H), 7.73 (tt, J = 7.5, 2.1 Hz, 1H), 7.66–7.59 (m, 2H), 7.39 (dd, J = 7.7, 
1.4 Hz, 1H), 6.87 (dd, J = 7.7, 5.2 Hz, 1H);
 13
C NMR (101 MHz, CDCl3) δ 167.8 (C), 
158.7 (C), 143.5 (CH), 140.3 (C), 139.9 (CH), 133.5 (CH), 126.2 (2×CH), 115.6 
(2×CH), 114.1 (CH); IR νmax/cm
-1
 3109, 3044, 1596, 1528, 1470, 1400, 1298, 1250, 
1181; HRMS (ES-TOF): m/z: calcd. for C11H9N4O: 213.0776 found: 213.0775 [M+H]
+
. 
Pyridinium N-(thiazolo[4,5-c]pyridin-2-yl) amide (503) 
Following GP15 using N-aminopyridinium iodide (176.2 mg, 
0.79 mmol), compound 499 (150.9 mg, 0.82 mmol), and potassium 
carbonate (307.2 mg, 2.22 mmol) for 17 h. After purification by flash chromatography 
[CH2Cl2:methanol (95:5)] aminide 503 was isolated as a yellow solid (140.5 mg, 78%); 
mp. 193–195 oC; 1H NMR (300 MHz, CDCl3) δ 9.57–9.50 (m, 2H), 8.65 (s, 1H), 8.16 
(d, J = 5.2 Hz, 1H), 7.71–7.55 (m, 3H), 7.49 (d, J = 5.2 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 172.7 (C), 150.7 (C), 140.7 (2×CH), 140.1 (C), 139.2 (CH), 138.8 (CH), 
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132.7 (CH), 126.2 (2×CH), 115.7 (CH); IR νmax/cm
-1
 3032, 1574, 1498, 1461, 1409, 
916; HRMS (ES-TOF): m/z: calcd. for C11H9N4S: 229.0548 found: 229.0549 [M+H]
+
. 
Pyridinium N-(thiazolo[5,4-c]pyridin-2-yl) amide (504) 
Following GP15 using N-aminopyridinium iodide (117.5 mg, 0.53 
mmol), compound 500 (100.3 mg, 0.55 mmol) and potassium 
carbonate (206.2 mg, 1.49 mmol) for 22 h. After purification by flash chromatography 
[CH2Cl2:methanol (9:1)] aminide 504 was isolated as a yellow solid (108.8 mg, 90%); 
mp. 223–225 oC; 1H NMR (300 MHz, CDCl3) δ 9.38 (d, J = 5.9 Hz, 2H), 8.65 (s, 1H), 
8.30 (d, J = 5.6 Hz, 1H), 7.78 (t, J = 7.6 Hz, 1H), 7.65 (app. t, J = 7.0 Hz, 2H), 7.19 (d, 
J = 5.6 Hz, 1H);
 13
C NMR (101 MHz, CDCl3) δ 176.3 (C), 159.5 (C), 145.5 (CH), 141.1 
(2×CH), 140.1 (CH), 134.2 (CH), 128.7 (C), 126.3 (2×CH), 112.2 (CH); IR νmax/cm
-1
 
3027, 1478, 1439, 1320, 1195, 809; HRMS (ES-TOF): m/z: calcd. for C11H9N4S: 
229.0548 found: 229.0550 [M+H]
+
. 
Pyridinium N-(1-(Methylsulfonyl)-1H-imidazo[5,4-b]pyridin-2-yl) amide (535) 
Following GP15 using N-aminopyridinium iodide (202.4 mg, 0.90 
mmol), sulfone 534 (260.6 mg, 0.94 mmol) and potassium carbonate 
(352.2 mg, 2.53 mmol) for 22 h. After purification by flash chromatography 
[CH2Cl2:MeOH (92:8)] aminide 535 was isolated as a yellow solid (38.5 mg, 15%); mp. 
199–201 oC; 1H NMR (300 MHz, CDCl3) δ 9.45 (d, J = 6.2 Hz, 2H), 8.17 (dd, J = 5.1, 
1.3 Hz, 1H), 7.91 (dd, J = 7.9, 1.3 Hz, 1H), 7.77 (t, J = 7.5 Hz, 1H), 7.63 (app. t, J = 7.0 
Hz, 2H), 6.87 (dd, J = 7.9, 5.1 Hz, 1H), 3.54 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 
158.9 (C), 156.2 (C), 144.1 (CH), 140.9 (2×CH), 134.4 (CH), 126.2 (2×CH), 124.9 (C), 
118.8 (CH), 115.5 (CH), 41.5 (CH3); IR νmax/cm
-1
 2994, 2909, 1581, 1513, 1466, 1397, 
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1351, 1293, 1155; HRMS (ES-TOF): m/z: calcd. for C12H12N5O2S: 290.0712 found: 
290.0710 [M+H]
+
. 
Pyridinium N-(1,3,7-trimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl) aminide 
(538) 
Following GP14 using N-aminopyridinium iodide (200.2 mg, 0.90 
mmol), 537 (255.3 mg, 0.93 mmol) and potassium carbonate 
(375.3 mg, 2.72 mmol) for 24 h. After purification by flash 
chromatography [CH2Cl2:methanol (95:5)] aminide 538 was isolated as a bright orange 
solid (221.3 mg, 86%); mp. 226–228 oC; 1H NMR (300 MHz, CDCl3) δ 9.32 (dd, J = 
5.6, 2.8 Hz, 2H), 7.47–7.43 (m, 3H), 3.73 (s, 3H), 3.53 (s, 3H), 3.40 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 155.8 (C), 154.1 (C), 151.9 (C), 147.9 (C), 137.3 (2×CH), 129.2 
(CH), 125.8 (2×CH), 102.7 (C), 30.0 (CH3), 29.7 (CH3), 27.6 (CH3); IR νmax/cm
-1
 3057, 
2945, 1687, 1646, 1486, 1444, 1214, 1140; HRMS (ES-TOF): m/z: calcd. for 
C13H14N6O2Na: 309.1076 found: 309.1075 [M+Na]
+
. 
5.5 Cycloaddition products for Chapter 4 
General Procedure 16 (GP16) 
 
A heat gun-dried Schlenk tube was charged with the corresponding ynamide (1.0 eq.) [if 
the ynamide was an oil it was added as a stock solution in the reaction solvent], 
heterocyclic aminide (1.2 eq.) and dichloro(2-pyridinecarboxylate)gold (PicAuCl2) 
Chapter 5 
173 
 
(5 mol%) under an argon atmosphere. Dry solvent (1,2-dichlorobenzene or 1,4-dioxane, 
[0.1 M relative to the amount of ynamide] was then added and the mixture was stirred 
under argon at the specified temperature (90 or 125 °C) for the indicated period of time. 
The reaction mixture was then allowed to cool and either (A) added directly onto a 
silica gel column to be purified by flash chromatography (when using 1,2-
dichlorobenzene), or (B) concentrated under reduced pressure and the residue purified 
by silica gel flash chromatography (when using 1,4-dioxane). 
Imidazo[2,1-b]benzoxazole 451 
Following GP16 using ynamide 264 (41.5 mg, 0.20 mmol) and aminide 
436 (51.2 mg, 0.24 mmol) in 1,2-DCB for 6 h. After purification by 
flash chromatography [hexane:ethyl acetate (3:2)] compound 451 was 
isolated as a pale yellow solid (57.0 mg, 84%); mp. 170–172 oC; 1H NMR (300 MHz, 
CDCl3) δ 7.83 (d, J = 7.0 Hz, 2H), 7.61–7.51 (m, 3H), 7.51–7.43 (m, 2H), 7.35 (app. td, 
J = 8.0, 1.2 Hz, 1H), 7.31–7.23 (m, 1H), 3.26 (s, 3H), 3.22 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 151.9 (C), 150.2 (C), 135.7 (C), 128.9 (2×CH), 128.7 (CH), 128.4 (2×CH), 
127.2 (C), 126.8 (C), 124.9 (CH), 124.1 (CH), 121.5 (C), 112.5 (CH), 112.3 (CH), 39.0 
(CH3), 36.8 (CH3); IR νmax/cm
-1
 2989, 1636, 1588, 1554, 1475, 1407, 1381, 1232, 1147, 
1090; HRMS (ES-TOF): m/z: calcd. for C17H15N3O3SNa: 364.0732 found: 364.0734 
[M+Na]
+
. 
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Imidazo[2,1-b]benzothiazole 452 
Following GP16 using ynamide 264 (41.2 mg, 0.20 mmol) and aminide 
437 (55.3 mg, 0.24 mmol) in 1,2-DCB for 8 h. After purification by 
flash chromatography [hexane:ethyl acetate (1:1)] compound 452 was 
isolated as a white solid (61.2 mg, 87%); mp. 180–182 oC; 1H NMR (300 MHz, CDCl3) 
δ 7.68–7.56 (m, 3H), 7.51–7.43 (m, 3H), 7.28–7.20 (m, 1H), 7.16–7.09 (m, 2H), 3.14 (s, 
3H), 3.11 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 144.7 (C), 140.5 (C), 133.1 (C), 130.3 
(2×CH), 129.6 (C), 129.4 (CH), 128.8 (2×CH), 127.3 (C), 125.9 (CH), 125.8 (C), 125.0 
(CH), 124.1 (CH), 114.0 (CH), 39.1 (CH3), 36.9 (CH3); IR νmax/cm
-1
 3026, 1487, 1361, 
1327, 1146, 975; HRMS (ES-TOF): m/z: calcd. for C17H15N3O2S2Na: 380.0503 found: 
380.0501 [M+Na]
+
. 
Imidazo[1,2-a]benzimidazole 446 
Following GP16 using ynamide 264 (29.4 mg, 0.14 mmol) and aminide 
443 (48.2 mg, 0.17 mmol) in 1,2-DCB for 24 h. After purification by 
flash chromatography [hexane:ethyl acetate (3:2)] compound 446 was 
isolated as an off-white foam (20.4 mg, 35%); 
1
H NMR (300 MHz, CDCl3) δ 8.04 (d, J 
= 8.4 Hz, 1H), 7.79–7.73 (m, 2H), 7.59–7.44 (m, 3H), 7.42–7.32 (m, 2H), 7.25 (app. td, 
J = 7.8, 1.1 Hz, 1H), 3.44 (s, 3H), 3.23 (s, 3H), 3.22 (s, 3H);
 13
C NMR (101 MHz, 
CDCl3) δ 141.5 (C), 137.7 (C), 132.3 (C), 129.1 (2×CH), 129.1 (CH), 128.9 (2×CH), 
126.9 (C), 126.3 (C), 125.3 (CH), 124.5 (CH), 121.9 (C), 115.1 (CH), 112.4 (CH), 40.7 
(CH3), 39.1 (CH3), 37.4 (CH3); IR νmax/cm
-1
 3029, 2929, 1602, 1572, 1474, 1366, 1339, 
964, 908; HRMS (ES-TOF): m/z: calcd. for C18H18N4O4S2Na: 441.0667 found: 
441.0666 [M+Na]
+
. 
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Imidazo[2,1-b]benzoxazole 453 
Following GP16 using ynamide 266 (57.4 mg, 0.20 mmol) and aminide 
436 (50.8 mg, 0.24 mmol) in 1,2-DCB for 1 h. After purification by 
flash chromatography [hexane:ethyl acetate (3:2)] compound 453 was 
isolated as a white solid (77.3 mg, 92%); mp. 56–58 oC; 1H NMR (300 
MHz, CDCl3) δ 7.51 (d, J = 7.9 Hz, 1H), 7.41–7.33 (m, 5H), 7.33–7.22 (m, 2H), 7.21–
7.13 (m, 1H), 7.10–7.02 (m, 1H), 7.01–6.92 (m, 4H), 4.69 (s, 2H), 3.28 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 151.8 (C), 150.1 (C), 134.7 (C), 133.2 (C), 129.1 (2×CH), 
128.6 (2×CH), 128.4 (CH), 128.4 (2×CH), 127.9 (2×CH), 127.6 (CH), 126.9 (C), 126.7 
(C), 124.8 (CH), 124.0 (CH), 123.4 (C), 112.4 (CH), 112.2 (CH), 55.3 (CH2), 38.3 
(CH3); IR νmax/cm
-1
 3029, 1735, 1631, 1604, 1577, 1477, 1384, 1281, 1185, 1043, 1025; 
HRMS (ES-TOF): m/z: calcd. for C23H19N3O3SNa: 440.1045 found: 440.1060 
[M+Na]
+
. 
Imidazo[2,1-b]benzothiazole 454 
Following GP16 using ynamide 266 (57.1 mg, 0.20 mmol) and aminide 
437 (54.5 mg, 0.24 mmol) in 1,2-DCB for 3 h. After purification by 
flash chromatography [hexane:ethyl acetate (3:2)] compound 454 was 
isolated as a white solid (80.6 mg, 93%); mp. 128–130 oC; 1H NMR 
(300 MHz, CDCl3) δ 7.66 (dd, J = 8.0, 0.8 Hz, 1H), 7.45–7.38 (m, 1H), 7.34 (app. t, J = 
7.3 Hz, 2H), 7.29–7.21 (m, 1H), 7.19–7.08 (m, 4H), 7.07–6.94 (m, 5H), 4.70 (s, 2H), 
3.25 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 144.5 (C), 138.1 (C), 135.0 (C), 133.0 (C), 
130.5 (2×CH), 129.5 (C), 129.1 (2×CH), 128.9 (CH), 128.3 (2×CH), 128.1 (2×CH), 
127.7 (C), 127.6 (CH), 126.9 (C), 125.8 (CH), 124.9 (CH), 124.0 (CH), 113.9 (CH), 
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55.1 (CH2), 38.2 (CH3); IR νmax/cm
-1
 2991, 1608, 1581, 1488, 1379, 1255, 1160, 1028, 
879; HRMS (ES-TOF): m/z: calcd. for C23H19N3O2S2Na: 456.0816 found: 456.0820 
[M+Na]
+
. 
Imidazo[2,1-b]benzothiazole 455 
Following GP16 using ynamide 537 (72.3 mg, 0.20 mmol) and aminide 
437 (54.4 mg, 0.24 mmol) in 1,2-DCB for 2 h. After purification by flash 
chromatography [hexane:ethyl acetate (4:1)] compound 455 was isolated 
as a white solid (92.9 mg, 91%); mp. 166–168 oC; 1H NMR (300 MHz, 
CDCl3) δ 7.87 (d, J = 7.8 Hz, 2H), 7.65 (d, J = 7.9 Hz, 1H), 7.46 (t, J = 7.3 Hz, 1H), 
7.43–7.42 (m, 4H), 7.25–7.16 (m, 3H), 7.11 (app. t, J = 7.9 Hz, 2H), 7.01 (app. t, J = 7.5 
Hz, 2H), 6.97–6.89 (m, 3H), 4.51 (s, 2H), 2.48 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
144.2 (C), 143.7 (C), 137.9 (C), 135.9 (C), 135.1 (C), 133.0 (C), 130.7 (2×CH), 129.7 
(C), 129.6 (2×CH), 129.1 (2×CH), 128.9 (C), 128.6 (2×CH), 128.2 (2×CH), 128.0 
(CH), 128.0 (2×CH), 127.4 (CH), 127.3 (C), 125.7 (CH), 124.7 (CH), 123.9 (CH), 
113.9 (CH), 54.4 (CH2), 21.7 (CH3); IR νmax/cm
-1
 3030, 1594, 1583, 1484, 1362, 1346, 
1237, 1153, 1074; HRMS (ES-TOF): m/z: calcd. for C29H24N3O2S2: 510.1310 found: 
510.1315 [M+H]
+
. 
This reaction was also performed using ynamide 537 (0.90 g, 2.49 mmol), aminide 437 
(0.68 g, 2.99 mmol) and dichloro(2-pyridinecarboxylate)gold (PicAuCl2) (48.5 mg, 0.13 
mmol) in 1,2-DCB (25 mL) for 1 h. After this time, solvent was removed under reduced 
pressure and the residue purified as above, to afford 455 (1.08 g, 85%). 
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(R)-(–)-Imidazo[2,1-b]benzoxazole 456 
Following GP16 using ynamide 538 (60.1 mg, 0.20 mmol) and aminide 
436 (50.7 mg, 0.24 mmol) in 1,2-DCB for 2 h. After purification by 
flash chromatography [hexane:ethyl acetate (4:1)] compound 456 was 
isolated as an off-white foam (44.0 mg, 51% at ~95% purity estimated 
by 
1
H NMR);     
    -43.9 (c 1.0, CH2Cl2); Some resonances are broadened due to 
restricted rotation. 
1
H NMR (300 MHz, CDCl3) δ 7.68–6.76 (m, 14H), 5.39–5.08 (m, 
1H), 3.00 (br., 3H), 1.37 (br., 3H);
 13
C NMR (101 MHz, CDCl3) δ 151.5 (C), 150.2 (C), 
139.6 (C), 131.0 (C), 128.7 (2×CH), 128.6 (CH), 128.5 (CH), 128.1 (2×CH), 127.9 
(CH), 127.8 (CH), 127.4 (C), 126.8 (C), 124.8 (2×CH), 124.4 (C), 123.9 (2×CH), 112.4 
(CH), 112.3 (CH), 59.7 (CH), 41.0 (CH3), 29.7 (CH3); IR νmax/cm
-1
 3069, 3033, 2983, 
1630, 1576, 1477, 1339, 1185, 1160; HRMS (ES-TOF): m/z: calcd. for 
C24H21N3O3SNa: 454.1201 found: 454.1196 [M+Na]
+
. 
(R)-(–)-Imidazo[2,1-b]benzothiazole 457 
Following GP16 using ynamide 538 (60.2 mg, 0.20 mmol) and aminide 
437 (54.4 mg, 0.24 mmol) in 1,2-DCB for 15 h. After purification by 
flash chromatography [hexane:ethyl acetate (4:1)] compound 457 was 
isolated as an off-white foam (51.0 mg, 57% at ~90% purity estimated 
by 
1
H NMR);     
    -58.3 (c 1.0, CH2Cl2); Some resonances are broadened due to 
restricted rotation. 
1
H NMR (300 MHz, CDCl3) δ 7.76–6.90 (m, 14H), 5.25 (q, J = 7.1 
Hz, 1H), 3.03 (br., 3H), 1.47 (br., 3H);
 13
C NMR (101 MHz, CDCl3) δ 144.1 (C), 140.0 
(C), 135.9 (C), 133.1 (C), 130.5 (CH), 129.7 (C), 128.9 (CH), 128.7 (C), 128.4 (CH), 
128.2 (2×CH), 128.1 (2×CH), 127.7 (CH), 127.4 (C), 125.8 (CH), 124.9 (2×CH), 124.0 
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(2×CH), 114.1 (CH), 59.4 (CH), 40.8 (CH3), 29.7 (CH3); IR νmax/cm
-1
 3026, 2854, 1487, 
1341, 1220, 1160, 968, 754; HRMS (ES-TOF): m/z: calcd. for C24H21N3O2S2Na: 
470.0973 found: 470.0977 [M+Na]
+
. 
The reaction was also carried out following GP16 using ynamide 538 (30.1 mg, 
0.10 mmol) and aminide 437 (27.2 mg, 0.12 mmol) in 1,4-dioxane at 90 
o
C for 24 h, 
affording 457 (34.2 mg, 76%). 
Imidazo[2,1-b]benzoxazole 459 
 Following GP16 using ynamide 276 (61.2 mg, 0.20 mmol) and 
aminide 436 (50.7 mg, 0.24 mmol) in 1,2-DCB for 1 h. After 
purification by flash chromatography [hexane:ethyl acetate (3:2)] 
compound 459 was isolated as a white solid (75.7 mg, 86%); mp. 164–
166 
o
C; 
1
H NMR (300 MHz, CDCl3) 7.89–7.81 (m, 1H), 7.57–7.47 (m, 
2H), 7.39–7.28 (m, 2H), 7.07 (d, J = 8.7 Hz, 2H), 6.90 (dd, J = 3.5, 0.6 Hz, 1H), 6.65 (d, 
J = 8.7 Hz, 2H), 6.50 (dd, J = 3.5, 1.8 Hz, 1H), 4.75 (s, 2H), 3.71 (s, 3H), 3.17 (s, 3H);
 
13
C NMR (101 MHz, CDCl3) δ 159.2 (C), 151.7 (C), 150.1 (C), 141.9 (C), 141.5 (CH), 
133.0 (C), 130.3 (2×CH), 127.1 (C), 126.8 (C), 125.0 (CH), 124.3 (CH), 115.4 (C), 
113.9 (CH), 113.5 (2×CH), 112.2 (CH), 112.0 (CH), 109.7 (CH), 55.1 (CH3), 54.5 
(CH2), 38.2 (CH3); IR νmax/cm
-1
 2931, 1630, 1578, 1472, 1342, 1155; HRMS (ES-TOF): 
m/z: calcd. for C22H19N3O5SNa: 460.0943 found: 460.0945 [M+Na]
+
. 
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Imidazo[2,1-b]benzoxazole 462 
Following GP16 using ynamide 539 (46.9 mg, 0.20 mmol) and 
aminide 436 (50.6 mg, 0.24 mmol) in 1,4-dioxane at 90 ºC for 45 min. 
After cooling down the reaction mixture, the product precipitated and 
was filtered off and washed with ice-cooled diethyl ether followed by hexane and dried 
under air, to afford the pure compound 462 as a pale brown solid (55.4 mg, 75%); mp. 
255 
o
C (degradation); 
1
H NMR (300 MHz, CDCl3) δ 7.83–7.76 (m, 1H), 7.60–7.53 (m, 
3H), 7.44–7.24 (m, 7H), 3.35 (s, 3H), 3.14 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
150.1 (C), 136.9 (C), 136.6 (C), 130.3 (CH), 128.8 (2×CH), 128.2 (CH), 127.1 (C), 
126.6 (2×CH), 124.9 (CH), 124.4 (CH), 121.1 (C), 113.3 (CH), 112.7 (CH), 112.5 
(CH), 38.6 (CH3), 36.3 (CH3); One resonance for a quaternary carbon was not visible; 
IR νmax/cm
-1
 3025, 1636, 1584, 1469, 1333, 1147, 732; HRMS (ES-TOF): m/z: calcd. 
for C19H17N3O3SNa: 390.0888 found: 390.0889 [M+Na]
+
. 
Imidazo[2,1-b]benzoxazole 463 
Following GP16 using ynamide 279 (47.6 mg, 0.20 mmol) and aminide 
436 (50.7 mg, 0.24 mmol) in 1,2-DCB for 4 h. After purification by flash 
chromatography [hexane:ethyl acetate (3:2)] compound 463 was isolated 
as a pale yellow solid (50.0 mg, 68%); mp. 200–202 oC; 1H NMR (300 
MHz, CDCl3) δ 7.79–7.65 (m, 3H), 7.59–7.51 (m, 1H), 7.45–7.26 (m, 5H), 3.28 (s, 3H), 
1.91 (tt, J = 8.2, 5.3 Hz, 1H), 1.16–0.96 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 150.7 
(C), 150.0 (C), 141.1 (C), 135.5 (C), 129.2 (2×CH), 127.4 (CH), 127.3 (2×CH), 126.9 
(C), 124.5 (CH), 124.2 (CH), 122.5 (C), 112.4 (CH), 111.9 (CH), 38.5 (CH3), 5.9 
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(2×CH2), 3.8 (CH); IR νmax/cm
-1
 2922, 1628, 1568, 479, 1395, 1165, 1092, 742; HRMS 
(ES-TOF): m/z: calcd. for C19H18N3O3S: 368.1069 found: 368.1061 [M+H]
+
. 
Imidazo[2,1-b]benzothiazole 464 
Following GP16 using ynamide 279 (47.6 mg, 0.20 mmol) and aminide 
437 (54.7 mg, 0.24 mmol) in 1,2-DCB for 4 h. After purification by flash 
chromatography [hexane:ethyl acetate (3:2)] compound 464 was isolated 
as a pale yellow solid (50.6 mg, 66%); mp. 174–176 oC; 1H NMR (300 
MHz, CDCl3) δ 8.13 (d, J = 8.0 Hz, 1H), 7.82–7.66 (m, 3H), 7.50–7.26 (m, 3H), 3.30 (s, 
3H), 1.93 (app. quin, J = 5.5 Hz, 1H), 1.23–1.07 (m, 4H); 13C NMR (101 MHz, CDCl3) 
δ 143.3 (C), 141.2 (C), 139.8 (C), 133.5 (C), 129.6 (C), 129.2 (2×CH), 127.3 (CH), 
127.3 (2×CH), 126.8 (C), 126.1 (CH), 124.8 (CH), 124.0 (CH), 114.2 (CH), 38.6 (CH3), 
6.9 (2×CH2), 4.7 (CH); IR νmax/cm
-1
 3027, 2931, 1582, 1487, 1377, 1343, 1288, 1166, 
774; HRMS (ES-TOF): m/z: calcd. for C19H18N3O2S2: 384.0840 found: 384.0840 
[M+H]
+
. 
Imidazo[2,1-b]benzothiazole 505 
Following GP16 using ynamide 540 (58.6 mg, 0.20 mmol) and aminide 
480 (58.7 mg, 0.24 mmol) in 1,2-DCB for 1 h. After purification by 
flash chromatography [hexane:ethyl acetate (4:1)] compound 505 was 
isolated as a pale green solid (72.5 mg, 79%); mp. 182–184 oC; 1H NMR 
(300 MHz, CDCl3) δ 7.49 (dd, J = 5.2, 1.2 Hz, 1H), 7.40 (dd, J = 7.9, 
2.5 Hz, 1H), 7.20–7.07 (m, 5H), 7.05 (d, J = 4.5 Hz, 1H), 6.98–6.88 (m, 2H), 4.75 (s, 
3H), 3.19 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 159.7 (d, JC-F = 246.5 Hz, C), 144.9 
(C), 140.1 (C), 135.3 (C), 131.5 (CH), 130.9 (d, JC-F = 10.0 Hz, C), 129.4 (C), 129.0 
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(CH), 128.9 (2×CH), 128.3 (2×CH), 127.7 (CH), 127.2 (CH), 126.0 (C), 120.5 (C), 
114.8 (d, JC-F = 8.8 Hz, CH), 113.7 (d, JC-F = 24.2 Hz, CH), 111.1 (d, JC-F = 27.2 Hz, 
CH), 54.9 (CH3), 38.1 (CH3); IR νmax/cm
-1
 3082, 2924, 1609, 1579, 1488, 1338, 1155; 
HRMS (ES-TOF): m/z: calcd. for C21H16N3O2S3FNa: 480.0286 found: 480.0283 
[M+Na]
+
. 
Imidazo[2,1-b]benzoxazole 506 
Following GP16 using ynamide 266 (57.5 mg, 0.20 mmol) and 
aminide 472 (58.6 mg, 0.24 mmol) in 1,2-DCB for 1 h. After 
purification by flash chromatography [hexane:ethyl acetate (3:1)] 
compound 506 was isolated as a white solid (78.4 mg, 87%); mp. 
168–170 oC; 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.8 Hz, 1H), 7.41–7.36 (m, 
3H), 7.36–7.31 (m, 2H), 7.28 (dd, J = 8.8, 2.1 Hz, 1H), 7.22 (d, J = 2.1 Hz, 1H), 7.10–
7.03 (m, 1H), 7.00–6.93 (m, 4H), 4.68 (s, 2H), 3.27 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 152.1 (C), 148.6 (C), 134.6 (C), 133.7 (C), 129.6 (C), 129.1 (2×CH), 128.8 
(CH), 128.6 (2×CH), 128.5 (2×CH), 127.9 (2×CH), 127.7 (CH), 127.4 (C), 126.5 (C), 
124.8 (CH), 123.6 (C), 113.2 (CH), 112.5 (CH), 55.2 (CH2), 38.3 (CH3); IR νmax/cm
-1
 
3004, 2923, 1634, 1582, 1335, 1145; HRMS (ES-TOF): m/z: calcd. for 
C23H18N3O3SClNa: 474.0655 found: 474.0648 [M+Na]
+
. 
Imidazo[2,1-b]benzoxazole 507 
Following GP16 using ynamide 539 (46.8 mg, 0.20 mmol) and 
aminide 472 (59.0 mg, 0.24 mmol) in 1,4-dioxane at 90 ºC for 1 h. 
After cooling down to room temperature the resulting precipitate was 
filtered off, washed with cold diethyl ether followed by hexane and dried under air, to 
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afford the pure compound 507 as a white solid (60.3 mg, 75%); mp. 270 
o
C 
(degradation); 
1
H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 2.0 Hz, 1H), 7.57 (d, J = 7.7 
Hz, 2H), 7.50 (d, J = 9.0 Hz, 1H), 7.41 (app. t, J = 7.7 Hz, 2H), 7.37 (dd, J = 9.0, 2.0 
Hz, 1H), 7.35–7.30 (m, 1H), 7.28 (d, J = 16.6 Hz, 1H), 7.19 (d, J = 16.6 Hz, 1H), 3.33 
(s, 3H), 3.13 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 152.4 (C), 148.6 (C), 137.1 (C), 
136.3 (C), 131.0 (CH), 129.9 (C), 128.9 (2×CH), 128.4 (CH), 127.7 (C), 126.7 (2×CH), 
125.0 (CH), 121.2 (C), 113.4 (CH), 112.9 (CH), 112.8 (CH), 38.5 (CH3), 36.3 (CH3); IR 
νmax/cm
-1
 3004, 1632, 1570, 1482, 1335, 1148; HRMS (ES-TOF): m/z: calcd. for 
C19H16N3O3SClNa: 424.0499 found: 424.0496 [M+Na]
+
. 
Imidazo[2',1':2,3]thiazolo[5,4-b]pyridine 508 
Following GP16 using ynamide 542 (71.5 mg, 0.20 mmol) and 
aminide 501 (54.6 mg, 0.24 mmol) in 1,2-DCB for 1 h. After 
purification by flash chromatography [hexane:ethyl acetate (1:1)] 
compound 508 was isolated as a white solid (93.3 mg, 92%); mp. 
196–198 oC; 1H NMR (300 MHz, CDCl3) δ 8.36 (dd, J = 4.8, 1.5 Hz, 1H), 7.46–7.32 
(m, 3H), 7.24–7.14 (m, 3H), 7.14–7.00 (m, 6H), 4.56 (d, J = 7.0 Hz, 2H), 4.33 (dd, J = 
11.0, 4.6 Hz, 2H), 3.91 (dd, J = 19.3, 11.0 Hz, 2H), 1.12 (s, 3H), 0.92 (s, 3H);
 13
C NMR 
(101 MHz, CDCl3) δ 153.3 (C), 145.5 (CH), 142.5 (C), 139.3 (d, JC-P = 4.1 Hz, C), 
136.7 (d, JC-P = 4.8 Hz, C), 130.2 (2×CH), 129.0 (CH), 128.8 (2×CH), 128.5 (2×CH), 
128.1 (2×CH), 127.4 (C), 127.3 (CH), 125.1 (d, JC-P = 6.4 Hz, C), 120.0 (CH), 119.8 
(CH), 76.6 (d, JC-P = 5.3 Hz, 2×CH2), 53.7 (d, JC-P = 5.4 Hz, CH2), 32.1 (d, J = 5.3 Hz, 
C), 22.1 (CH3), 21.0 (CH3); One resonance for a quaternary carbon was not visible. IR 
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νmax/cm
-1
 2965, 1487, 1381, 1255, 1056, 1006; HRMS (ES-TOF): m/z: calcd. for 
C26H25N4O3S
31
PNa: 527.1283 found: 527.1281 [M+Na]
+
. 
Imidazo[2',1':2,3]oxazolo[4,5-b]pyridine 509 
Following GP16 using ynamide 264 (41.7 mg, 0.20 mmol) and aminide 
502 (51.0 mg, 0.24 mmol) in 1,2-DCB for 1 h. After purification by 
flash chromatography [hexane:ethyl acetate (1:1)] compound 509 was 
isolated as a white solid (65.4 mg, 95%); mp. 240–242 oC; 1H NMR (400 MHz, CDCl3) 
δ 8.35 (dd, J = 5.1, 1.2 Hz, 1H), 8.21 (d, J = 7.3 Hz, 2H), 7.83 (dd, J = 8.2, 1.2 Hz, 1H), 
7.52 (app. t, J = 7.5 Hz, 2H), 7.41 (t, J = 7.4 Hz, 1H), 7.34 (dd, J = 8.2, 5.1 Hz, 1H), 
3.27 (s, 3H), 3.21 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 151.7 (C), 143.7 (CH), 143.6 
(C), 141.9 (C), 136.3 (C), 128.5 (2×CH), 128.5 (CH), 128.3 (2×CH), 126.5 (C), 123.1 
(C), 120.2 (CH), 119.5 (CH), 38.7 (CH3), 37.1 (CH3); HRMS (ES-TOF): m/z: calcd. for 
C16H14N4O3SNa: 365.0684 found: 365.0686 [M+Na]
+
. 
Imidazo[2',1':2,3]oxazolo[4,5-b]pyridine 510 
Following GP16 using ynamide 539 (47.14 mg, 0.20 mmol) and 
aminide 502 (50.97 mg, 0.24 mmol) in 1,4-dioxane at 90 ºC for 1 h. 
After purification by flash chromatography [hexane:ethyl acetate (1:1)] 
compound 510 was isolated as a white solid (55.83 mg, 76%); mp. 246–248 oC; 1H 
NMR (300 MHz, CDCl3) δ 8.49–8.35 (m, 2H), 7.84 (dd, J = 8.2, 1.3 Hz, 1H), 7.63 (d, J 
= 7.3 Hz, 2H), 7.42–7.34 (m, 3H), 7.32–7.29 (m, 1H), 7.28–7.24 (m, 1H), 3.37 (s, 3H), 
3.12 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 152.1 (C), 143.7 (CH), 143.5 (C), 141.7 
(C), 137.4 (C), 137.2 (C), 131.4 (CH), 128.6 (2×CH), 127.8 (CH), 126.9 (2×CH), 123.9 
(C), 120.2 (CH), 119.5 (CH), 112.6 (CH), 38.7 (CH3), 36.2 (CH3); IR νmax/cm
-1
 3093, 
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3021, 1633, 1581, 1471, 1453, 1341, 1149, 959; HRMS (ES-TOF): m/z: calcd. for 
C18H16N4O3SNa: 391.0841 found: 391.0839 [M+Na]
+
. 
Imidazo[2',1':2,3]thiazolo[4,5-c]pyridine 511 
Following GP16 using ynamide 542 (70.9 mg, 0.20 mmol) and 
aminide 503 (54.7 mg, 0.24 mmol) in 1,2-DCB for 8 h. After 
purification by flash chromatography [ethyl acetate:methanol (95:5)] 
compound 511 was isolated as a white solid (65.8 mg, 65%); mp. 
119–121 oC; 1H NMR (300 MHz, CDCl3) δ 8.41 (d, J = 5.3 Hz, 1H), 8.31 (d, J = 0.4 
Hz, 1H), 7.63 (dd, J = 5.3, 0.4 Hz, 1H), 7.49–7.32 (m, 3H), 7.24–7.17 (m, 2H), 7.17–
7.01 (m, 5H), 4.56 (d, J = 7.1 Hz, 2H), 4.34 (dd, J = 10.9, 4.1 Hz, 2H), 3.89 (dd, J = 
19.8, 10.9 Hz, 2H), 1.12 (s, 3H), 0.90 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 144.2 
(CH), 143.1 (C), 142.8 (C), 140.1 (d, JC-P = 3.5 Hz, C), 139.6 (CH), 136.7 (d, JC-P = 4.7 
Hz, C), 134.6 (CH), 130.6 (C), 130.2 (2×CH), 129.2 (C), 128.8 (2×CH), 128.7 (2×CH), 
128.1 (2×C), 127.3 (CH), 125.5 (d, JC-P = 6.2 Hz, C), 118.7 (CH), 76.6 (d, JC-P = 6.1 Hz, 
2×CH2), 53.8 (d, J = 5.3 Hz, CH2), 32.1 (d, JC-P = 5.2 Hz, C), 22.2 (CH3), 20.9 (CH3); 
IR νmax/cm
-1
 2922, 1577, 1489, 1251, 1056, 1001; HRMS (ES-TOF): m/z: calcd. for 
C26H25N4O3S
31
PNa: 527.1283 found: 527.1284 [M+Na]
+
. 
Imidazo[2',1':2,3]thiazolo[5,4-c]pyridine 512 
Following GP16 using ynamide 542 (71.2 mg, 0.20 mmol) and 
aminide 504 (55.2 mg, 0.24 mmol) in 1,2-DCB for 22 h. After 
purification by flash chromatography [ethyl acetate:methanol (9:1)] 
compound 512 was isolated as a white solid (21.9 mg, 22%); mp. 
100–102 oC; 1H NMR (300 MHz, CDCl3) δ 8.90 (s, 1H), 8.35 (d, J = 5.6 Hz, 1H), 7.53–
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7.36 (m, 3H), 7.24–7.01 (m, 7H), 6.90 (d, J = 5.6 Hz, 1H), 4.58 (d, J = 7.1 Hz, 2H), 
4.37 (dd, J = 10.9, 4.2 Hz, 2H), 3.92 (dd, J = 19.7, 10.9 Hz, 2H), 1.15 (s, 3H), 0.93 (s, 
3H);
 13
C NMR (101 MHz, CDCl3) δ 146.1 (CH), 145.1 (CH), 144.8 (C), 140.8 (d, JC-P = 
3.2 Hz, C), 138.6 (C), 136.6 (d, JC-P = 5.0 Hz, C), 130.3 (2×CH), 129.2 (CH), 128.8 
(2×CH), 128.5 (2×CH), 128.1 (2×CH), 127.3 (CH), 127.1 (d, JC-P = 8.3 Hz, C), 125.4 
(d, JC-P = 5.9 Hz, C), 108.2 (CH), 76.6 (d, JC-P = 5.3 Hz, 2×CH2), 53.7 (d, JC-P = 5.2 Hz, 
CH2), 32.1 (d, JC-P = 5.1 Hz, C), 22.1 (CH3), 20.9 (CH3); One resonance for a 
quaternary carbon was not visible; IR νmax/cm
-1
 2935, 1706, 1569, 1489, 1248, 1052; 
HRMS (ES-TOF): m/z: calcd. for C26H25N4O3S
31
PNa: 527.1283 found: 527.1285 
[M+Na]
+
. 
Imidazo[2',1':2,3]thiazolo[5,4-c]pyridine 513 
Following GP16 using ynamide 266 (56.0 mg, 0.20 mmol) and aminide 
504 (54.8 mg, 0.24 mmol) in 1,2-DCB for 22 h. After purification by 
flash chromatography [hexane:ethyl acetate (3:7)] compound 513 was 
isolated as a white solid (25.0 mg, 29%); mp. 102–104 oC; 1H NMR 
(300 MHz, CDCl3) δ 8.93 (s, 1H), 8.35 (d, J = 5.6 Hz, 1H), 7.51–7.43 (m, 1H), 7.36 
(app. t, J = 7.4 Hz, 2H), 7.18–7.09 (m, 3H), 7.03 (app. t, J = 7.4 Hz, 2H), 7.06–6.96 (m, 
2H), 6.90 (d, J = 5.6 Hz, 1H), 4.69 (s, 2H), 3.25 (s, 3H);
 13
C NMR (101 MHz, CDCl3) δ 
147.7 (C), 146.3 (CH), 145.2 (CH), 139.3 (C), 138.5 (C), 134.8 (C), 130.3 (2×CH), 
129.4 (CH), 129.1 (2×CH), 128.5 (2×CH), 128.2 (2×CH), 127.7 (CH), 127.0 (C), 126.2 
(C), 108.4 (CH), 55.1 (CH2), 38.3 (CH3); One resonance for a quaternary carbon was 
not visible; IR νmax/cm
-1
 2923, 1572, 1491, 1339, 1151, 960; HRMS (ES-TOF): m/z: 
calcd. for C22H18N4O2S2Na: 457.0769 found: 457.0775 [M+Na]
+
. 
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Imidazo[1,2-e]purine 539 
Following GP16 using ynamide 264 (41.8 mg, 0.20 mmol) and 
aminide 538 (68.8 mg, 0.24 mmol) in 1,4-dioxane at 90 ºC for 24 h. 
After purification by flash chromatography [ethyl acetate (100%)] 
compound 539 was isolated as a white solid (53.2 mg, 64%); mp. 
280–282 oC; 1H NMR (300 MHz, CDCl3) δ 7.56–7.51 (m, 2H), 7.49–7.45 (m, 3H), 3.98 
(s, 3H), 3.42 (s, 3H), 3.16 (s, 3H), 3.11 (s, 3H), 2.92 (s, 3H);
 13
C NMR (101 MHz, 
CDCl3) δ 155.4 (C), 150.5 (C), 145.6 (C), 141.6 (C), 131.1 (2×CH), 130.6 (C), 129.7 
(CH), 129.1 (2×CH), 128.9 (C), 118.3 (C), 107.1 (C), 38.6 (CH3), 37.3 (CH3), 35.5 
(CH3), 31.1 (CH3), 28.4 (CH3); IR νmax/cm
-1
 2956, 1706, 1670, 1642, 1343, 1153; 
HRMS (ES-TOF): m/z: calcd. for C18H20N6O4SNa: 439.1164 found: 439.1160 
[M+Na]
+
. 
Imidazo[1,2-e]purine 540 
Following GP16 using ynamide 541 (69.4 mg, 0.20 mmol) and 
aminide 538 (69.3 mg, 0.24 mmol) in 1,4-dioxane at 90 ºC for 24 h. 
After purification by flash chromatography [hexane:ethyl acetate (3:2)] 
compound 540 was isolated as a white solid (54.0 mg, 49%); mp. 208–
210 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.3 Hz, 2H), 7.47–7.41 (m, 2H), 
7.28–7.22 (m, 5H), 4.42 (q, J = 7.1 Hz, 2H), 3.98 (s, 3H), 3.64 (s, 3H), 3.44 (s, 3H), 
2.42 (s, 3H), 1.50 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 159.7 (C), 155.4 
(C), 151.0 (C), 150.1 (C), 146.5 (C), 143.7 (C), 139.8 (C), 136.2 (C), 132.1 (C), 129.1 
(2×CH), 128.8 (2×CH), 128.7 (2×CH), 128.1 (2×CH), 127.7 (CH), 112.5 (C), 107.7 
(C), 61.8 (CH2), 36.5 (CH3), 31.4 (CH3), 28.4 (CH3), 21.6 (CH3), 14.4 (CH3); IR 
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νmax/cm
-1
 2985, 1707, 1666, 1638, 1497, 1090; HRMS (ES-TOF): m/z: calcd. for 
C26H26N6O6SNa: 573.1532 found: 573.1534 [M+Na]
+
. 
Imidazo[1,2-e]purine 541 
Following GP16 using ynamide 543 (47.7 mg, 0.20 mmol) and 
aminide 538 (68.5 mg, 0.24 mmol) in 1,4-dioxane at 90 ºC for 4 h. 
After purification by flash chromatography [ethyl acetate (100%)] 
compound 541 was isolated as a white solid (67.5 mg, 75%); mp. 
258–260 oC; 1H NMR (300 MHz, CDCl3) δ 7.44 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 
8.8 Hz, 2H), 3.97 (s, 3H), 3.86 (s, 3H), 3.42 (s, 3H), 3.16 (s, 3H), 3.12 (s, 3H), 2.97 (s, 
3H);
 13
C NMR (101 MHz, CDCl3) δ 160.6 (C), 155.4 (C), 150.4 (C), 145.4 (C), 141.5 
(C), 132.7 (2×CH), 130.7 (C), 120.8 (C), 118.2 (C), 114.5 (2×CH), 106.9 (C), 55.3 
(CH3), 38.6 (CH3), 37.3 (CH3), 35.5 (CH3), 31.1 (CH3), 28.4 (CH3); IR νmax/cm
-1
 3029, 
2945, 1706, 1670, 1640, 1489, 1333; HRMS (ES-TOF): m/z: calcd. for 
C19H22N6O5SNa: 469.1270 found: 469.1269 [M+Na]
+
. 
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Appendix 1.1 Selected NMR Spectra 
 
 
284 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (Pendant, 101 MHz, CDCl3) 
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396 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (Pendant, 101 MHz, CDCl3) 
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398 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (UDEFT, 101 MHz, CDCl3) 
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403 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (Pendant, 101 MHz, CDCl3) 
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405 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (Pendant, 101 MHz, CDCl3) 
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462 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (UDEFT, 101 MHz, CDCl3) 
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452 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (UDEFT, 101 MHz, CDCl3) 
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446 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (UDEFT, 101 MHz, CDCl3) 
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539 - 1H-NMR (300 MHz, CDCl3) and 
13C-NMR (UDEFT, 101 MHz, CDCl3) 
Appendix 1 
198 
 
Appendix 1.2 Assignment of the structure for compound 507 
1
H-NMR: 
 
Figure 15: 
1
H-NMR spectrum for compound 507 
1
H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 2.0 Hz, 1H), 7.57 (d, J = 7.7 Hz, 2H), 7.50 
(d, J = 9.0 Hz, 1H), 7.41 (app. t, J = 7.7 Hz, 2H), 7.37 (dd, J = 9.0, 2.0 Hz, 1H), 7.35–
7.30 (m, 1H), 7.28 (d, J = 16.6 Hz, 1H), 7.19 (d, J = 16.6 Hz, 1H), 3.33 (s, 3H), 3.13 (s, 
3H) 
Key correlations from 
1
H-NMR spectrum; Resonances in the spectra have been labelled 
with letters for clarity: 
 A (δ 7.74): aromatic proton splitted as a doublet with a J value of 2.0 Hz. This is 
the H surrounded by the chlorine atom and the oxazole ring in the imidazo[2,1-
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a]benzoxazole core. The small splitting is due to the 
4
J coupling with E (δ 7.37), 
which is also coupled with C (δ 7.50) with a 3J = 9.0 Hz. 
 B (δ 7.57): two equivalent aromatic protons from the phenyl fragment. The 
splitting as an apparent doublet (
3
J = 7.6 Hz) points towards the atoms in ortho 
position of the ring. Therefore, D (δ 7.41) corresponds to the two protons in 
meta-position and F (δ 7.35–7.30) to the one in para-position. 
 G (δ 7.28) and H (δ 7.19) correspond to the olefinic system and are coupled 
between themselves with a 
3
JTrans = 16.6 Hz. The resonance for the residual 
CHCl3 is merged into G. The assignment of G and H was done through 2D-
experiments. 
 
HSQC: 
13
C NMR (101 MHz, CDCl3) δ 152.4 (C), 148.6 (C), 137.1 (C), 136.3 (C), 131.0 (CH), 
129.9 (C), 128.9 (2×CH), 128.4 (CH), 127.7 (C), 126.7 (2×CH), 125.0 (CH), 121.2 (C), 
113.4 (CH), 112.9 (CH), 112.8 (CH), 38.5 (CH3), 36.3 (CH3) 
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Figure 16: HSQC spectroscopy experiment for compound 507 
HSQC spectroscopic experiments indicate the 
1
JC-H coupling. For instance, the aromatic 
proton at 7.57 ppm (B) can be seen directly connected to the carbon at 126.7 ppm as 
shown in the figure with the blue lines. Following the same analysis for every 
resonance, each proton was matched with its corresponding carbon.  
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HMBC: 
 
Figure 17: HMBC spectroscopy experiment for compound 507 
HMBC spectroscopic experiments indicate the 
3
JC-H coupling and in occasions,
 2
JC-H 
and 
1
JC-H. Key correlations for the assignment of the carbocyclic scaffold of 507 
(indicated with blue lines); Resonances in both axes of the spectra have been labelled 
with letters relative to the order in which they appear: 
 The methyl protons in Hj correlates with Cc. This indicates that the sulfonamide 
group is attached to Cc in the imidazo[2,1-a]benzoxazole core. 
 Correlation Hd – Cd. Carbon Cd corresponds to the ipso-position in the phenyl 
fragment. 
 Correlation Hg – Cj. This allows discerning between the two olefinic signals. Hg 
is the closest to the phenyl group. 
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 Correlation Hi – Cl. Carbon Cl is attached to the olefinic fragment. 
 
For the assignment of the remaining quaternary carbon atoms (indicated with a blue 
spot) the 
13
C-NMR spectrum of 507 was compared with that from analogous structures 
and tabulated values for the benzoxazole ring. 
 Ca is the most shifted carbon and, therefore it corresponds to the bridgehead 
between the imidazole and the oxazole rings. 
 Comparison of the spectra of 507 and 462 show a strong similarity between 
both. The main difference is that Cf (129.9 ppm) is a quaternary carbon in 462 
which disappears in the spectrum of 507 while a new CH appears at 124.4 ppm. 
Hence, Cf corresponds to the carbon atom connected to the chlorine.  
 
Figure 18: Comparison of the 
13
C-NMR spectra for compounds 507 and 462 
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 Tabulated values for 13C-chemical shifts in oxazoles indicate that the 5-position 
of the oxazole is more shifted than the 4- (138.1 ppm vs 125.4 ppm). By 
analogy, Cb is assigned to the carbon directly connected to the oxygen in the 
benzoxazole part of the molecule. 
 
 
Figure 19: Assignment of the carbocyclic scaffold for 507 
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Appendix 2.1 X-Ray crystal structure data 
Data was obtained and solved by Dr Louise Male. 
Appendix 2.1.1 Imidazo[1,2-c]pyrimidine 398 
 
Table 1. Crystal data and structure refinement for 398. 
Identification code  398 
Empirical formula  C19H15Cl N4O2S, CHCl3 
Formula weight  518.23 
Temperature  100.00(10) K 
Wavelength  1.5418 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 10.9178(2) Å α= 90°. 
 b = 13.2275(2) Å β= 95.469(2)°. 
 c = 15.1914(3) Å γ = 90°. 
Volume 2183.88(7) Å3 
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Z 4 
Density (calculated) 1.576 Mg/m3 
Absorption coefficient 6.051 mm-1 
F(000) 1056 
Crystal size 0.250 x 0.180 x 0.060 mm3 
Theta range for data collection 4.441 to 74.455°. 
Index ranges -13<=h<=13, -16<=k<=14, -18<=l<=10 
Reflections collected 8852 
Independent reflections 4329 [R(int) = 0.0251] 
Completeness to theta = 67.684° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.60334 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4329 / 0 / 281 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0308, wR2 = 0.0755 
R indices (all data) R1 = 0.0356, wR2 = 0.0794 
Extinction coefficient n/a 
Largest diff. peak and hole 0.416 and -0.589 e.Å-3 
Notes: 
The hydrogen atoms have been fixed as riding models. 
Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for 
398. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
C(1) 10265(2) 1466(2) 8782(1) 22(1) 
C(2) 10643(2) 2447(2) 8628(1) 22(1) 
C(3) 9934(2) 3080(2) 8055(1) 17(1) 
C(4) 8855(2) 2705(1) 7610(1) 13(1) 
C(5) 8484(2) 1714(2) 7742(1) 16(1) 
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C(6) 9182(2) 1101(2) 8342(1) 22(1) 
C(7) 8179(2) 2291(2) 5433(1) 17(1) 
C(8) 6876(2) 3513(1) 7087(1) 12(1) 
C(9) 4932(2) 3311(1) 6912(1) 13(1) 
C(10) 3700(2) 3034(2) 6685(1) 18(1) 
C(11) 2810(2) 3526(2) 7083(1) 19(1) 
C(12) 4195(2) 4532(1) 7899(1) 13(1) 
C(13) 6462(2) 4181(1) 7679(1) 11(1) 
C(14) 7201(2) 4848(1) 8298(1) 12(1) 
C(15) 7995(2) 5533(1) 7950(1) 15(1) 
C(16) 8772(2) 6128(2) 8511(1) 20(1) 
C(17) 8757(2) 6046(2) 9421(1) 21(1) 
C(18) 7967(2) 5364(2) 9772(1) 19(1) 
C(19) 7194(2) 4762(1) 9214(1) 15(1) 
N(1) 8143(1) 3349(1) 6983(1) 12(1) 
N(2) 5965(1) 2980(1) 6617(1) 14(1) 
N(3) 3062(1) 4294(1) 7686(1) 16(1) 
N(4) 5181(1) 4061(1) 7568(1) 11(1) 
O(1) 9908(1) 3502(1) 6073(1) 17(1) 
O(2) 7882(1) 4231(1) 5538(1) 20(1) 
S(1) 8595(1) 3438(1) 5973(1) 13(1) 
Cl(1) 4494(1) 5521(1) 8617(1) 17(1) 
C(101) 5008(2) 6692(2) 5487(1) 17(1) 
Cl(11) 5609(1) 7936(1) 5429(1) 23(1) 
Cl(12) 4133(1) 6601(1) 6397(1) 33(1) 
Cl(13) 6200(1) 5804(1) 5558(1) 25(1) 
 
Table 3. Bond lengths [Å] and angles [°] for 398. 
C(1)-C(6)  1.388(3) C(1)-C(2)  1.389(3) 
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C(1)-H(1)  0.9500 
C(2)-C(3)  1.389(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.393(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.392(3) 
C(4)-N(1)  1.448(2) 
C(5)-C(6)  1.392(3) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-S(1)  1.7625(19) 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
C(8)-N(2)  1.364(2) 
C(8)-C(13)  1.368(2) 
C(8)-N(1)  1.424(2) 
C(9)-N(2)  1.327(2) 
C(9)-C(10)  1.406(2) 
C(9)-N(4)  1.414(2) 
C(10)-C(11)  1.359(3) 
C(10)-H(10)  0.9500 
C(11)-N(3)  1.378(3) 
C(11)-H(11)  0.9500 
C(12)-N(3)  1.288(2) 
C(12)-N(4)  1.380(2) 
C(12)-Cl(1)  1.7140(18) 
C(13)-N(4)  1.402(2) 
C(13)-C(14)  1.472(2) 
C(14)-C(15)  1.392(2) 
C(14)-C(19)  1.398(2) 
C(15)-C(16)  1.389(3) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.388(3) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.389(3) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.389(3) 
C(18)-H(18)  0.9500 
C(19)-H(19)  0.9500 
N(1)-S(1)  1.6606(15) 
O(1)-S(1)  1.4298(13) 
O(2)-S(1)  1.4302(14) 
C(101)-Cl(13)  1.7486(19) 
C(101)-Cl(12)  1.7585(19) 
C(101)-Cl(11)  1.777(2) 
C(101)-H(101)  1.0000 
C(6)-C(1)-C(2) 119.82(19) 
C(6)-C(1)-H(1) 120.1 
C(2)-C(1)-H(1) 120.1 
C(3)-C(2)-C(1) 120.79(19) 
C(3)-C(2)-H(2) 119.6 
C(1)-C(2)-H(2) 119.6 
C(2)-C(3)-C(4) 119.01(19) 
C(2)-C(3)-H(3) 120.5 
C(4)-C(3)-H(3) 120.5 
C(5)-C(4)-C(3) 120.63(17) 
C(5)-C(4)-N(1) 120.26(16) 
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C(3)-C(4)-N(1) 119.08(17) 
C(6)-C(5)-C(4) 119.63(18) 
C(6)-C(5)-H(5) 120.2 
C(4)-C(5)-H(5) 120.2 
C(1)-C(6)-C(5) 120.1(2) 
C(1)-C(6)-H(6) 120.0 
C(5)-C(6)-H(6) 120.0 
S(1)-C(7)-H(7A) 109.5 
S(1)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 109.5 
S(1)-C(7)-H(7C) 109.5 
H(7A)-C(7)-H(7C) 109.5 
H(7B)-C(7)-H(7C) 109.5 
N(2)-C(8)-C(13) 114.13(15) 
N(2)-C(8)-N(1) 122.01(15) 
C(13)-C(8)-N(1) 123.82(16) 
N(2)-C(9)-C(10) 130.92(17) 
N(2)-C(9)-N(4) 110.97(15) 
C(10)-C(9)-N(4) 118.11(16) 
C(11)-C(10)-C(9) 118.30(18) 
C(11)-C(10)-H(10) 120.8 
C(9)-C(10)-H(10) 120.8 
C(10)-C(11)-N(3) 122.90(17) 
C(10)-C(11)-H(11) 118.6 
N(3)-C(11)-H(11) 118.6 
N(3)-C(12)-N(4) 124.15(16) 
N(3)-C(12)-Cl(1) 117.88(14) 
N(4)-C(12)-Cl(1) 117.95(13) 
C(8)-C(13)-N(4) 103.62(15) 
C(8)-C(13)-C(14) 127.67(16) 
N(4)-C(13)-C(14) 128.70(15) 
C(15)-C(14)-C(19) 119.63(16) 
C(15)-C(14)-C(13) 118.08(15) 
C(19)-C(14)-C(13) 122.12(16) 
C(16)-C(15)-C(14) 120.09(17) 
C(16)-C(15)-H(15) 120.0 
C(14)-C(15)-H(15) 120.0 
C(17)-C(16)-C(15) 120.19(18) 
C(17)-C(16)-H(16) 119.9 
C(15)-C(16)-H(16) 119.9 
C(16)-C(17)-C(18) 119.98(18) 
C(16)-C(17)-H(17) 120.0 
C(18)-C(17)-H(17) 120.0 
C(19)-C(18)-C(17) 120.08(17) 
C(19)-C(18)-H(18) 120.0 
C(17)-C(18)-H(18) 120.0 
C(18)-C(19)-C(14) 120.02(17) 
C(18)-C(19)-H(19) 120.0 
C(14)-C(19)-H(19) 120.0 
C(8)-N(1)-C(4) 118.84(14) 
C(8)-N(1)-S(1) 118.02(12) 
C(4)-N(1)-S(1) 117.47(11) 
C(9)-N(2)-C(8) 104.61(14) 
C(12)-N(3)-C(11) 118.31(16) 
C(12)-N(4)-C(13) 135.13(15) 
C(12)-N(4)-C(9) 118.05(14) 
C(13)-N(4)-C(9) 106.67(14) 
O(1)-S(1)-O(2) 120.14(8) 
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O(1)-S(1)-N(1) 106.77(8) 
O(2)-S(1)-N(1) 106.38(8) 
O(1)-S(1)-C(7) 108.21(8) 
O(2)-S(1)-C(7) 108.16(9) 
N(1)-S(1)-C(7) 106.41(9) 
Cl(13)-C(101)-Cl(12) 111.23(10) 
Cl(13)-C(101)-Cl(11) 110.44(10) 
Cl(12)-C(101)-Cl(11) 109.49(10) 
Cl(13)-C(101)-H(101) 108.5 
Cl(12)-C(101)-H(101) 108.5 
Cl(11)-C(101)-H(101) 108.5
 
Symmetry transformations used to generate equivalent atoms.  
 Table 4. Anisotropic displacement parameters (Å2x 103)for 398. The anisotropic displacement 
factor exponent takes the form: - 2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
Atom U11 U22 U33 U23 U13 U12 
C(1) 21(1)  32(1) 13(1)  2(1) 4(1)  12(1) 
C(2) 14(1)  35(1) 15(1)  -7(1) 0(1)  6(1) 
C(3) 15(1)  21(1) 16(1)  -7(1) 3(1)  0(1) 
C(4) 12(1)  16(1) 12(1)  -2(1) 4(1)  4(1) 
C(5) 13(1)  19(1) 18(1)  -1(1) 5(1)  1(1) 
C(6) 23(1)  22(1) 21(1)  5(1) 9(1)  5(1) 
C(7) 18(1)  17(1) 18(1)  -6(1) 3(1)  1(1) 
C(8) 10(1)  12(1) 14(1)  1(1) 3(1)  1(1) 
C(9) 14(1)  14(1) 12(1)  -1(1) 2(1)  -1(1) 
C(10) 15(1)  21(1) 17(1)  -3(1) 1(1)  -3(1) 
C(11) 13(1)  24(1) 21(1)  0(1) 3(1)  -2(1) 
C(12) 14(1)  11(1) 13(1)  1(1) 5(1)  2(1) 
C(13) 9(1)  10(1) 14(1)  2(1) 4(1)  0(1) 
C(14) 12(1)  10(1) 14(1)  -1(1) 2(1)  2(1) 
C(15) 15(1)  15(1) 15(1)  -1(1) 5(1)  -1(1) 
C(16) 19(1)  18(1) 25(1)  -3(1) 9(1)  -6(1) 
C(17) 17(1)  23(1) 24(1)  -11(1) 1(1)  -5(1) 
C(18) 21(1)  22(1) 14(1)  -3(1) 3(1)  0(1) 
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C(19) 15(1)  15(1) 16(1)  2(1) 3(1)  -1(1) 
N(1) 8(1)  16(1) 14(1)  -1(1) 4(1)  2(1) 
N(2) 12(1)  14(1) 15(1)  -2(1) 3(1)  -1(1) 
N(3) 13(1)  19(1) 18(1)  2(1) 4(1)  1(1) 
N(4) 10(1)  11(1) 12(1)  0(1) 3(1)  0(1) 
O(1) 10(1)  21(1) 20(1)  -1(1) 4(1)  -1(1) 
O(2) 20(1)  17(1) 23(1)  5(1) 6(1)  6(1) 
S(1) 12(1)  12(1) 14(1)  0(1) 4(1)  1(1) 
Cl(1) 16(1)  15(1) 22(1)  -5(1) 5(1)  2(1) 
C(101) 17(1)  17(1) 17(1)  0(1) 3(1)  5(1) 
Cl(11) 31(1)  16(1) 22(1)  -2(1) 7(1)  1(1) 
Cl(12) 39(1)  35(1) 27(1)  0(1) 18(1)  -2(1) 
Cl(13) 21(1)  19(1) 35(1)  -2(1) -1(1)  8(1) 
 
Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 398. 
Atom x  y  z  U(eq) 
H(1) 10746 1045 9187 27 
H(2) 11396 2688 8917 26 
H(3) 10181 3759 7969 21 
H(5) 7757 1458 7426 20 
H(6) 8918 432 8450 26 
H(7A) 8409 2314 4826 26 
H(7B) 7288 2192 5424 26 
H(7C) 8608 1730 5751 26 
H(10) 3495 2516 6263 21 
H(11) 1977 3332 6939 23 
H(15) 8006 5592 7327 18 
H(16) 9315 6592 8272 24 
H(17) 9286 6457 9803 26 
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H(18) 7955 5309 10395 23 
H(19) 6660 4291 9455 18 
H(101) 4457 6558 4935 20 
 
Table 6. Torsion angles [°] for 398. 
C(6)-C(1)-C(2)-C(3) 1.7(3) 
C(1)-C(2)-C(3)-C(4) -2.4(3) 
C(2)-C(3)-C(4)-C(5) 0.7(3) 
C(2)-C(3)-C(4)-N(1) -177.24(15) 
C(3)-C(4)-C(5)-C(6) 1.5(3) 
N(1)-C(4)-C(5)-C(6) 179.48(16) 
C(2)-C(1)-C(6)-C(5) 0.6(3) 
C(4)-C(5)-C(6)-C(1) -2.2(3) 
N(2)-C(9)-C(10)-C(11) -178.23(19) 
N(4)-C(9)-C(10)-C(11) 2.3(3) 
C(9)-C(10)-C(11)-N(3) 1.2(3) 
N(2)-C(8)-C(13)-N(4) -0.3(2) 
N(1)-C(8)-C(13)-N(4) -178.13(15) 
N(2)-C(8)-C(13)-C(14) 178.45(16) 
N(1)-C(8)-C(13)-C(14) 0.6(3) 
C(8)-C(13)-C(14)-C(15) 57.7(3) 
N(4)-C(13)-C(14)-C(15) -123.92(19) 
C(8)-C(13)-C(14)-C(19) -117.6(2) 
N(4)-C(13)-C(14)-C(19) 60.8(3) 
C(19)-C(14)-C(15)-C(16) -0.2(3) 
C(13)-C(14)-C(15)-C(16) -175.60(17) 
C(14)-C(15)-C(16)-C(17) -0.2(3) 
C(15)-C(16)-C(17)-C(18) 0.3(3) 
C(16)-C(17)-C(18)-C(19) 0.1(3) 
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C(17)-C(18)-C(19)-C(14) -0.6(3) 
C(15)-C(14)-C(19)-C(18) 0.7(3) 
C(13)-C(14)-C(19)-C(18) 175.83(17) 
N(2)-C(8)-N(1)-C(4) -98.0(2) 
C(13)-C(8)-N(1)-C(4) 79.7(2) 
N(2)-C(8)-N(1)-S(1) 54.8(2) 
C(13)-C(8)-N(1)-S(1) -127.47(16) 
C(5)-C(4)-N(1)-C(8) 56.7(2) 
C(3)-C(4)-N(1)-C(8) -125.35(18) 
C(5)-C(4)-N(1)-S(1) -96.29(17) 
C(3)-C(4)-N(1)-S(1) 81.68(18) 
C(10)-C(9)-N(2)-C(8) -179.1(2) 
N(4)-C(9)-N(2)-C(8) 0.4(2) 
C(13)-C(8)-N(2)-C(9) 0.0(2) 
N(1)-C(8)-N(2)-C(9) 177.86(16) 
N(4)-C(12)-N(3)-C(11) -0.7(3) 
Cl(1)-C(12)-N(3)-C(11) 177.54(14) 
C(10)-C(11)-N(3)-C(12) -2.1(3) 
N(3)-C(12)-N(4)-C(13) 178.93(18) 
Cl(1)-C(12)-N(4)-C(13) 0.7(3) 
N(3)-C(12)-N(4)-C(9) 4.2(3) 
Cl(1)-C(12)-N(4)-C(9) -174.06(13) 
C(8)-C(13)-N(4)-C(12) -174.71(18) 
C(14)-C(13)-N(4)-C(12) 6.6(3) 
C(8)-C(13)-N(4)-C(9) 0.46(18) 
C(14)-C(13)-N(4)-C(9) -178.25(17) 
N(2)-C(9)-N(4)-C(12) 175.61(15) 
C(10)-C(9)-N(4)-C(12) -4.8(2) 
N(2)-C(9)-N(4)-C(13) -0.5(2) 
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C(10)-C(9)-N(4)-C(13) 179.01(16) 
C(8)-N(1)-S(1)-O(1) 165.52(13) 
C(4)-N(1)-S(1)-O(1) -41.29(15) 
C(8)-N(1)-S(1)-O(2) 36.09(15) 
C(4)-N(1)-S(1)-O(2) -170.71(13) 
C(8)-N(1)-S(1)-C(7) -79.07(15) 
C(4)-N(1)-S(1)-C(7) 74.12(15) 
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Appendix 2.1.2 Imidazo[1,2-a]pyrimidine 402 
 
Table 1. Crystal data and structure refinement for 402 
Identification code  402 
Empirical formula  C25H19FN4O2S 
Formula weight  458.50 
Temperature  101(2) K 
Wavelength  1.5418 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 15.8138(10) Å α= 90°. 
 b = 13.1151(8) Å β= 90.830(5)°. 
 c = 10.3648(6) Å γ = 90°. 
Volume 2149.4(2) Å3 
Z 4 
Density (calculated) 1.417 Mg/m3 
Absorption coefficient 1.680 mm-1 
F(000) 952 
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Crystal size 0.320 x 0.020 x 0.010 mm3 
Theta range for data collection 6.538 to 66.567°. 
Index ranges -18<=h<=18, -15<=k<=13, -12<=l<=7 
Reflections collected 7206 
Independent reflections 3734 [R(int) = 0.0687] 
Completeness to theta = 67.684° 95.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.88084 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3734 / 0 / 299 
Goodness-of-fit on F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0557, wR2 = 0.1280 
R indices (all data) R1 = 0.0924, wR2 = 0.1504 
Extinction coefficient n/a 
Largest diff. peak and hole 0.401 and -0.422 e.Å-3 
Notes: 
 
The hydrogen atoms have been fixed as riding models. 
Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for 
402. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
C(1) 5593(2) 5947(3) 3892(3) 32(1) 
C(2) 5470(2) 4921(3) 3606(3) 31(1) 
C(3) 4762(2) 4612(3) 2909(3) 24(1) 
C(4) 4175(2) 5332(3) 2499(3) 22(1) 
C(5) 4286(2) 6357(3) 2792(3) 28(1) 
C(6) 5003(2) 6657(3) 3494(3) 34(1) 
C(7) 3895(2) 4086(3) -474(3) 28(1) 
C(8) 2907(2) 4259(3) 2324(3) 20(1) 
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C(9) 2342(2) 2808(2) 2629(3) 19(1) 
C(10) 1581(2) 1505(3) 3460(3) 22(1) 
C(11) 1283(2) 2108(3) 4510(3) 19(1) 
C(12) 1546(2) 3086(2) 4558(3) 18(1) 
C(13) 2437(2) 4399(3) 3425(3) 19(1) 
C(14) 2329(2) 5279(2) 4274(3) 19(1) 
C(15) 2392(2) 5207(3) 5613(3) 22(1) 
C(16) 2350(2) 6078(3) 6366(3) 29(1) 
C(17) 2253(2) 7021(3) 5797(4) 32(1) 
C(18) 2172(2) 7104(3) 4470(4) 33(1) 
C(19) 2205(2) 6235(3) 3709(3) 28(1) 
C(20) 738(2) 1679(2) 5534(3) 20(1) 
C(21) 819(2) 659(3) 5900(3) 23(1) 
C(22) 338(2) 305(3) 6902(3) 25(1) 
C(23) -218(2) 904(3) 7567(3) 29(1) 
C(24) -300(2) 1912(3) 7191(4) 30(1) 
C(25) 164(2) 2297(3) 6183(3) 26(1) 
N(1) 3430(2) 5022(2) 1776(3) 21(1) 
N(2) 2851(2) 3295(2) 1838(3) 21(1) 
N(3) 2084(2) 1830(2) 2550(3) 21(1) 
N(4) 2077(2) 3447(2) 3628(2) 18(1) 
O(1) 3958(1) 6037(2) -63(2) 27(1) 
O(2) 2557(1) 5215(2) -226(2) 26(1) 
F(1) 419(1) -689(2) 7239(2) 37(1) 
S(1) 3428(1) 5178(1) 182(1) 21(1) 
 
Table 3. Bond lengths [Å] and angles [°] for 402. 
C(1)-C(6)  1.378(5) C(1)-C(2)  1.391(5) 
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C(1)-H(1)  0.9500 
C(2)-C(3)  1.385(5) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.387(5) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.389(5) 
C(4)-N(1)  1.446(4) 
C(5)-C(6)  1.394(5) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-S(1)  1.754(3) 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
C(8)-N(2)  1.364(4) 
C(8)-C(13)  1.383(4) 
C(8)-N(1)  1.423(4) 
C(9)-N(2)  1.321(4) 
C(9)-N(3)  1.349(4) 
C(9)-N(4)  1.401(4) 
C(10)-N(3)  1.314(4) 
C(10)-C(11)  1.430(4) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.349(4) 
C(11)-C(20)  1.488(4) 
C(12)-N(4)  1.372(4) 
C(12)-H(12)  0.9500 
C(13)-N(4)  1.389(4) 
C(13)-C(14)  1.462(4) 
C(14)-C(15)  1.393(4) 
C(14)-C(19)  1.397(5) 
C(15)-C(16)  1.386(5) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.377(5) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.384(5) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.387(5) 
C(18)-H(18)  0.9500 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.396(5) 
C(20)-C(25)  1.398(4) 
C(21)-C(22)  1.377(5) 
C(21)-H(21)  0.9500 
C(22)-F(1)  1.355(4) 
C(22)-C(23)  1.373(5) 
C(23)-C(24)  1.383(5) 
C(23)-H(23)  0.9500 
C(24)-C(25)  1.382(5) 
C(24)-H(24)  0.9500 
C(25)-H(25)  0.9500 
N(1)-S(1)  1.664(3) 
O(1)-S(1)  1.429(2) 
O(2)-S(1)  1.435(2) 
C(6)-C(1)-C(2) 119.9(3) 
C(6)-C(1)-H(1) 120.1 
C(2)-C(1)-H(1) 120.1 
C(3)-C(2)-C(1) 120.3(4) 
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C(3)-C(2)-H(2) 119.9 
C(1)-C(2)-H(2) 119.9 
C(2)-C(3)-C(4) 119.5(3) 
C(2)-C(3)-H(3) 120.2 
C(4)-C(3)-H(3) 120.2 
C(5)-C(4)-C(3) 120.7(3) 
C(5)-C(4)-N(1) 119.0(3) 
C(3)-C(4)-N(1) 120.2(3) 
C(4)-C(5)-C(6) 119.1(3) 
C(4)-C(5)-H(5) 120.5 
C(6)-C(5)-H(5) 120.5 
C(1)-C(6)-C(5) 120.5(4) 
C(1)-C(6)-H(6) 119.7 
C(5)-C(6)-H(6) 119.7 
S(1)-C(7)-H(7A) 109.5 
S(1)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 109.5 
S(1)-C(7)-H(7C) 109.5 
H(7A)-C(7)-H(7C) 109.5 
H(7B)-C(7)-H(7C) 109.5 
N(2)-C(8)-C(13) 113.3(3) 
N(2)-C(8)-N(1) 122.6(3) 
C(13)-C(8)-N(1) 124.0(3) 
N(2)-C(9)-N(3) 127.5(3) 
N(2)-C(9)-N(4) 111.2(3) 
N(3)-C(9)-N(4) 121.4(3) 
N(3)-C(10)-C(11) 125.2(3) 
N(3)-C(10)-H(10) 117.4 
C(11)-C(10)-H(10) 117.4 
C(12)-C(11)-C(10) 116.8(3) 
C(12)-C(11)-C(20) 121.0(3) 
C(10)-C(11)-C(20) 122.2(3) 
C(11)-C(12)-N(4) 119.6(3) 
C(11)-C(12)-H(12) 120.2 
N(4)-C(12)-H(12) 120.2 
C(8)-C(13)-N(4) 103.4(3) 
C(8)-C(13)-C(14) 132.1(3) 
N(4)-C(13)-C(14) 124.5(3) 
C(15)-C(14)-C(19) 119.1(3) 
C(15)-C(14)-C(13) 122.6(3) 
C(19)-C(14)-C(13) 118.3(3) 
C(16)-C(15)-C(14) 120.1(3) 
C(16)-C(15)-H(15) 119.9 
C(14)-C(15)-H(15) 119.9 
C(17)-C(16)-C(15) 120.3(3) 
C(17)-C(16)-H(16) 119.8 
C(15)-C(16)-H(16) 119.8 
C(16)-C(17)-C(18) 120.3(3) 
C(16)-C(17)-H(17) 119.9 
C(18)-C(17)-H(17) 119.9 
C(17)-C(18)-C(19) 119.8(3) 
C(17)-C(18)-H(18) 120.1 
C(19)-C(18)-H(18) 120.1 
C(18)-C(19)-C(14) 120.4(3) 
C(18)-C(19)-H(19) 119.8 
C(14)-C(19)-H(19) 119.8 
C(21)-C(20)-C(25) 118.9(3) 
C(21)-C(20)-C(11) 120.3(3) 
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C(25)-C(20)-C(11) 120.7(3) 
C(22)-C(21)-C(20) 118.6(3) 
C(22)-C(21)-H(21) 120.7 
C(20)-C(21)-H(21) 120.7 
F(1)-C(22)-C(23) 118.7(3) 
F(1)-C(22)-C(21) 117.9(3) 
C(23)-C(22)-C(21) 123.5(3) 
C(22)-C(23)-C(24) 117.6(3) 
C(22)-C(23)-H(23) 121.2 
C(24)-C(23)-H(23) 121.2 
C(25)-C(24)-C(23) 121.0(3) 
C(25)-C(24)-H(24) 119.5 
C(23)-C(24)-H(24) 119.5 
C(24)-C(25)-C(20) 120.5(3) 
C(24)-C(25)-H(25) 119.8 
C(20)-C(25)-H(25) 119.8 
C(8)-N(1)-C(4) 117.7(3) 
C(8)-N(1)-S(1) 119.3(2) 
C(4)-N(1)-S(1) 118.1(2) 
C(9)-N(2)-C(8) 104.8(3) 
C(10)-N(3)-C(9) 116.8(3) 
C(12)-N(4)-C(13) 132.3(3) 
C(12)-N(4)-C(9) 120.4(3) 
C(13)-N(4)-C(9) 107.3(2) 
O(1)-S(1)-O(2) 118.92(15) 
O(1)-S(1)-N(1) 106.28(14) 
O(2)-S(1)-N(1) 106.57(13) 
O(1)-S(1)-C(7) 108.85(15) 
O(2)-S(1)-C(7) 108.77(16) 
N(1)-S(1)-C(7) 106.82(15) 
 
Symmetry transformations used to generate equivalent atoms.  
Table 4. Anisotropic displacement parameters (Å2x 103)for 402. The anisotropic displacement 
factor exponent takes the form: -2 2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
Atom U11 U22 U33 U23 U13 U12 
C(1) 34(2)  43(3) 19(2)  -5(2) 2(2)  -10(2) 
C(2) 30(2)  42(2) 21(2)  5(2) 3(1)  -4(2) 
C(3) 29(2)  21(2) 24(2)  0(2) 6(1)  -5(1) 
C(4) 25(2)  25(2) 16(2)  1(1) 6(1)  -6(1) 
C(5) 35(2)  23(2) 26(2)  0(2) 6(2)  -4(2) 
C(6) 46(2)  28(2) 28(2)  -4(2) 6(2)  -16(2) 
C(7) 35(2)  30(2) 20(2)  1(2) 9(1)  -1(2) 
C(8) 24(2)  17(2) 18(2)  2(1) 2(1)  -1(1) 
C(9) 25(2)  14(2) 18(2)  -1(1) 2(1)  1(1) 
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C(10) 28(2)  14(2) 22(2)  1(1) -2(1)  -2(1) 
C(11) 18(2)  18(2) 21(2)  2(1) 2(1)  1(1) 
C(12) 22(2)  18(2) 15(1)  0(1) 3(1)  0(1) 
C(13) 24(2)  16(2) 18(2)  2(1) 1(1)  -5(1) 
C(14) 21(2)  15(2) 21(2)  1(1) 5(1)  -2(1) 
C(15) 25(2)  20(2) 23(2)  2(2) 2(1)  -1(1) 
C(16) 35(2)  31(2) 20(2)  -7(2) 6(1)  -4(2) 
C(17) 40(2)  20(2) 35(2)  -9(2) 9(2)  -1(2) 
C(18) 48(2)  15(2) 36(2)  3(2) 8(2)  1(2) 
C(19) 42(2)  20(2) 21(2)  2(2) 4(2)  -3(2) 
C(20) 23(2)  16(2) 21(2)  -1(1) 1(1)  -4(1) 
C(21) 24(2)  19(2) 27(2)  -4(2) 5(1)  -2(1) 
C(22) 28(2)  16(2) 32(2)  3(2) 2(1)  -5(1) 
C(23) 30(2)  27(2) 30(2)  2(2) 11(2)  -7(2) 
C(24) 30(2)  24(2) 36(2)  -3(2) 11(2)  0(2) 
C(25) 31(2)  16(2) 32(2)  1(2) 7(2)  -2(1) 
N(1) 26(1)  21(2) 16(1)  0(1) 3(1)  -6(1) 
N(2) 27(1)  20(2) 17(1)  1(1) 4(1)  0(1) 
N(3) 29(1)  16(2) 19(1)  -3(1) 4(1)  0(1) 
N(4) 27(1)  13(1) 14(1)  -1(1) 2(1)  -1(1) 
O(1) 33(1)  27(1) 22(1)  5(1) 4(1)  -7(1) 
O(2) 24(1)  29(1) 24(1)  7(1) -1(1)  -1(1) 
F(1) 42(1)  21(1) 49(1)  14(1) 12(1)  0(1) 
S(1) 25(1)  22(1) 16(1)  3(1) 4(1)  -2(1) 
Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 402. 
Atom x  y  z  U(eq) 
H(1) 6083 6157 4362 38 
H(2) 5874 4430 3891 37 
H(3) 4680 3911 2711 29 
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H(5) 3879 6848 2519 34 
H(6) 5085 7356 3698 41 
H(7A) 3572 3482 -225 42 
H(7B) 4478 4024 -148 42 
H(7C) 3898 4142 -1417 42 
H(10) 1400 815 3418 26 
H(12) 1365 3522 5232 22 
H(15) 2463 4559 6010 27 
H(16) 2388 6025 7279 34 
H(17) 2242 7616 6318 38 
H(18) 2094 7754 4081 39 
H(19) 2142 6291 2799 33 
H(21) 1198 218 5466 28 
H(23) -535 637 8261 35 
H(24) -681 2345 7633 36 
H(25) 91 2988 5928 31 
Table 6. Torsion angles [°] for 402. 
C(6)-C(1)-C(2)-C(3) 0.8(5) 
C(1)-C(2)-C(3)-C(4) -0.2(5) 
C(2)-C(3)-C(4)-C(5) -0.6(5) 
C(2)-C(3)-C(4)-N(1) -179.7(3) 
C(3)-C(4)-C(5)-C(6) 0.7(5) 
N(1)-C(4)-C(5)-C(6) 179.8(3) 
C(2)-C(1)-C(6)-C(5) -0.7(5) 
C(4)-C(5)-C(6)-C(1) -0.1(5) 
N(3)-C(10)-C(11)-C(12) -0.1(5) 
N(3)-C(10)-C(11)-C(20) -177.8(3) 
C(10)-C(11)-C(12)-N(4) -0.4(5) 
C(20)-C(11)-C(12)-N(4) 177.3(3) 
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N(2)-C(8)-C(13)-N(4) 0.6(4) 
N(1)-C(8)-C(13)-N(4) -176.6(3) 
N(2)-C(8)-C(13)-C(14) 178.1(3) 
N(1)-C(8)-C(13)-C(14) 0.9(6) 
C(8)-C(13)-C(14)-C(15) -132.3(4) 
N(4)-C(13)-C(14)-C(15) 44.7(5) 
C(8)-C(13)-C(14)-C(19) 44.2(5) 
N(4)-C(13)-C(14)-C(19) -138.8(3) 
C(19)-C(14)-C(15)-C(16) -1.5(5) 
C(13)-C(14)-C(15)-C(16) 174.9(3) 
C(14)-C(15)-C(16)-C(17) -0.5(5) 
C(15)-C(16)-C(17)-C(18) 1.9(6) 
C(16)-C(17)-C(18)-C(19) -1.3(6) 
C(17)-C(18)-C(19)-C(14) -0.8(6) 
C(15)-C(14)-C(19)-C(18) 2.1(5) 
C(13)-C(14)-C(19)-C(18) -174.5(3) 
C(12)-C(11)-C(20)-C(21) -146.2(3) 
C(10)-C(11)-C(20)-C(21) 31.4(5) 
C(12)-C(11)-C(20)-C(25) 31.2(5) 
C(10)-C(11)-C(20)-C(25) -151.3(3) 
C(25)-C(20)-C(21)-C(22) -1.1(5) 
C(11)-C(20)-C(21)-C(22) 176.3(3) 
C(20)-C(21)-C(22)-F(1) 179.5(3) 
C(20)-C(21)-C(22)-C(23) -0.1(6) 
F(1)-C(22)-C(23)-C(24) -178.9(3) 
C(21)-C(22)-C(23)-C(24) 0.7(6) 
C(22)-C(23)-C(24)-C(25) -0.1(6) 
C(23)-C(24)-C(25)-C(20) -1.1(6) 
C(21)-C(20)-C(25)-C(24) 1.7(5) 
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C(11)-C(20)-C(25)-C(24) -175.6(3) 
N(2)-C(8)-N(1)-C(4) -109.5(3) 
C(13)-C(8)-N(1)-C(4) 67.4(4) 
N(2)-C(8)-N(1)-S(1) 45.3(4) 
C(13)-C(8)-N(1)-S(1) -137.7(3) 
C(5)-C(4)-N(1)-C(8) -124.6(3) 
C(3)-C(4)-N(1)-C(8) 54.4(4) 
C(5)-C(4)-N(1)-S(1) 80.2(3) 
C(3)-C(4)-N(1)-S(1) -100.8(3) 
N(3)-C(9)-N(2)-C(8) 179.3(3) 
N(4)-C(9)-N(2)-C(8) -0.6(4) 
C(13)-C(8)-N(2)-C(9) 0.0(4) 
N(1)-C(8)-N(2)-C(9) 177.2(3) 
C(11)-C(10)-N(3)-C(9) 0.7(5) 
N(2)-C(9)-N(3)-C(10) 179.3(3) 
N(4)-C(9)-N(3)-C(10) -0.8(5) 
C(11)-C(12)-N(4)-C(13) 179.3(3) 
C(11)-C(12)-N(4)-C(9) 0.3(5) 
C(8)-C(13)-N(4)-C(12) 180.0(3) 
C(14)-C(13)-N(4)-C(12) 2.2(5) 
C(8)-C(13)-N(4)-C(9) -0.9(3) 
C(14)-C(13)-N(4)-C(9) -178.6(3) 
N(2)-C(9)-N(4)-C(12) -179.7(3) 
N(3)-C(9)-N(4)-C(12) 0.3(5) 
N(2)-C(9)-N(4)-C(13) 1.0(4) 
N(3)-C(9)-N(4)-C(13) -178.9(3) 
C(8)-N(1)-S(1)-O(1) 175.7(2) 
C(4)-N(1)-S(1)-O(1) -29.5(3) 
C(8)-N(1)-S(1)-O(2) 48.0(3) 
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C(4)-N(1)-S(1)-O(2) -157.3(2) 
C(8)-N(1)-S(1)-C(7) -68.2(3) 
C(4)-N(1)-S(1)-C(7) 86.6(3) 
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Appendix 2.1.3 Aminide 436 
 
Table 1 Crystal data and structure refinement for 436. 
Identification code 436 
Empirical formula C12H9N3O 
Formula weight 211.22 
Temperature/K 100.01(10) 
Crystal system monoclinic 
Space group P21/n 
a/Å 6.0637(3) 
b/Å 18.6004(7) 
c/Å 8.8473(3) 
α/° 90 
β/° 103.992(4) 
γ/° 90 
Volume/Å3 968.26(7) 
Z 4 
ρcalcg/cm
3 1.449 
μ/mm-1 0.097 
F(000) 440.0 
Crystal size/mm3 0.2414 × 0.179 × 0.0859 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.458 to 52.736 
Index ranges -7 ≤ h ≤ 7, -16 ≤ k ≤ 23, -10 ≤ l ≤ 11 
Reflections collected 3935 
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Independent reflections 1979 [Rint = 0.0286, Rsigma = 0.0486] 
Data/restraints/parameters 1979/0/145 
Goodness-of-fit on F
2
 1.120 
Final R indexes [I>=2σ (I)] R1 = 0.0492, wR2 = 0.1157 
Final R indexes [all data] R1 = 0.0685, wR2 = 0.1305 
Largest diff. peak/hole / e Å-3 0.48/-0.27 
 
  
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement Parameters 
(Å
2
×10
3
) for 436. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 4129(3) 1512.3(11) 4965(2) 18.3(5) 
C2 2353(4) 1551.8(11) 5708(2) 19.5(5) 
C3 4770(3) 736.1(11) 6817(2) 17.4(4) 
C4 4115(4) 1966.5(12) 3728(2) 23.3(5) 
C5 2321(4) 2439.7(12) 3289(2) 26.1(5) 
C6 570(4) 2470.6(11) 4043(2) 24.2(5) 
C7 539(4) 2016.7(11) 5287(2) 22.9(5) 
C8 8668(3) -157.6(11) 7096(2) 20.8(5) 
C9 10534(4) -606.9(11) 7370(2) 22.8(5) 
C10 11007(4) -1055.9(11) 8647(2) 24.5(5) 
C11 9578(4) -1041.5(11) 9649(2) 24.4(5) 
C12 7736(4) -594.0(11) 9367(2) 22.9(5) 
N1 5668(3) 977.0(9) 5698.3(19) 20.3(4) 
N2 5353(3) 252.5(10) 7968(2) 22.9(4) 
N3 7285(3) -155.3(9) 8088.9(19) 19.8(4) 
O1 2725(2) 1056.2(8) 6890.5(16) 23.1(4) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for 436. The Anisotropic displacement 
factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 17.4(10) 17(1) 18.8(10) -3.1(9) 0.9(8) -3.0(8) 
C2 25.3(11) 18.3(10) 13.6(9) 0.2(8) 2.0(8) -6.9(9) 
C3 16.8(10) 18.1(10) 17.1(10) -2.9(8) 3.6(8) -2.0(8) 
C4 23.0(11) 27.3(12) 20.5(10) 0.5(9) 7.0(9) -6.1(10) 
C5 29.9(12) 24.8(12) 22.9(11) 6(1) 4.8(9) -5.6(10) 
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C6 25.2(11) 20.7(11) 24.0(11) -1.6(9) 0.7(9) 2.6(9) 
C7 20.8(11) 28.0(12) 21(1) -6.5(9) 7.3(9) -2.6(9) 
C8 23.0(11) 20.4(10) 17.9(10) -2.0(9) 2.8(8) -5.8(9) 
C9 22.1(11) 22.0(11) 23.6(11) -6.6(9) 4.2(9) -4.6(9) 
C10 24.5(12) 18.7(11) 28.0(11) -3.2(9) 2.0(9) 1.6(9) 
C11 30.0(12) 19.4(11) 21.8(11) 1.2(9) 2.4(9) 0.4(10) 
C12 27.3(12) 21.5(11) 19.6(10) 0.1(9) 5.1(9) -4.2(10) 
N1 18.3(9) 23.6(9) 18.9(8) -1.7(8) 4.2(7) -4.4(8) 
N2 21.9(9) 26.2(10) 21.0(9) 3.3(8) 6.0(7) 0.6(8) 
N3 18.6(9) 19.8(9) 18.6(8) -1.7(7) 0.0(7) -1.0(8) 
O1 23.3(8) 26.3(8) 20.3(7) 4.6(6) 6.8(6) 0.2(7) 
  
Table 4 Bond Lengths for 436. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.393(3)   C5 C6 1.385(3) 
C1 C4 1.381(3)   C6 C7 1.391(3) 
C1 N1 1.411(3)   C8 C9 1.380(3) 
C2 C7 1.378(3)   C8 N3 1.353(3) 
C2 O1 1.371(2)   C9 C10 1.378(3) 
C3 N1 1.318(3)   C10 C11 1.382(3) 
C3 N2 1.341(3)   C11 C12 1.367(3) 
C3 O1 1.392(2)   C12 N3 1.368(3) 
C4 C5 1.380(3)   N2 N3 1.378(2) 
  
Table 5 Bond Angles for 436. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 C1 N1 108.73(17)   C2 C7 C6 115.6(2) 
C4 C1 C2 118.99(19)   N3 C8 C9 119.88(19) 
C4 C1 N1 132.3(2)   C10 C9 C8 120.7(2) 
C7 C2 C1 124.27(19)   C9 C10 C11 118.4(2) 
O1 C2 C1 108.74(18)   C12 C11 C10 120.4(2) 
O1 C2 C7 127.0(2)   C11 C12 N3 120.4(2) 
N1 C3 N2 135.9(2)   C3 N1 C1 103.75(17) 
N1 C3 O1 115.12(17)   C3 N2 N3 119.40(17) 
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N2 C3 O1 108.99(17)   C8 N3 C12 120.25(18) 
C5 C4 C1 117.8(2)   C8 N3 N2 126.89(17) 
C4 C5 C6 122.3(2)   C12 N3 N2 112.86(17) 
C5 C6 C7 121.0(2)   C2 O1 C3 103.65(16) 
  
Table 6 Torsion Angles for 436. 
A B C D Angle/˚   A B C D Angle/˚ 
C1 C2 C7 C6 -0.7(3)   C9 C10 C11 C12 0.4(3) 
C1 C2 O1 C3 0.6(2)   C10 C11 C12 N3 0.0(3) 
C1 C4 C5 C6 0.0(3)   C11 C12 N3 C8 -0.4(3) 
C2 C1 C4 C5 -0.1(3)   C11 C12 N3 N2 179.16(18) 
C2 C1 N1 C3 -0.5(2)   N1 C1 C2 C7 -179.68(18) 
C3 N2 N3 C8 -4.1(3)   N1 C1 C2 O1 0.0(2) 
C3 N2 N3 C12 176.41(17)   N1 C1 C4 C5 -179.9(2) 
C4 C1 C2 C7 0.4(3)   N1 C3 N2 N3 -4.1(3) 
C4 C1 C2 O1 -179.94(17)   N1 C3 O1 C2 -1.0(2) 
C4 C1 N1 C3 179.4(2)   N2 C3 N1 C1 -177.5(2) 
C4 C5 C6 C7 -0.4(3)   N2 C3 O1 C2 177.89(16) 
C5 C6 C7 C2 0.7(3)   N3 C8 C9 C10 0.1(3) 
C7 C2 O1 C3 -179.81(19)   O1 C2 C7 C6 179.70(18) 
C8 C9 C10 C11 -0.4(3)   O1 C3 N1 C1 0.9(2) 
C9 C8 N3 C12 0.3(3)   O1 C3 N2 N3 177.38(15) 
C9 C8 N3 N2 -179.15(18)             
  
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters (Å
2
×10
3
) for 
436. 
Atom x y z U(eq) 
H4 5301 1954 3196 28 
H5 2286 2755 2440 31 
H6 -627 2807 3706 29 
H7 -656 2026 5811 27 
H8 8355 149 6212 25 
H9 11503 -607 6672 27 
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H10 12284 -1368 8834 29 
H11 9878 -1344 10540 29 
H12 6763 -588 10063 27 
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Appendix 2.1.4 Aminide 437 
 
Table 1 Crystal data and structure refinement for 437. 
Identification code 437 
Empirical formula C12H9N3S 
Formula weight 227.28 
Temperature/K 99.99(10) 
Crystal system monoclinic 
Space group P21/c 
a/Å 6.0554(3) 
b/Å 21.6832(9) 
c/Å 8.2470(3) 
α/° 90 
β/° 108.988(5) 
γ/° 90 
Volume/Å3 1023.91(8) 
Z 4 
ρcalcg/cm
3 1.474 
μ/mm-1 0.287 
F(000) 472.0 
Crystal size/mm3 0.2247 × 0.2101 × 0.114 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.436 to 52.742 
Index ranges -7 ≤ h ≤ 5, -27 ≤ k ≤ 13, -10 ≤ l ≤ 10 
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Reflections collected 4136 
Independent reflections 2101 [Rint = 0.0212, Rsigma = 0.0388] 
Data/restraints/parameters 2101/0/145 
Goodness-of-fit on F2 1.039 
Final R indexes [I>=2σ (I)] R1 = 0.0376, wR2 = 0.0785 
Final R indexes [all data] R1 = 0.0491, wR2 = 0.0857 
Largest diff. peak/hole / e Å-3 0.30/-0.27 
 
  
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement Parameters 
(Å
2
×10
3
) for 437. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 5286(3) 3563.5(9) 10151(2) 14.3(4) 
C2 3042(3) 3317.8(9) 9897(2) 15.1(4) 
C3 3283(3) 4276.9(9) 8317(2) 14.2(4) 
C4 7237(3) 3249.7(9) 11213(2) 17.4(4) 
C5 6921(3) 2703.4(9) 11980(2) 19.2(4) 
C6 4690(3) 2468.3(9) 11732(2) 18.9(4) 
C7 2729(3) 2773.9(9) 10682(2) 17.5(4) 
C8 6424(3) 5160.9(9) 7726(2) 16.6(4) 
C9 7766(3) 5604.8(9) 7293(2) 18.0(4) 
C10 6764(3) 6053.7(10) 6099(2) 19.2(4) 
C11 4351(4) 6042.3(9) 5330(2) 19.3(4) 
C12 3044(3) 5595.8(9) 5751(2) 17.3(4) 
N1 5384(3) 4101.7(7) 9270.4(19) 14.3(3) 
N2 2472(3) 4745.6(8) 7225(2) 16.1(4) 
N3 4062(3) 5156.4(7) 6949.7(19) 14.1(3) 
S1 967.8(8) 3788.4(2) 8469.6(6) 16.95(14) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for 437. The Anisotropic displacement 
factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 16.4(9) 15.1(10) 12.0(9) -2.9(8) 5.5(7) 1.4(8) 
C2 15.0(9) 18.7(10) 11.3(9) -0.4(8) 3.7(7) 1.6(8) 
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C3 13.5(9) 15.6(10) 14.4(9) -1.9(8) 5.8(7) -0.8(8) 
C4 14.6(9) 19.8(11) 15.5(9) -2.4(8) 1.7(7) 0.1(8) 
C5 20.1(10) 19.3(11) 15.9(9) 1.5(8) 2.7(8) 5.2(8) 
C6 25.6(10) 14.7(10) 17.8(10) 2.3(8) 8.9(8) 1.6(9) 
C7 18(1) 19.3(11) 16.1(9) -1.1(8) 7.0(8) -0.6(8) 
C8 15.6(9) 15.6(10) 18.0(9) -0.5(8) 4.8(8) 2.4(8) 
C9 16.0(9) 18.0(11) 20.2(10) -4.2(8) 6.1(8) -0.9(8) 
C10 23(1) 18.7(11) 18.1(10) -2.4(8) 9.5(8) -4.9(8) 
C11 23.7(10) 16.4(10) 16.2(10) 0.8(8) 4.2(8) 0.4(8) 
C12 17.7(9) 17.6(11) 14.9(9) -0.2(8) 3.1(8) 0.4(8) 
N1 14.7(8) 14.4(9) 13.3(8) 0.1(6) 3.7(6) 1.1(7) 
N2 14.3(8) 16.0(9) 18.0(8) 2.4(7) 5.2(7) -0.7(7) 
N3 15.4(8) 13.0(8) 14.2(8) -1.3(6) 5.3(6) 0.2(6) 
S1 12.0(2) 19.1(3) 18.4(2) 4.1(2) 3.08(18) -0.5(2) 
  
Table 4 Bond Lengths for 437. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.411(3)   C5 C6 1.395(3) 
C1 C4 1.397(3)   C6 C7 1.389(3) 
C1 N1 1.386(2)   C8 C9 1.380(3) 
C2 C7 1.388(3)   C8 N3 1.363(2) 
C2 S1 1.7443(19)   C9 C10 1.377(3) 
C3 N1 1.315(2)   C10 C11 1.391(3) 
C3 N2 1.341(2)   C11 C12 1.365(3) 
C3 S1 1.7939(19)   C12 N3 1.367(2) 
C4 C5 1.385(3)   N2 N3 1.384(2) 
  
Table 5 Bond Angles for 437. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C4 C1 C2 119.09(18)   C2 C7 C6 118.51(18) 
N1 C1 C2 116.34(16)   N3 C8 C9 119.99(18) 
N1 C1 C4 124.54(17)   C10 C9 C8 121.23(19) 
C1 C2 S1 109.06(14)   C9 C10 C11 117.82(19) 
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C7 C2 C1 121.54(17)   C12 C11 C10 120.43(19) 
C7 C2 S1 129.38(15)   C11 C12 N3 121.05(18) 
N1 C3 N2 133.80(18)   C3 N1 C1 110.99(16) 
N1 C3 S1 114.45(14)   C3 N2 N3 118.41(15) 
N2 C3 S1 111.75(13)   C8 N3 C12 119.47(16) 
C5 C4 C1 119.26(18)   C8 N3 N2 127.38(16) 
C4 C5 C6 121.08(18)   C12 N3 N2 113.14(15) 
C7 C6 C5 120.51(18)   C2 S1 C3 89.14(9) 
  
Table 6 Torsion Angles for 437. 
A B C D Angle/˚   A B C D Angle/˚ 
C1 C2 C7 C6 -0.3(3)   C9 C10 C11 C12 -0.4(3) 
C1 C2 S1 C3 0.26(14)   C10 C11 C12 N3 0.9(3) 
C1 C4 C5 C6 -1.1(3)   C11 C12 N3 C8 -0.6(3) 
C2 C1 C4 C5 0.5(3)   C11 C12 N3 N2 179.41(17) 
C2 C1 N1 C3 -1.0(2)   N1 C1 C2 C7 178.64(16) 
C3 N2 N3 C8 -3.0(3)   N1 C1 C2 S1 0.3(2) 
C3 N2 N3 C12 176.96(16)   N1 C1 C4 C5 -177.80(17) 
C4 C1 C2 C7 0.2(3)   N1 C3 N2 N3 0.5(3) 
C4 C1 C2 S1 -178.05(14)   N1 C3 S1 C2 -0.86(15) 
C4 C1 N1 C3 177.30(17)   N2 C3 N1 C1 -178.14(19) 
C4 C5 C6 C7 1.0(3)   N2 C3 S1 C2 178.61(14) 
C5 C6 C7 C2 -0.3(3)   N3 C8 C9 C10 0.9(3) 
C7 C2 S1 C3 -177.86(18)   S1 C2 C7 C6 177.59(15) 
C8 C9 C10 C11 -0.5(3)   S1 C3 N1 C1 1.2(2) 
C9 C8 N3 C12 -0.3(3)   S1 C3 N2 N3 -178.84(12) 
C9 C8 N3 N2 179.68(17)             
  
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters (Å
2
×10
3
) for 
437. 
Atom x y z U(eq) 
H4 8762 3409 11406 21 
H5 8245 2485 12687 23 
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H6 4511 2096 12285 23 
H7 1208 2614 10506 21 
H8 7145 4858 8564 20 
H9 9413 5601 7829 22 
H10 7691 6361 5810 23 
H11 3608 6347 4506 23 
H12 1400 5590 5202 21 
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Appendix 2.1.5 Aminide 443 
 
Table 1 Crystal data and structure refinement for 443. 
Identification code 443 
Empirical formula C13H12N4O2S 
Formula weight 288.33 
Temperature/K 99.9(5) 
Crystal system triclinic 
Space group P-1 
a/Å 7.32392(19) 
b/Å 8.8468(2) 
c/Å 21.5625(5) 
α/° 99.806(2) 
β/° 90.086(2) 
γ/° 113.273(3) 
Volume/Å3 1261.02(6) 
Z 4 
ρcalcg/cm
3 1.519 
μ/mm-1 2.362 
F(000) 600.0 
Crystal size/mm3 0.2973 × 0.2478 × 0.1435 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.346 to 136.466 
Index ranges -8 ≤ h ≤ 8, -10 ≤ k ≤ 10, -25 ≤ l ≤ 25 
Reflections collected 20480 
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Independent reflections 4617 [Rint = 0.0163, Rsigma = 0.0114] 
Data/restraints/parameters 4617/0/363 
Goodness-of-fit on F
2
 1.062 
Final R indexes [I>=2σ (I)] R1 = 0.0292, wR2 = 0.0776 
Final R indexes [all data] R1 = 0.0310, wR2 = 0.0790 
Largest diff. peak/hole / e Å-3 0.28/-0.47 
 
 
Table 2 Fractional Atomic Coordinates (×10
4
) and Equivalent Isotropic Displacement Parameters 
(Å
2
×10
3
) for 443. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 2296(2) 5977.9(18) 4102.7(6) 16.2(3) 
C2 2882(2) 7337.5(18) 3794.5(7) 19.3(3) 
C3 2133(2) 7074.8(19) 3177.0(7) 21.3(3) 
C4 805(2) 5501.7(19) 2868.6(7) 20.2(3) 
C5 160(2) 4131.9(18) 3173.0(7) 18.1(3) 
C6 938(2) 4401.2(17) 3787.4(6) 15.6(3) 
C7 1928(2) 4362.9(17) 4785.8(6) 15.1(3) 
C8 4319(2) 6029.2(18) 5947.5(7) 18.0(3) 
C9 5277(2) 6703.6(19) 6543.7(7) 20.0(3) 
C10 4871(2) 5765(2) 7016.5(7) 21.7(3) 
C11 3458(2) 4133.9(19) 6878.7(7) 20.7(3) 
C12 2494(2) 3492.4(18) 6288.6(7) 18.0(3) 
C13 -2080(2) 734.0(18) 4663.0(7) 20.4(3) 
N1 2881.3(17) 5928.0(14) 4710.7(5) 16.0(2) 
N2 667.9(18) 3341.6(14) 4233.9(5) 16.4(2) 
N3 1848.7(18) 3547.6(14) 5260.0(5) 17.2(2) 
N4 2927.5(17) 4424.2(14) 5823.0(5) 15.3(2) 
O1 -1442.1(18) 789.5(13) 3475.4(5) 28.2(3) 
O2 1114.6(16) 627.1(13) 4164.0(5) 23.6(2) 
S1 -382.8(5) 1250.5(4) 4083.9(2) 17.74(10) 
C101 6334(2) -906.6(17) 911.4(6) 16.0(3) 
C102 5626(2) -2245.4(18) 1231.6(7) 18.8(3) 
C103 5247(2) -1928.5(19) 1860.3(7) 20.8(3) 
C104 5564(2) -317.8(19) 2167.2(7) 20.2(3) 
C105 6216(2) 1026.9(18) 1850.8(7) 18.6(3) 
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C106 6572(2) 694.8(17) 1222.0(6) 15.8(3) 
C107 7516(2) 665.2(17) 214.3(6) 15.0(3) 
C108 8271(2) -1063.0(17) -938.4(7) 17.6(3) 
C109 8595(2) -1761.8(18) -1528.9(7) 19.2(3) 
C110 9147(2) -835.7(19) -2004.8(7) 20.2(3) 
C111 9343(2) 815.9(19) -1872.4(7) 19.4(3) 
C112 8978(2) 1478.4(17) -1289.5(7) 17.3(3) 
C113 7096(2) 4305.4(18) 286.3(7) 19.7(3) 
N101 6919.7(17) -900.2(14) 297.4(5) 15.9(2) 
N102 7286.0(17) 1721.9(14) 764.5(5) 16.1(2) 
N103 8246.3(18) 1458.6(14) -262.0(5) 16.8(2) 
N104 8462.3(16) 554.2(14) -821.6(5) 14.9(2) 
O101 7447.0(17) 4283.7(13) 1484.5(5) 25.7(2) 
O102 10306.4(15) 4454.3(13) 864.6(5) 24.0(2) 
S101 8189.8(5) 3810.8(4) 901.3(2) 17.27(10) 
  
Table 3 Anisotropic Displacement Parameters (Å
2
×10
3
) for 443. The Anisotropic displacement 
factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
C1 15.3(6) 17.4(7) 17.0(7) 3.1(5) 2.6(5) 7.5(5) 
C2 18.1(7) 17.2(7) 21.8(7) 5.1(6) 3.1(6) 5.6(6) 
C3 21.3(7) 24.0(8) 22.7(7) 11.9(6) 6.4(6) 10.3(6) 
C4 22.4(7) 28.2(8) 14.9(7) 5.9(6) 3.1(5) 14.4(6) 
C5 20.0(7) 19.5(7) 16.5(7) 1.5(5) 1.0(5) 10.4(6) 
C6 17.4(7) 15.0(7) 16.9(7) 4.0(5) 3.8(5) 8.9(5) 
C7 15.4(6) 15.0(7) 14.2(6) 0.0(5) 0.6(5) 6.3(5) 
C8 17.9(7) 16.3(7) 19.4(7) 3.1(5) 2.2(5) 6.5(6) 
C9 17.0(7) 19.5(7) 20.5(7) -1.7(6) -0.4(5) 6.3(6) 
C10 18.9(7) 29.9(8) 16.1(7) -0.9(6) -2.0(5) 11.8(6) 
C11 22.6(7) 26.9(8) 16.3(7) 5.7(6) 2.6(6) 13.2(6) 
C12 19.9(7) 17.4(7) 18.0(7) 4.2(5) 3.0(5) 8.5(6) 
C13 20.9(7) 16.0(7) 21.6(7) 3.3(6) 1.6(6) 4.8(6) 
N1 17.5(6) 15.4(6) 15.0(6) 2.6(5) 0.5(4) 6.4(5) 
N2 20.9(6) 13.0(6) 13.5(5) 1.9(4) -1.3(5) 5.4(5) 
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N3 20.3(6) 15.0(6) 13.2(6) 0.6(4) -2.6(4) 4.8(5) 
N4 16.1(6) 15.7(6) 14.4(6) 0.8(4) 0.1(4) 7.5(5) 
O1 40.4(7) 17.6(5) 18.0(5) -0.2(4) -7.4(5) 4.2(5) 
O2 29.1(6) 18.1(5) 26.6(6) 4.8(4) 6.1(4) 12.3(4) 
S1 23.65(19) 11.97(17) 15.10(17) 0.81(13) -0.58(13) 5.22(14) 
C101 13.9(6) 17.2(7) 16.1(7) 2.6(5) -0.9(5) 5.7(5) 
C102 19.2(7) 16.3(7) 21.3(7) 4.3(6) 0.6(5) 7.3(6) 
C103 18.4(7) 24.2(8) 21.3(7) 11.2(6) 2.1(6) 7.3(6) 
C104 17.4(7) 27.3(8) 14.6(7) 4.9(6) 1.6(5) 7.1(6) 
C105 16.5(7) 19.6(7) 17.3(7) 0.7(6) 0.6(5) 5.7(6) 
C106 13.5(6) 16.2(7) 16.3(7) 4.2(5) -0.5(5) 4.0(5) 
C107 14.6(6) 14.7(7) 14.2(6) 0.3(5) -0.8(5) 5.3(5) 
C108 18.1(7) 15.9(7) 18.6(7) 3.8(5) -0.3(5) 6.5(6) 
C109 19.9(7) 18.7(7) 19.1(7) -0.7(6) -2.2(5) 9.6(6) 
C110 18.6(7) 27.1(8) 14.8(7) -0.7(6) -1.0(5) 10.9(6) 
C111 18.3(7) 23.6(7) 15.3(7) 5.1(6) 0.6(5) 6.9(6) 
C112 17.6(7) 14.9(7) 17.7(7) 4.0(5) -0.7(5) 4.3(5) 
C113 24.2(7) 16.7(7) 19.2(7) 3.1(6) -0.9(6) 9.5(6) 
N101 16.4(6) 14.6(6) 16.1(6) 3.0(5) 0.8(4) 5.3(5) 
N102 20.1(6) 12.3(6) 14.2(6) 2.0(4) 1.8(4) 5.0(5) 
N103 22.4(6) 14.4(6) 13.0(6) 0.6(4) 2.6(5) 7.4(5) 
N104 14.3(6) 15.0(6) 14.0(5) 1.1(4) -0.2(4) 5.2(5) 
O101 40.3(6) 18.3(5) 17.8(5) 0.1(4) 3.5(5) 12.3(5) 
O102 20.6(5) 16.7(5) 30.4(6) 5.2(4) -4.3(4) 2.6(4) 
S101 21.53(19) 12.02(17) 15.95(17) 0.73(13) -1.17(13) 5.07(14) 
  
Table 4 Bond Lengths for 443. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.392(2)   C101 C102 1.394(2) 
C1 C6 1.406(2)   C101 C106 1.403(2) 
C1 N1 1.3919(18)   C101 N101 1.3926(18) 
C2 C3 1.385(2)   C102 C103 1.388(2) 
C3 C4 1.392(2)   C103 C104 1.393(2) 
C4 C5 1.394(2)   C104 C105 1.392(2) 
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C5 C6 1.3854(19)   C105 C106 1.385(2) 
C6 N2 1.4165(18)   C106 N102 1.4153(18) 
C7 N1 1.3204(18)   C107 N101 1.3219(18) 
C7 N2 1.4336(17)   C107 N102 1.4343(17) 
C7 N3 1.3370(18)   C107 N103 1.3356(18) 
C8 C9 1.380(2)   C108 C109 1.381(2) 
C8 N4 1.3612(18)   C108 N104 1.3596(18) 
C9 C10 1.383(2)   C109 C110 1.383(2) 
C10 C11 1.384(2)   C110 C111 1.389(2) 
C11 C12 1.369(2)   C111 C112 1.367(2) 
C12 N4 1.3655(18)   C112 N104 1.3664(18) 
C13 S1 1.7505(15)   C113 S101 1.7501(14) 
N2 S1 1.6702(12)   N102 S101 1.6696(12) 
N3 N4 1.3754(16)   N103 N104 1.3758(16) 
O1 S1 1.4333(11)   O101 S101 1.4335(11) 
O2 S1 1.4306(11)   O102 S101 1.4324(11) 
  
Table 5 Bond Angles for 443. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 C1 C6 119.46(13)   C102 C101 C106 119.60(13) 
N1 C1 C2 128.68(13)   N101 C101 C102 128.58(13) 
N1 C1 C6 111.86(12)   N101 C101 C106 111.80(12) 
C3 C2 C1 118.39(14)   C103 C102 C101 118.29(13) 
C2 C3 C4 121.47(14)   C102 C103 C104 121.23(13) 
C3 C4 C5 121.13(13)   C105 C104 C103 121.33(13) 
C6 C5 C4 116.99(13)   C106 C105 C104 116.98(13) 
C1 C6 N2 104.36(12)   C101 C106 N102 104.50(12) 
C5 C6 C1 122.53(13)   C105 C106 C101 122.49(13) 
C5 C6 N2 133.11(13)   C105 C106 N102 132.95(13) 
N1 C7 N2 111.44(12)   N101 C107 N102 111.25(11) 
N1 C7 N3 134.43(13)   N101 C107 N103 134.63(13) 
N3 C7 N2 114.10(12)   N103 C107 N102 114.11(12) 
N4 C8 C9 119.78(13)   N104 C108 C109 119.86(13) 
C8 C9 C10 121.05(14)   C108 C109 C110 121.15(13) 
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C9 C10 C11 118.19(13)   C109 C110 C111 117.86(13) 
C12 C11 C10 120.08(14)   C112 C111 C110 120.25(14) 
N4 C12 C11 121.19(13)   N104 C112 C111 121.16(13) 
C7 N1 C1 106.04(11)   C107 N101 C101 106.09(11) 
C6 N2 C7 106.28(11)   C106 N102 C107 106.28(11) 
C6 N2 S1 126.22(10)   C106 N102 S101 125.74(9) 
C7 N2 S1 125.51(9)   C107 N102 S101 126.46(9) 
C7 N3 N4 119.02(11)   C107 N103 N104 119.07(11) 
C8 N4 C12 119.70(12)   C108 N104 C112 119.70(12) 
C8 N4 N3 127.73(12)   C108 N104 N103 127.67(12) 
C12 N4 N3 112.56(11)   C112 N104 N103 112.61(11) 
N2 S1 C13 104.24(6)   N102 S101 C113 104.97(6) 
O1 S1 C13 109.66(7)   O101 S101 C113 109.10(7) 
O1 S1 N2 105.69(6)   O101 S101 N102 105.86(6) 
O2 S1 C13 109.59(7)   O102 S101 C113 109.53(7) 
O2 S1 N2 109.03(6)   O102 S101 N102 108.77(6) 
O2 S1 O1 117.72(7)   O102 S101 O101 117.81(7) 
  
Table 6 Torsion Angles for 443. 
A B C D Angle/˚   A B C D Angle/˚ 
C1 C2 C3 C4 0.9(2)   C101 C102 C103 C104 -0.1(2) 
C1 C6 N2 C7 -1.16(14)   C101 C106 N102 C107 -2.66(14) 
C1 C6 N2 S1 -165.75(10)   C101 C106 N102 S101 -169.32(10) 
C2 C1 C6 C5 0.7(2)   C102 C101 C106 C105 3.0(2) 
C2 C1 C6 N2 -179.37(12)   C102 C101 C106 N102 -179.57(12) 
C2 C1 N1 C7 -179.86(14)   C102 C101 N101 C107 -178.58(14) 
C2 C3 C4 C5 0.7(2)   C102 C103 C104 C105 2.0(2) 
C3 C4 C5 C6 -1.6(2)   C103 C104 C105 C106 -1.3(2) 
C4 C5 C6 C1 0.9(2)   C104 C105 C106 C101 -1.2(2) 
C4 C5 C6 N2 -179.06(14)   C104 C105 C106 N102 -177.75(14) 
C5 C6 N2 C7 178.81(15)   C105 C106 N102 C107 174.36(15) 
C5 C6 N2 S1 14.2(2)   C105 C106 N102 S101 7.7(2) 
C6 C1 C2 C3 -1.5(2)   C106 C101 C102 C103 -2.3(2) 
C6 C1 N1 C7 0.00(15)   C106 C101 N101 C107 -0.11(15) 
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C6 N2 S1 C13 -131.97(12)   C106 N102 S101 C113 -135.65(12) 
C6 N2 S1 O1 -16.38(13)   C106 N102 S101 O101 -20.30(13) 
C6 N2 S1 O2 111.06(12)   C106 N102 S101 O102 107.20(12) 
C7 N2 S1 C13 66.30(12)   C107 N102 S101 C113 60.33(13) 
C7 N2 S1 O1 -178.12(11)   C107 N102 S101 O101 175.68(11) 
C7 N2 S1 O2 -50.67(13)   C107 N102 S101 O102 -56.82(13) 
C7 N3 N4 C8 -9.4(2)   C107 N103 N104 C108 -9.6(2) 
C7 N3 N4 C12 171.48(12)   C107 N103 N104 C112 172.11(12) 
C8 C9 C10 C11 -0.8(2)   C108 C109 C110 C111 -0.7(2) 
C9 C8 N4 C12 -0.2(2)   C109 C108 N104 C112 -0.10(19) 
C9 C8 N4 N3 -179.25(13)   C109 C108 N104 N103 -178.23(13) 
C9 C10 C11 C12 -0.4(2)   C109 C110 C111 C112 -0.6(2) 
C10 C11 C12 N4 1.3(2)   C110 C111 C112 N104 1.6(2) 
C11 C12 N4 C8 -1.0(2)   C111 C112 N104 C108 -1.2(2) 
C11 C12 N4 N3 178.19(12)   C111 C112 N104 N103 177.19(13) 
N1 C1 C2 C3 178.31(14)   N101 C101 C102 C103 176.07(13) 
N1 C1 C6 C5 -179.22(12)   N101 C101 C106 C105 -175.61(12) 
N1 C1 C6 N2 0.76(15)   N101 C101 C106 N102 1.81(15) 
N1 C7 N2 C6 1.26(15)   N101 C107 N102 C106 2.82(15) 
N1 C7 N2 S1 165.99(10)   N101 C107 N102 S101 169.36(10) 
N1 C7 N3 N4 1.2(2)   N101 C107 N103 N104 1.2(2) 
N2 C7 N1 C1 -0.78(15)   N102 C107 N101 C101 -1.68(15) 
N2 C7 N3 N4 -177.02(11)   N102 C107 N103 N104 -177.69(11) 
N3 C7 N1 C1 -179.01(15)   N103 C107 N101 C101 179.39(15) 
N3 C7 N2 C6 179.88(11)   N103 C107 N102 C106 -178.01(11) 
N3 C7 N2 S1 -15.39(17)   N103 C107 N102 S101 -11.48(17) 
N4 C8 C9 C10 1.1(2)   N104 C108 C109 C110 1.1(2) 
  
Table 7 Hydrogen Atom Coordinates (Å×10
4
) and Isotropic Displacement Parameters (Å
2
×10
3
) for 
443. 
Atom x y z U(eq) 
H2 3754 8397 3998 23 
H3 2527 7969 2964 26 
H4 341 5363 2452 24 
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H5 -752 3084 2973 22 
H8 4624 6669 5632 22 
H9 6211 7807 6629 24 
H10 5531 6217 7416 26 
H11 3162 3473 7187 25 
H12 1527 2402 6203 22 
H13A -1384 1197 5074 31 
H13B -2729 -462 4616 31 
H13C -3060 1184 4617 31 
H102 5414 -3323 1029 23 
H103 4772 -2808 2081 25 
H104 5336 -137 2592 24 
H105 6403 2100 2052 22 
H108 7922 -1697 -622 21 
H109 8440 -2874 -1608 23 
H110 9379 -1304 -2401 24 
H111 9723 1474 -2182 23 
H112 9083 2577 -1210 21 
H11A 7472 3880 -110 29 
H11B 7545 5499 338 29 
H11C 5672 3809 294 29 
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